Title:
Cytotoxic T-Lymphocyte-Inducing Immunogens for Prevention, Treatment and Diagnosis of Cancer
Kind Code:
A1


Abstract:
The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as ovarian carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against cancer.



Inventors:
Ramakrishna, Venky (Charlottesville, VA, US)
Ross, Mark M. (Charlottesville, VA, US)
Philip, Ramila (Ivyland, PA, US)
Application Number:
13/030563
Publication Date:
06/16/2011
Filing Date:
02/18/2011
Assignee:
Immunotope, Inc. (Doylestown, PA, US)
Primary Class:
Other Classes:
514/19.3, 424/85.1
International Classes:
A61K9/127; A61K38/16; A61K38/19; A61K39/00; A61P35/00
View Patent Images:



Other References:
Ibragimova and Eade (Biophysical Journal, Oct 1999, Vol. 77, pp. 2191-2198)
Primary Examiner:
BRISTOL, LYNN ANNE
Attorney, Agent or Firm:
BALLARD SPAHR LLP (ATLANTA, GA, US)
Claims:
We claim:

1. A method for eliciting a CTL response against tumor cells presenting at least one of the following epitopic peptides: SEQ ID NO: 1516, 1517, 1519, 1521, 1527, 1528, or 1529 in a subject, comprising administering to said subject a composition comprising at least one polypeptide comprising an epitopic peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1516, 1517, 1519, 1521, 1527, 1528, and 1529 in an amount sufficient to induce a CTL response to said tumor cells; or at least one polypeptide comprising an epitopic peptide having no more than one amino acid difference from an amino acid sequence selected from the group consisting of SEQ ID NO: 1516, 1517, 1519, 1521, 1527, 1528, and 1529 in an amount sufficient to induce a CTL response to said tumor cells.

2. The method of claim 1, wherein said amino acid difference is the result of a conservative amino acid substitution.

3. The method of claim 1, wherein said amino acid difference is the result of a substitution of one hydrophobic amino acid with another hydrophobic amino acid.

4. The method of claim 1, wherein said amino acid difference is the result of an addition or deletion of one amino acid to or from said epitopic peptide.

5. The method of claim 1, wherein said composition further comprises an adjuvant.

6. The method of claim 5, wherein said adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, Montanide ISA-51, LAG-3, aluminum phosphate, aluminum hydroxide, alum, and saponin.

7. The method of claim 1, wherein said composition further comprises a cytokine.

8. The method of claim 7, wherein said cytokine is GM-CSF.

9. The method of claim 1, wherein said composition further comprises a vehicle.

10. The method of claim 9, where said vehicle is selected from the group consisting of a liposome, an immunostimulating complex (ISCOM), and slow-releasing particles.

11. The method of claim 10, wherein said liposome comprises an emulsion, a foam, a micelle, an insoluble monolayer, a liquid crystal, a phospholipid dispersion, or a lamellar layer.

12. The method of claim 1, wherein said polypeptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 1516, 1517, 1519, 1521, 1527, 1528, and 1529; or an amino acid sequence having no more than one amino acid differences from an amino acid sequence selected from the group consisting of SEQ ID NO: 1516, 1517, 1519, 1521, 1527, 1528, and 1529.

13. The method of claim 1, wherein said tumor cells are part of a carcinoma.

14. The method of claim 1, wherein said cancer is tumor cells are part of an ovarian carcinoma.

15. The method of claim 1, wherein said polypeptide comprises at least two epitopic peptides.

16. The method of claim 15, wherein said polypeptide comprises at least three epitopic peptides.

17. The method of claim 1, wherein said composition comprises an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1516; an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1517; an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1519; an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1521; an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1527; an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1528; and an epitopic peptide comprising an amino acid sequence of SEQ ID NO: 1529.

Description:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/426,161, filed Jun. 23, 2006, which is a continuation-in-part of U.S. application Ser. No. 10/006,177, filed Dec. 4, 2001, now U.S. Pat. No. 7,083,789, which claims priority from U.S. provisional application No. 60/251,022, filed Dec. 4, 2000, and U.S. provisional application No. 60/256,824, filed Dec. 20, 2000, the disclosures of which are all herein incorporated by reference in their entireties.

SEQUENCE LISTING

The Sequence Listing has been submitted electronically as file 091910002U5_sequence_listing.txt, 5.96 MB, created Feb. 17, 2011 and is hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention relates generally to the field of immunogens whose structures incorporate polypeptides comprising epitopic peptides derived from proteins expressed by cancer cells and to uses of said immunogens in eliciting cytotoxic T lymphocyte (CTL) responses for the diagnosis, prevention and treatment of cancer, preferably carcinoma, most preferably ovarian carcinoma.

BACKGROUND OF THE INVENTION

The mammalian immune system has evolved a variety of mechanisms to protect the host from cancerous cells, an important component of this response being mediated by cells referred to as T cells. Cytotoxic T lymphocytes (CTLs) are specialized T cells that function primarily by recognizing and killing cancerous cells or infected cells, but also by secreting soluble molecules referred to as cytokines that can mediate a variety of effects on the immune system.

Evidence suggests that immunotherapy designed to stimulate a tumor-specific CTL response would be effective in controlling cancer. For example, it has been shown that human CTLs recognize sarcomas (Slovin, S. F. et al., J. Immunol., 137:3042-3048, (1987)), renal cell carcinomas (Schendel, D. J. et al., J. Immunol., 151:4209-4220, (1993)), colorectal carcinomas (Jacob, L. et al., Int. J. Cancer, 71:325-332, (1997)), ovarian carcinomas (Loannides, C. G. et al., J. Immunol., 146:1700-1707, (1991)) (Peoples, G. E. et al., Surgery, 114:227-234, (1993)), pancreatic carcinomas (Peiper, M. et al., Eur. J. Immunol., 27:1115-1123, (1997); Wolfel, T. et al., Int. J. Cancer, 54:636-644, (1993)), squamous tumors of the head and neck (Yasumura, S. et al., Cancer Res., 53:1461-1468, (1993)), and squamous carcinomas of the lung (Slingluff, C. L. Jr et al., Cancer Res., 54:2731-2737, (1994); Yoshino, I. et al., Cancer Res., 54:3387-3390, (1994)). The largest number of reports of human tumor-reactive CTLs have concerned cancers (Boon, T. et al., Ann. Rev. Immunol., 12:337-365, (1994)). The ability of tumor-specific CTLs to mediate tumor regression, in both human (Rosenberg, S. A. et al., N. Engl. J. Med., 319:1676-1680, (1988)) and animal models (Celluzzi, C. M. et al., J. Exp. Med., 183:283-287, (1996); Mayordomo, J. I. et al., Nat. Med., 1:1297-1302, (1995); Zitvogel, L. et al., J. Exp. Med., 183:87-97, (1996)), suggests that methods directed at increasing CTL activity would likely have a beneficial effect with respect to tumor treatment.

In order for CTLs to kill or secrete cytokines in response to a cancer cell, the CTL must first recognize that cell as being cancerous. This process involves the interaction of the T cell receptor, located on the surface of the CTL, with what is generically referred to as an MHC-peptide complex which is located on the surface of the cancerous cell. MHC (major histocompatibility-complex)-encoded molecules have been subdivided into two types, and are referred to as class I and class II MHC-encoded molecules.

In the human immune system, MHC molecules are referred to as human leukocyte antigens (HLA). Within the MHC, located on chromosome six, are three different genetic loci that encode for class I MHC molecules. MHC molecules encoded at these loci are referred to as HLA-A, HLA-B, and HLA-C. The genes that can be encoded at each of these loci are extremely polymorphic, and thus, different individuals within the population express different class I MHC molecules on the surface of their cells. HLA-A1, HLA-A2, HLA-A3, HLA-B7, and HLA-B8 are examples of different class I MHC molecules that can be expressed from these loci. The present disclosure involves peptides that are associated with the HLA-A1, HLA-A2, or HLA-A11 molecules, HLA-A1 supertypes, HLA-A2 supertypes, and HLA-A11 supertypes and with the gene and protein that gives rise to these peptides. A supertype is a group of HLA molecules that present at least one shared epitope.

The peptides that associate with the MHC molecules can either be derived from proteins made within the cell, in which case they typically associate with class I MHC molecules (Rock, K. L. and Golde, U., Ann. Rev. Immunol., 17:739-779, (1999)) or they can be derived from proteins that are acquired from outside of the cell, in which case they typically associate with class II MHC molecules (Watts, C., Ann. Rev. Immunol., 15:821-850, (1997)). Peptides that evoke a cancer-specific CTL response most typically associate with class I MHC molecules. The peptides that associate with a class I MHC molecule are typically nine amino acids in length, but can vary from a minimum length of eight amino acids to a maximum of fourteen amino acids in length. A class I MHC molecule with its bound peptide, or a class II MHC molecule with its bound peptide, is referred to as an MHC-peptide complex.

The process by which intact proteins are degraded into peptides is referred to as antigen processing. Two major pathways of antigen processing occur within cells (Rock, K. L. and Golde, U., Ann. Rev. Immunol., 17:739-779, (1999); Watts, C., Ann. Rev. Immunol., 15:821-850, (1997)). One pathway, which is largely restricted to cells that are antigen presenting cells such as dendritic cells, macrophages, and B cells, degrades proteins that are typically phagocytosed or endocytosed into the cell. Peptides derived in this pathway typically bind to class II MHC molecules. A second pathway of antigen processing is present in essentially all cells of the body. This second pathway primarily degrades proteins that are made within the cells, and the peptides derived from this pathway primarily bind to class I MHC molecules. It is the peptides from this second pathway of antigen processing that are referred to herein. Antigen processing by this latter pathway involves polypeptide synthesis and proteolysis in the cytoplasm. The peptides produced are then transported into the endoplasmic reticulum of the cell, associate with newly synthesized class I MHC molecules, and the resulting MHC-peptide complexes are then transported to the cell surface. Peptides derived from membrane and secreted proteins have also been identified. In some cases these peptides correspond to the signal sequence of the proteins that are cleaved from the protein by the signal peptidase. In other cases, it is thought that some fraction of the membrane and secreted proteins are transported from the endoplasmic reticulum into the cytoplasm where processing subsequently occurs.

Once bound to the class I MHC molecule and displayed on the surface of a cell, the peptides are recognized by antigen-specific receptors on CTLs. Mere expression of the class I MHC molecule itself is insufficient to trigger the CTL to kill the target cell if the antigenic peptide is not bound to the class I MHC molecule. Several methods have been developed to identify the peptides recognized by CTL, each method relying on the ability of a CTL to recognize and kill only those cells expressing the appropriate class I MHC molecule with the peptide bound to it (Rosenberg, S. A., Immunity, 10:281-287, (1999)). Such peptides can be derived from a non-self source, such as a pathogen (for example, following the infection of a cell by a bacterium or a virus) or from a self-derived protein within a cell, such as a cancerous cell. Examples of sources of self-derived proteins in cancerous cells have been reviewed (Gilboa, E., Immunity, 11:263-270, (1999); Rosenberg, S. A., Immunity, 10:281-287, (1999)) and include: (i) mutated genes; (ii) aberrantly expressed genes such as an alternative open reading frame or through an intron-exon boundary; (iii) normal genes that are selectively expressed in only the tumor and the testis; and (iv) normal differentiation genes that are expressed in the tumor and the normal cellular counterpart.

Four different methodologies have typically been used for identifying the peptides that are recognized by CTLs. These are: (i) the genetic method; (2) motif analysis; (3) SErological analysis of REcombinant cDNA expression libraries (SEREX™); and (iv) the analytical chemistry approach or the Direct Identification of Relevant Epitopes for Clinical Therapeutics (DIREC™).

The genetic method is an approach in which progressively smaller subsets of cDNA libraries from tumor cells are transfected into cells that express the appropriate MHC molecule but not the tumor-specific epitope. The molecular clones encoding T cell epitopes are identified by their ability to reconstitute tumor specific T cell recognition of transfected cells. The exact T cell epitope is then identified by a combination of molecular subcloning and the use of synthetic peptides based on the predicted amino acid sequence. Such methods, however, are susceptible to inadvertent identification of cross-reacting peptides, and are not capable of identifying important post-translational modifications.

Motif analysis involves scanning a protein for peptides containing known class I MHC binding motifs, followed by synthesis and assay of the predicted peptides for their ability to be recognized by tumor-specific CTL. This approach requires prior knowledge of the protein from which the peptides are derived. This approach is also greatly hampered by the fact that not all of the predicted peptide epitopes are presented on the surface of a cell (Yewdell, J. W. and Bennink, J. R., Ann. Rev. Immunol., 17:51-88, (1999)), thus additional experimentation is required to determine which of the predicted epitopes is useful.

The SEREX™ approach relies on using antibodies in the serum of cancer patients to screen cDNA expression libraries for a clone that expresses a protein recognized by the antibody. This methodology presumes that an antibody response will necessarily have developed in the presence of a T cell response, and thus, the identified clone is good candidate to encode a protein that can be recognized by T cells.

DIREC™ involves a combination of cellular immunology and mass spectrometry. This approach involves the actual identification of CTL epitopes by sequencing the naturally occurring peptides associated with class I MHC molecules. In this approach, cells are first lysed in a detergent solution, the peptides associated with the class I MHC molecules are purified, and the peptides fractionated by high performance liquid chromatography (HPLC). The peptides are then used to reconstitute recognition by tumor-specific CTLs on a non-tumor cell expressing the appropriate MHC molecules. Sequencing is readily performed by tandem mass spectrometry (Henderson, R. A. et al., Proc. Natl. Acad. Sci.U.S.A, 90:10275-10279, (1993); Hogan, K. T. et al., Cancer Res., 58:5144-5150, (1998); Hunt, D. F. et al., Science, 255:1261-1263, (1992); Slingluff, C. L. Jr et al., J. Immunol., 150:2955-2963, (1993)).

Immunization with cancer-derived, class I MHC-encoded molecule-associated peptides, or with a precursor polypeptide or protein that contains the peptide, or with a gene that encodes a polypeptide or protein containing the peptide, are forms of immunotherapy that can be employed in the treatment of cancer. These forms of immunotherapy require that immunogens be identified so that they can be formulated into an appropriate vaccine. Although a variety of cancer-derived antigens have been identified (Rosenberg, S. A., Immunity, 10:281-287, (1999)), not all of these are appropriate for broad-based immunotherapy as the expression of some peptides is limited to the tumor derived from a specific patient. Furthermore, the number of class I MHC molecules from which tumor-derived peptides have been discovered is largely restricted to HLA-A2. Thus, it would be useful to identify additional peptides that complex with class I MHC molecules other than HLA-A2. Such peptides would be particularly useful in the treatment of cancer patients who do not express the HLA-A2 molecule, HLA-A1 or HLA-A11 antigens, HLA-A1 supertypes, HLA-A2 supertypes and HLA-A11 supertypes, for example. It is also particularly useful to identify antigenic peptides that are derived from different original proteins, even if the derived peptides associate with the same class I MHC molecule. Because an active immune response can result in the outgrowth of tumor cells that have lost the expression of a particular precursor protein for a given antigenic peptide, it is advantageous to stimulate an immune response against peptides derived from more than one protein, as the chances of the tumor cell losing the expression of both proteins is the multiple of the chances of losing each of the individual proteins.

SUMMARY OF THE INVENTION

The present invention relates to Immunogens comprising polypeptides with amino acid sequences comprising epitopic sequences selected from the sequences of SEQ ID NO: 1-791 and 1514-1533 and which immunogens facilitate a cytotoxic T lymphocyte (CTL)-mediated immune response against cancers. The present invention also relates to nucleic acid molecules that encode for the polypeptides and/or the full length proteins from which the polypeptides are derived, of such immunogens, and which can also be used to facilitate an immune response against cancer.

The present invention provides compositions comprising the immunogen described herein, and polynucleotides that direct the synthesis of such polypeptides, whereby the oligopeptides and polypeptides of such immunogens are capable of inducing a CTL response against cells expressing a protein comprising an epitopic sequence of at least one of SEQ ID NO: 1-791 and 1514-1533. The cells are usually cancer cells, preferably carcinoma cells, most preferably ovarian carcinomas expressing such proteins.

The present invention further relates to polynucleotides comprising the gene coding for a polypeptide of the immunogens disclosed herein.

The present invention also provides methods that comprise contacting a lymphocyte, especially a CTL, with an immunogen of the invention under conditions that induce a CTL response against a tumor cell, and more specifically against a cancer cell. The methods may involve contacting the CTL with the immunogenic peptide in vivo, in which case the peptides, polypeptides, and polynucleotides of the invention are used as vaccines, and will be delivered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the immunogen, typically along with an adjuvant or one or more cytokines.

Alternatively, the immunogens of the present invention can be used to induce a CTL response in vitro. The generated CTL can then be introduced into a patient with cancer, more specifically cancer, colorectal carcinoma, ovarian carcinoma, breast carcinoma, lung carcinoma, or prostate carcinoma. Alternatively, the ability to generate CTL in vitro could serve as a diagnostic for cancer generally, including colorectal carcinoma, ovarian carcinoma, breast carcinoma, lung carcinoma, or prostate carcinoma.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein and except as noted otherwise, all terms are defined as given below.

The term “peptide” is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The peptides are typically 9 amino acids in length, but can be as short as 8 amino acids in length, and as long as 14 amino acids in length.

The term “oligopeptide” is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the oligopeptide is not critical to the invention as long as the correct epitope or epitopes are maintained therein. The oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 14 amino acids in length.

The term “polypeptide” designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the polypeptide is not critical to the invention as long as the correct epitopes are maintained. In contrast to the terms peptide or oligopeptide, the term polypeptide is meant to refer to protein molecules of longer than about 30 residues in length.

A peptide, oligopeptide, protein, or polynucleotide coding for such a molecule is “immunogenic” (and thus an “immunogen” within the present invention) if it is capable of inducing an immune response. In the case of the present invention, immunogenicity is more specifically defined as the ability to induce a CTL-mediated response. Thus, an “immunogen” would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a CTL response.

A T cell “epitope” is a short peptide molecule that binds to a class I or II MHC molecule and that is subsequently recognized by a T cell. T cell epitopes that bind to class I MHC molecules are typically 8-14 amino acids in length, and most typically 9 amino acids in length. T cell epitopes that bind to class II MHC molecules are typically 12-20 amino acids in length. In the case of epitopes that bind to class II MHC molecules, the same T cell epitope may share a common core segment, but differ in the length of the carboxy- and amino-terminal flanking sequences due to the fact that ends of the peptide molecule are not buried in the structure of the class II MHC molecule peptide-binding cleft as they are in the class I MHC molecule peptide-binding cleft.

There are three different genetic loci that encode for class I MHC molecules: HLA-A, HLA-B, and HLA-C. HLA-A1, HLA-A2, and HLA-A11 are examples of different class I MHC molecules that can be expressed from these loci. The present invention also involves peptides that are associated with HLA-A1 supertypes, HLA-A2 supertypes, and HLA-A11 supertypes. A supertype is a group of HLA molecules that present at least one shared epitope. MHC molecule peptides that have been found to bind to one member of the MHC allele supertype family (A1 for example) are thought to be likely to bind to other members of the same supertype family (A32 for example; see Table 1, below.

TABLE 1
SupertypeMotifGenotypes
A1x[TI(SVLM)]A*0101, A*0102, A*2501, A*2601, A*2604,
xxxxxx[WFY]A*3201, A*3601, A*4301, A*8001
A2x[LIVMATQ]A*0201, A*0202, A*0203, A*0204, A*0205,
xxxxxx[LIVMAT]A*0206, A*0207, A*6802, A*6901
A3x[AILMVST]A*0301, A*1101, A*3101, A*3301, A*6801
xxxxxx[RK]
A24x[YF(WIVLMT)]A*2301, A*2402, A*2403, A*2404, A*3001,
xxxxxx[FI(YWLM)]A*3002, A*3003
B7x[P]xxxxxxB*0702, B*0703, B*0704, B*0705, B*1508, B*3501,
[ALIMVFWY]B*3502, B*3503, B*51, B*5301, B*5401, B*5501,
B*5502, B*5601, B*5602, B*6701, B*7801
B27x[RKH]xxxxxxB*1401, B*1402, B*1503, B*1509, B*1510, B*1518,
[FLY(WMI)]B*2701, B*2702, B*2703, B*2704, B*2705, B*2706,
B*2707, B*2708, B*3801, B*3802, B*3901, B*3902,
B*3903, B*3904, B*4801, B*4802, B*7301
B44x[E(D)]xxxxxxB*18, B*3701, B*4001, B*4006, B*4101, B*4402,
[FWYLIMVA]B*4403, B*4501, B*4901, B*5001
B58x[AST]xxxxxxB*1516, B*1517, B*5701, B*5702, B*58
[FWY(LIV)]
B62x[QL(IVMP)]B*1301, B*1302, B*1501, B*1502, B*1506, B*1512,
xxxxxx[FWY(MIV)]B*1513, B*1514, B*1519, B*1521, B*4601, B*52

As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence.

The term “coding region” refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene. The coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

The term “nucleotide sequence” refers to a heteropolymer of deoxyribonucleotides. The nucleotide sequence encoding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they may be synthetically constructed. Generally, DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

The term “expression product” means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

The term “fragment,” when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

The term “DNA segment” refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, by using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

The term “primer” means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3′0H end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

The term “promoter” means a region of DNA involved in binding of RNA polymerase to initiate transcription.

The term “open reading frame (ORF)” means a series of triplets coding for amino acids without any termination codons and is a sequence (potentially) translatable into protein.

The term “isolated” means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in “purified” form. The term “purified” does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, the claimed polypeptide which has a purity of preferably 0.001%, or at least 0.01% or 0.1%; and even desirably 1% by weight or greater is expressly contemplated.

The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in “enriched form.” As used herein, the term “enriched” means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01%, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.

The term “active fragment” means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human, such immune response taking the form of stimulating a CTL response within the recipient animal, such as a human. Alternatively, the “active fragment” may also be used to induce a CTL response in vitro.

As used herein, the terms “portion,” “segment,” and “fragment,” when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. This means that any such fragment will necessarily contain as part of its amino acid sequence a segment, fragment or portion, that is substantially identical, if not exactly identical, to a sequence of SEQ ID NO: 792-1513, which correspond to the naturally occurring, or “parent” proteins of the SEQ ID NO: 1-791 and 1514-1533. When used in relation to polynucleotides, such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.

In accordance with the present invention, the term “percent identity” or “percent identical,” when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the “Compared Sequence”) with the described or claimed sequence (the “Reference Sequence”). The Percent Identity is then determined according to the following formula:


Percent Identity=100[1−(C/R)]

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the herein above calculated Percent Identity is less than the specified Percent Identity.

The present invention relates generally to immunogens and immunogenic compositions, and methods of use therefore, for the prevention, treatment, and diagnosis of cancer, especially carcinomas, including ovarian carcinomas. Disclosed according to the invention are immunogens comprising proteins or polypeptides whose amino acid sequences comprises one or more epitopic oligopeptides with sequences selected from the group SEQ ID NO: 1-791 and 1514-1533. In addition, the invention further relates to polynucleotides that can be used to stimulate a CTL response against cancer, and more specifically carcinoma, especially ovarian carcinomas.

In accordance with the present invention there are disclosed specific oligopeptide sequences with amino acid sequences shown in SEQ ID NO: 1-791 and 1514-1533, which represent epitopic peptides (i.e. immunogenic oligopeptide sequences) of at least about 8 amino acids in length, preferably about 9 amino acids in length (i.e., nonapeptides), and no longer than about 10 amino acids in length and present as part of a larger structure, such as a polypeptide or full length protein.

The polypeptides forming the immunogens of the present invention have amino acid sequences that comprise at least one stretch, possibly two, three, four, or more stretches of about 8 to 10 residues in length and which stretches differ in amino acid sequence from the sequences of SEQ ID NO: 1-791 and 1514-1533 by no more than about 1 amino acid residue, preferably a conservative amino acid residue, especially amino acids of the same general chemical character, such as where they are hydrophobic amino acids.

Said polypeptides can be of any desired length so long as they have immunogenic activity in that they are able, under a given set of desirable conditions, to elicit in vitro or in vivo the activation of cytotoxic T lymphocytes (CTLs) (i.e., a CTL response) against a presentation of a cancer specific protein, especially a carcinoma or sarcoma specific protein, most especially MAGE D, MAGE 4, MFG-E8 or human retinoblastoma-like protein, especially when such proteins are presented along with MHC-1 proteins, such as where said proteins are presented in vitro or in vivo by an antigen presenting cell (APC). The proteins and polypeptides forming the immunogens of the present invention can be naturally occurring or may be synthesized chemically. According to the present invention the polypeptides may comprise at least one of SEQ ID NO: 792-1513.

The present invention is also directed to an isolated polypeptide, especially one having immunogenic activity, the sequence of which comprises within it one or more stretches comprising any 2 or more of the sequences of SEQ ID NO: 1-791 and 1514-1533 and in any relative quantities and wherein said sequences may differ by one amino acid residues from the sequences of SEQ ID NO: 1-791 and 1514-1533 in any given stretch of 8 to 10 amino acid residues. Thus, within the present invention, by way of a non-limiting example only, such polypeptide may contain as part of its amino acid sequence, nonapeptide fragments having up to 8 amino acids identical to a sequence of SEQ ID NO: 1-4 such that the polypeptide comprises, in a specific embodiment, 2 segments with at least 8 residues identical to SEQ ID NO: 1 and one segment with at least 8 residues identical to SEQ ID NO: 3. In other embodiments, other combinations and permutations of the epitopic sequences disclosed herein may be part of an immunogen of the present invention or of such a polypeptide so long as any such polypeptide comprises at least 2 such epitopes, whether such epitopes are different or the same. Thus, in a specific embodiment, a polypeptide of the present invention may comprise 2 copies of the sequence of SEQ ID NO: 2 at some point or points within its length. Of course, any combinations and permutations of the epitopes disclosed herein, as long as they are present at least two in number in such polypeptides, are expressly contemplated.

All of the epitopic peptides of SEQ ID NO: 1-791 and 1514-1533 are derived from proteins expressed by cancer cells and sequences and were identified through the method of Automated High Through-put Sequencing (HTPS). Accordingly, SEQ ID NO: 792-1513 are polypeptides that comprise at least one of SEQ ID NO: 1-791 and 1514-1533.

Oligopeptides as disclosed herein may themselves be prepared by methods well known to those skilled in the art. (Grant, G. A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York).

Besides the sequences of SEQ ID NO:1-791 and 1514-1533, the proteins and polypeptides forming the immunogens of the present invention may also comprise one or more other immunogenic amino acid stretches known to be associated with cancer, and more specifically with carcinomas and melanomas, including colorectal carcinoma, ovarian carcinoma, breast carcinoma, lung carcinoma, or prostate carcinoma, and which may stimulate a CTL response whereby the immunogenic peptides associate with HLA-A1 or HLA-A11, or HLA-A2, or another class I MHC (i.e., MHC-1) molecule.

The immunogens of the present invention can be in the form of a composition of one or more of the different immunogens and wherein each immunogen is present in any desired relative abundance. Such compositions can be homogeneous or heterogeneous with respect to the individual immunogenic peptide components present therein, having only one or more than one of such peptides.

The oligopeptides and polypeptides useful in practicing the present invention may be derived by fractionation of naturally occurring proteins by methods such as protease treatment, or they may be produced by recombinant or synthetic methodologies that are well known and clear to the skilled artisan (Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). The polypeptide may comprise a recombinant or synthetic polypeptide that comprises at least one of SEQ ID NO:1-791 and 1514-1533 which sequences may also be present in multiple copies. Thus, oligopeptides and polypeptides of the present invention may have one, two, three, or more such immunogenic peptides within the amino acid sequence of said oligopeptides and polypeptides, and said immunogenic peptides, or epitopes, may be the same or may be different, or may have any number of such sequences wherein some of them are identical to each other in amino acid sequence while others within the same polypeptide sequence are different from each other and said epitopic sequences may occur in any order within said immunogenic polypeptide sequence. The location of such sequences within the sequence of a polypeptide forming an immunogen of the invention may affect relative immunogenic activity. In addition, immunogens of the present invention may comprise more than one protein comprising the amino acid sequences disclosed herein. Such polypeptides may be part of a single composition or may themselves be covalently or non-covalently linked to each other.

The immunogenic peptides disclosed herein may also be linked directly to, or through a spacer or linker to: an immunogenic carrier such as serum albumin, tetanus toxoid, keyhole limpet hemocyanin, dextran, or a recombinant virus particle; an immunogenic peptide known to stimulate a T helper cell type immune response; a cytokine such as interferon gamma or GMCSF; a targeting agent such as an antibody or receptor ligand; a stabilizing agent such as a lipid; or a conjugate of a plurality of epitopes to a branched lysine core structure, such as the so-called “multiple antigenic peptide” described in (Posneft, D. N. et al., J. Biol. Chem., 263:1719-1725, (1988)); a compound such as polyethylene glycol to increase the half life of the peptide; or additional amino acids such as a leader or secretory sequence, or a sequence employed for the purification of the mature sequence. Spacers and linkers are typically comprised of relatively small, neutral molecules, such as amino acids and which are substantially uncharged under physiological conditions. Such spacers are typically selected from the group of nonpolar or neutral polar amino acids, such as glycine, alanine, serine and other similar amino acids. Such optional spacers or linkers need not be comprised of the same residues and thus may be either homo- or hetero-oligomers. When present, such linkers will commonly be of length at least one or two, commonly 3, 4, 5, 6, and possibly as much as 10 or even up to 20 residues (in the case of amino acids). In addition, such linkers need not be composed of amino acids but any oligomeric structures will do as well so long as they provide the correct spacing so as to optimize the desired level of immunogenic activity of the immunogens of the present invention. The immunogen may therefore take any form that is capable of eliciting a CTL response.

In addition, the immunogenic peptides of the present invention may be part of an immunogenic structure via attachments other than conventional peptide bonds. Thus, any manner of attaching the peptides of the invention to an immunogen of the invention, such as an immunogenic polypeptide as disclosed herein, could provide an immunogenic structure as claimed herein. Thus, immunogens, such as proteins of the invention, are structures that contain the peptides disclosed according to the present invention but such immunogenic peptides may not necessarily be attached thereto by the conventional means of using ordinary peptide bounds. The immunogens of the present invention simply contain such peptides as part of their makeup, but how such peptides are to be combined to form the final immunogen is left to the talent and imagination of the user and is in no way restricted or limited by the disclosure contained herein.

The peptides that are naturally processed and bound to a class I MHC molecule, and which are recognized by a tumor-specific CTL, need not be the optimal peptides for stimulating a CTL response. See, for example, (Parkhurst, M. R. et al., J. Immunol., 157:2539-2548, (1996); Rosenberg, S. A. et al., Nat. Med., 4:321-327, (1998)). Thus, there can be utility in modifying a peptide, such that it more readily induces a CTL response. Generally, peptides may be modified at two types of positions. The peptides may be modified at amino acid residues that are predicted to interact with the class I MHC molecule, in which case the goal is to create a peptide that has a higher affinity for the class I MHC molecule than does the original peptide. The peptides can also be modified at amino acid residues that are predicted to interact with the T cell receptor on the CTL, in which case the goal is to create a peptide that has a higher affinity for the T cell receptor than does the original peptide. Both of these types of modifications can result in a variant peptide that is related to an original peptide, but which is better able to induce a CTL response than is the original peptide. As used herein, the term “original peptide” means an oligopeptide with the amino acid sequence selected from SEQ ID NO: 1-791 and 1514-1533.

The original peptides disclosed herein can be modified by the substitution of one or more residues at different, possibly selective, sites within the peptide chain. Such substitutions may be of a conservative nature, for example, where one amino acid is replaced by an amino acid of similar structure and characteristics, such as where a hydrophobic amino acid is replaced by another hydrophobic amino acid. Even more conservative would be replacement of amino acids of the same or similar size and chemical nature, such as where leucine is replaced by isoleucine. In studies of sequence variations in families of naturally occurring homologous proteins, certain amino acid substitutions are more often tolerated than others, and these are often show correlation with similarities in size, charge, polarity, and hydrophobicity between the original amino acid and its replacement, and such is the basis for defining “conservative substitutions.”

Conservative substitutions are herein defined as exchanges within one of the following five groups: Group 1—small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2—polar, negatively charged residues and their amides (Asp, Asn, Glu, Gln); Group 3—polar, positively charged residues (His, Arg, Lys); Group 4—large, aliphatic, nonpolar residues (Met, Leu, lie, Val, Cys); and Group 4—large, aromatic residues (Phe, Tyr, Trp).

Less conservative substitutions might involve the replacement of one amino acid by another that has similar characteristics but is somewhat different in size, such as replacement of an alanine by an isoleucine residue. Highly nonconservative replacements might involve substituting an acidic amino acid for one that is polar, or even for one that is basic in character. Such radical substitutions cannot, however, be dismissed as potentially ineffective since chemical effects are not totally predictable and radical substitutions might well give rise to serendipitous effects not otherwise predictable from simple chemical principles.

Of course, such substitutions may involve structures other than the common L-amino acids. Thus, D-amino acids might be substituted for the L-amino acids commonly found in the antigenic peptides of the invention and yet still be encompassed by the disclosure herein. In addition, amino acids possessing non-standard R groups (i.e., R groups other than those found in the common 20 amino acids of natural proteins) may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.

If substitutions at more than one position are found to result in a peptide with substantially equivalent or greater antigenic activity as defined below, then combinations of those substitutions will be tested to determine if the combined substitutions result in additive or syngeneic effects on the antigenicity of the peptide. At most, no more than 4 positions within the peptide would simultaneously be substituted.

Based on cytotoxicity assays, an epitope is considered substantially identical to the reference peptide if it has at least 10% of the antigenic activity of the reference peptide as defined by the ability of the substituted peptide to reconstitute the epitope recognized by a CTL in comparison to the reference peptide. Thus, when comparing the lytic activity in the linear portion of the effector:target curves with equimolar concentrations of the reference and substituted peptides, the observed percent specific killing of the target cells incubated with the substituted peptide should be equal to that of the reference peptide at an effector:target ratio that is no greater than 10-fold above the reference peptide effector:target ratio at which the comparison is being made.

Preferably, when the CTLs specific for a peptide of SEQ ID NO:1-791 and 1514-1533 are tested against the substituted peptides, the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1 μM, more preferably no more than about 1 nM, and still more preferably no more than about 100 μM, and most preferably no more than about 10 μM. It is also preferred that the substituted peptide be recognized by CTLs from more than one individual, at least two, and more preferably three individuals.

Thus, the epitopes of the present invention may be identical to naturally occurring tumor-associated or tumor-specific epitopes or may include epitopes that differ by no more than 4 residues from the reference peptide, as long as they have substantially identical antigenic activity.

It should be appreciated that an immunogen may consist only of a peptide of SEQ ID NO:1-791 or 1514-1533, or comprise a peptide of SEQ ID NO:1-791 or 1514-1533, or comprise a plurality of peptides selected from SEQ ID NO:1-791 and 1514-1533, or comprise a polypeptide that itself comprises one or more of the epitopic peptides of SEQ ID NO: 1-791 and 1514-1533.

The immunogenic peptides and polypeptides of the invention can be prepared synthetically, by recombinant DNA technology, or they can be isolated from natural sources such as tumor cells expressing the original protein product.

The polypeptides and oligopeptides disclosed herein can be synthesized in solution or on a solid support in accordance with conventional techniques. Various automated peptide synthesizers are commercially available and can be used in accordance with known protocols. See, for example, (Grant, G. A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York). Fragments of polypeptides of the invention can also be synthesized as intermediates in the synthesis of a larger polypeptide.

Recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide or polypeptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell, and cultivated under conditions suitable for expression. These procedures are well known in the art to the skilled artisan, as described in (Coligan, J. E. et al, Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York; Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). Thus, recombinantly produced peptides or polypeptides can be used as the immunogens of the invention.

The coding sequences for peptides of the length contemplated herein can be synthesized on commercially available automated DNA synthesizers using protocols that are well know in the art. See for example, (Grant, G. A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York). The coding sequences can also be modified such that a peptide or polypeptide will be produced that incorporates a desired amino acid substitution. The coding sequence can be provided with appropriate linkers, be ligated into suitable expression vectors that are commonly available in the art, and the resulting DNA or RNA molecule can be transformed or transfected into suitable hosts to produce the desired fusion protein. A number of such vectors and suitable host systems are available, and their selection is left to the skilled artisan. For expression of the fusion proteins, the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions, and a replication system to provide an expression vector for expression in the desired host cell. For example, promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence. The resulting expression vectors are transformed into suitable bacterial hosts. Of course, yeast, insect, and mammalian host cells may also be used, employing suitable vectors and control sequences.

Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector. The vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.

More particularly, the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above. The constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation. In a preferred aspect of this embodiment, the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vectors and promoters are known to those of skill in the art, and are commercially available.

In a further embodiment, the present invention relates to host cells containing the above-described constructs. The host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell. Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor). Such cells can routinely be utilized for assaying CTL activity by having said genetically engineered, or recombinant, host cells express the immunogenic peptides of the present invention.

Various mammalian cell culture systems can also be employed to express recombinant protein. Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines. Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5′ flanking non-transcribed sequences. DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

The polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. High performance liquid chromatography (HPLC) can be employed for final purification steps.

The immunogenic peptides of the present invention may be used to elicit CTLs ex vivo from either healthy individuals or from cancer patients with cancer, such as colorectal carcinoma, lung carcinoma, ovarian carcinoma, breast carcinoma, or prostate carcinoma. Such responses are induced by incubating in tissue culture the individual's CTL precursor lymphocytes together with a source of antigen presenting cells and the appropriate immunogenic peptide. Examples of suitable antigen presenting cells include dendritic cells, macrophages, and activated B cells. Typically, the peptide at concentrations between 10 and 40 μg/ml, would be pre-incubated with the antigen presenting cells for periods ranging from 1 to 18 hrs. β2-microglobulin (4 μg/ml) can be added during this time period to enhance binding. The antigen presenting cells may also be held at room temperature during the incubation period (Ljunggren, H.-G. et al., Nature, 346:476-480, (1990)) or pretreated with acid (Zeh, H. J., III et al., Hum. Immunol., 39:79-86, (1994)) to promote the generation of denatured class I MHC molecules which can then bind the peptide. The precursor CTLs (responders) are then added to the antigen presenting cells to which the immunogenic peptide has bound (stimulators) at responder to stimulator ratios of between 5:1 and 50:1, and most typically between 10:1 and 20:1. The co-cultivation of the cells is carried out at 37° C. in RPMI 1640, 10% fetal bovine serum, 2 mM L-glutamine, and IL-2 (5-20 Units/ml). Other cytokines, such as IL-1, IL-7, and IL-12 may also be added to the culture. Fresh IL-2-containing media is added to the cultures every 2-4 days, typically by removing one-half the old media and replenishing it with an equal volume of fresh media. After 7-10 days, and every 7-10 days thereafter, the CTL are re-stimulated with antigen presenting cells to which immunogenic peptide has been bound as described above. Fresh IL-2-containing media is added to the cells throughout their culture as described above. Three to four rounds of stimulation, and sometimes as many five to eight rounds of stimulation, are required to generate a CTL response that can then be measured in vitro. The above described protocol is illustrative only and should not be considered limiting. Many in vitro CTL stimulation protocols have been described and the choice of which one to use is well within the knowledge of the skilled artisan. The peptide-specific CTL can be further expanded to large numbers by treatment with anti-CD3 antibody. For example, see (Riddell, S. R. and Greenberg, P. D., J. Immunol. Methods, 128:189-201, (1990); Walter, E. A. et al., N. Engl. J. Med., 333:1038-1044, (1995)).

Antigen presenting cells that are to be used to stimulate a CTL response are typically incubated with peptide of an optimal length, most commonly a nonapeptide, that allows for direct binding of the peptide to the class I MHC molecule without additional processing. Larger oligopeptides and polypeptides are generally ineffective in binding to class I MHC molecules as they are not efficiently processed into an appropriately sized peptide in the extracellular milieu. There a variety of approaches that are known in the art, however, that allow oligopeptides and polypeptides to be exogenously acquired by a cell, which then allows for their subsequent processing and presentation by a class I MHC molecule. Representative, but non-limiting examples of such approaches include electroporation of the molecules into the cell (Harding, C. H. III, Eur. J. Immunol., 22:1865-1869, (1992)), encapsulation of the molecules in liposomes which are fused to the cells of interest (Reddy, R. et al., J. Immunol. Methods, 141:157-163, (1991)), or osmotic shock in which the molecules are taken up via pinocytosis (Moore, M. W. et al., Cell, 54:777-785, (1988)). Thus, oligopeptides and polypeptides that comprise one or more of the peptides of the invention can be provided to antigen presenting cells in such a fashion that they are delivered to the cytoplasm of the cell, and are subsequently processed to allow presentation of the peptides.

Antigen presenting cells suitable for stimulating an in vitro CTL response that is specific for one or more of the peptides of the invention can also be prepared by introducing polynucleotide vectors encoding the sequences into the cells. These polynucleotides can be designed such that they express only a single peptide of the invention, multiple peptides of the invention, or even a plurality of peptides of the invention. There are a variety of approaches that are known in the art, that allow polynucleotides to be introduced and expressed in a cell, thus providing one or more peptides of the invention to the class I MHC molecule binding pathway. Representative, but non-limiting examples of such approaches include the introduction of plasmid DNA through particle-mediated gene transfer or electroporation (Tuting, T. et al., J. Immunol., 160:1139-1147, (1998)), or the transduction of cells with an adenovirus expressing the polynucleotide of interest (Perez-Diez, A. et al., Cancer Res., 58:5305-5309, (1998)). Thus, oligonucleotides that code for one or more of the peptides of the invention can be provided to antigen presenting cells in such a fashion that the peptides associate with class I MHC molecules and are presented on the surface of the antigen presenting cell, and consequently are available to stimulate a CTL response.

By preparing the stimulator cells used to generate an in vitro CTL response in different ways, it is possible to control the peptide specificity of CTL response. For example, the CTLs generated with a particular peptide will necessarily be specific for that peptide Likewise, CTLs that are generated with a polypeptide or polynucleotide expressing or coding for particular peptides will be limited to specificities that recognize those peptides. More broadly, stimulator cells, and more specifically dendritic cells, can be incubated in the presence of the whole protein. As a further alternative, stimulator cells, and more specifically dendritic cells, can be transduced or transfected with RNA or DNA comprising the polynucleotide sequence encoding the protein. Under these alternative conditions, peptide epitopes that are naturally cleaved out of the protein, and which are generated in addition to peptide epitopes of SEQ ID NO:1-791 and 1514-1533 can associate with an appropriate class I MHC molecule, which may or may not include HLA-A1, -A2, or -A3. The selection of antigen presenting cells and the type of antigen with which to stimulate the CTL, is left to the ordinary skilled artisan.

In certain embodiments, the methods of the present invention include a method for inducing a CTL response in vitro that is specific for a tumor cell expressing a molecule from A1, A2, or A3 supertypes (A11 is a member of the A3 supertype), whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has bound an immunogen comprising one or more of the peptides disclosed according to the invention.

In specific embodiments, the methods of the present invention include a method for inducing a CTL response in vitro that is specific for a tumor cell expressing a molecule from A1, A2, or A3 supertypes, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has exogenously acquired an immunogenic oligopeptide or polypeptide that comprises one or more of the peptides disclosed according to the invention.

A yet additional embodiment of the present invention is directed to a process for inducing a CTL response in vitro that is specific for a tumor cell expressing a molecule from A1, A2, or A3 supertypes, comprising contacting a CTL precursor lymphocyte with an antigen presenting cell that is expressing a polynucleotide coding for a polypeptide of the invention and wherein said polynucleotide is operably linked to a promoter.

In specific embodiments, the methods of the present invention include a method for inducing a CTL response in vitro that is specific for a tumor cell expressing HLA-A1, HLA-A2, or HLA-A11, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has bound an immunogen comprising one or more of the peptides disclosed according to the invention.

In specific embodiments, the methods of the present invention include a method for inducing a CTL response in vitro that is specific for a tumor cell expressing HLA-A1, HLA-A2, or HLA-A11, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has exogenously acquired an immunogenic oligopeptide or polypeptide that comprises one or more of the peptides disclosed according to the invention.

A yet additional embodiment of the present invention is directed to a process for inducing a CTL response in vitro that is specific for a tumor cell expressing HLA-A1, HLA-A2, or HLA-A11, comprising contacting a CTL precursor lymphocyte with an antigen presenting cell that is expressing a polynucleotide coding for a polypeptide of the invention and wherein said polynucleotide is operably linked to a promoter.

A variety of techniques exist for assaying the activity of CTL. These techniques include the labeling of target cells with radionuclides such as Na251Cr04 or 3H-thymidine, and measuring the release or retention of the radionuclides from the target cells as an index of cell death. Such assays are well-known in the art and their selection is left to the skilled artisan. Alternatively, CTL are known to release a variety of cytokines when they are stimulated by an appropriate target cell, such as a tumor cell expressing the relevant class I MHC molecule and the corresponding peptide. Non-limiting examples of such cytokines include IFN-γ, TNFα, and GM-CSF. Assays for these cytokines are well known in the art, and their selection is left to the skilled artisan. Methodology for measuring both target cell death and cytokine release as a measure of CTL reactivity are given in (Coligan, J. E. et al, Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York).

After expansion of the antigen-specific CTLs, the latter are then adoptively transferred back into the patient, where they will destroy their specific target cell. The utility of such adoptive transfer is demonstrated in North, R. J. et al. (Infect. Immun., 67:2010-2012, (1999)) and Riddell, S. R. et al. (Science, 257:238-241, (1992)). In determining the amount of cells to reinfuse, the skilled physician will be guided by the total number of cells available, the activity of the CTL as measured in vitro, and the condition of the patient. Preferably, however, about 1×106 to about 1×1012, more preferably about 1×108 to about 1×1011, and even more preferably, about 1×109 to about 1×1010 peptide-specific CTL are infused. Methodology for reinfusing the T cells into a patient are well known and exemplified in U.S. Pat. No. 4,844,893 to Honski, et al., and U.S. Pat. No. 4,690,915 to Rosenberg.

The peptide-specific CTL can be purified from the stimulator cells prior to infusion into the patient. For example, monoclonal antibodies directed towards the cell surface protein CD8, present on CTL, can be used in conjunction with a variety of isolation techniques such as antibody panning, flow cytometric sorting, and magnetic bead separation to purify the peptide-specific CTL away from any remaining non-peptide specific lymphocytes or from the stimulator cells. These methods are well known in the art, and are their selection is left to the skilled artisan. It should be appreciated that generation of peptide-specific CTL in this manner, obviates the need for stimulating the CTL in the presence of tumor. Thus, there is no chance of inadvertently reintroducing tumor cells into the patient.

Thus, one embodiment of the present invention relates to a process for treating a subject with cancer characterized by tumor cells expressing complexes of a molecule from A1, A2, or A3 supertypes, for example, HLA-A1, HLA-A2, or HLA-A11, whereby CTLs produced in vitro according to the present invention are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

Another embodiment of the present invention is directed to a process for treating a subject with cancer characterized by tumor cells expressing any class I MHC molecule and an epitope of SEQ ID NO: 1-791 and 1514-1533, whereby the CTLs are produced in vitro and are specific for the epitope or original protein and are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.

In the foregoing embodiments the cancer to be treated may include a colorectal carcinoma, an ovarian carcinoma, a breast carcinoma, a lung carcinoma, and prostate carcinoma, but especially ovarian carcinoma.

The ex vivo generated CTL can be used to identify and isolate the T cell receptor molecules specific for the peptide. The genes encoding the alpha and beta chains of the T cell receptor can be cloned into an expression vector system and transferred and expressed in naive T cells from peripheral blood, T cells from lymph nodes, or T lymphocyte progenitor cells from bone marrow. These T cells, which would then be expressing a peptide-specific T cell receptor, would then have anti-tumor reactivity and could be used in adoptive therapy of cancer, and more specifically cancer, colorectal carcinoma, ovarian carcinoma, breast carcinoma, lung carcinoma, and prostate carcinoma.

In addition to their use for therapeutic or prophylactic purposes, the immunogenic peptides of the present invention are useful as screening and diagnostic agents. Thus, the immunogenic peptides of the present invention, together with modern techniques of gene screening, make it possible to screen patients for the presence of genes encoding such peptides on cells obtained by biopsy of tumors detected in such patients. The results of such screening may help determine the efficacy of proceeding with the regimen of treatment disclosed herein using the immunogens of the present invention.

Alternatively, the immunogenic peptides disclosed herein, as well as functionally similar homologs thereof, may be used to screen a sample for the presence of CTLs that specifically recognize the corresponding epitopes. The lymphocytes to be screened in this assay will normally be obtained from the peripheral blood, but lymphocytes can be obtained from other sources, including lymph nodes, spleen, tumors, and pleural fluid. The peptides of the present invention may then be used as a diagnostic tool to evaluate the efficacy of the immunotherapeutic treatments disclosed herein. Thus, the in vitro generation of CTL as described above would be used to determine if patients are likely to respond to the peptide in vivo. Similarly, the in vitro generation of CTL could be done with samples of lymphocytes obtained from the patient before and after treatment with the peptides. Successful generation of CTL in vivo should then be recognized by a correspondingly easier ability to generate peptide-specific CTL in vitro from lymphocytes obtained following treatment in comparison to those obtained before treatment.

The oligopeptides of the invention, such as SEQ ID NO: 1-791 and 1514-1533, can also be used to prepare class I MHC tetramers which can be used in conjunction with flow cytometry to quantitate the frequency of peptide-specific CTL that are present in a sample of lymphocytes from an individual. Specifically, for example, class I MHC molecules comprising peptides of SEQ ID NO: 1-791 and 1514-1533, would be combined to form tetramers as exemplified in U.S. Pat. No. 5,635,363. Said tetramers would find use in monitoring the frequency of CTLs in the peripheral blood, lymph nodes, or tumor mass of an individual undergoing immunotherapy with the peptides, proteins, or polynucleotides of the invention, and it would be expected that successful immunization would lead to an increase in the frequency of the peptide-specific CTL.

As stated above, a vaccine in accordance with the present invention may include one or more of the hereinabove described polypeptides or active fragments thereof, or a composition, or pool, of immunogenic peptides disclosed herein. When employing more than one polypeptide or active fragment, two or more polypeptides and/or active fragments may be used as a physical mixture or as a fusion of two or more polypeptides or active fragments. The fusion fragment or fusion polypeptide may be produced, for example, by recombinant techniques or by the use of appropriate linkers for fusing previously prepared polypeptides or active fragments.

The immunogenic molecules of the invention, including vaccine compositions, may be utilized according to the present invention for purposes of preventing, suppressing or treating diseases causing the expression of the immunogenic peptides disclosed herein, such as where the antigen is being expressed by tumor cells. As used in accordance with the present invention, the term “prevention” relates to a process of prophylaxis in which an animal, especially a mammal, and most especially a human, is exposed to an immunogen of the present invention prior to the induction or onset of the disease process. This could be done where an individual has a genetic pedigree indicating a predisposition toward occurrence of the disease condition to be prevented. For example, this might be true of an individual whose ancestors show a predisposition toward certain types of cancer. Alternatively, the immunogen could be administered to the general population as is frequently done for infectious diseases. Alternatively, the term “suppression” is often used to describe a condition wherein the disease process has already begun but obvious symptoms of said condition have yet to be realized. Thus, the cells of an individual may have become cancerous but no outside signs of the disease have yet been clinically recognized. In either case, the term prophylaxis can be applied to encompass both prevention and suppression. Conversely, the term “treatment” is often utilized to mean the clinical application of agents to combat an already existing condition whose clinical presentation has already been realized in a patient. This would occur where an individual has already been diagnosed as having a tumor.

It is understood that the suitable dosage of an immunogen of the present invention will depend upon the age, sex, health, and weight of the recipient, the kind of concurrent treatment, if any, the frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as determined by the researcher or clinician. The total dose required for any given treatment will commonly be determined with respect to a standard reference dose as set by a manufacturer, such as is commonly done with vaccines, such dose being administered either in a single treatment or in a series of doses, the success of which will depend on the production of a desired immunological result (i.e., successful production of a CTL-mediated response to the antigen, which response gives rise to the prevention and/or treatment desired). Thus, the overall administration schedule must be considered in determining the success of a course of treatment and not whether a single dose, given in isolation, would or would not produce the desired immunologically therapeutic result or effect.

The therapeutically effective amount of a composition containing one or more of the immunogens of this invention, is an amount sufficient to induce an effective CTL response to the antigen and to cure or arrest disease progression. Thus, this dose will depend, among other things, on the identity of the immunogens used, the nature of the disease condition, the severity of the disease condition, the extent of any need to prevent such a condition where it has not already been detected, the manner of administration dictated by the situation requiring such administration, the weight and state of health of the individual receiving such administration, and the sound judgment of the clinician or researcher. Thus, for purposes of prophylactic or therapeutic administration, effective amounts would generally lie within the range of from 1.0 μg to about 5,000 μg of peptide for a 70 kg patient, followed by boosting dosages of from about 1.0 μg to about 1,000 μg of peptide pursuant to a boosting regimen over days, weeks or even months, depending on the recipient's response and as necessitated by subsequent monitoring of CTL-mediated activity within the bloodstream. Of course, such dosages are to be considered only a general guide and, in a given situation, may greatly exceed such suggested dosage regimens where the clinician believes that the recipient's condition warrants more a aggressive administration schedule. Needless to say, the efficacy of administering additional doses, and of increasing or decreasing the interval, may be re-evaluated on a continuing basis, in view of the recipient's immunocompetence (for example, the level of CTL activity with respect to tumor-associated or tumor-specific antigens).

For such purposes, the immunogenic compositions according to the present invention may be used against a disease condition such as cancer by administration to an individual by a variety of routes. The composition may be administered parenterally or orally, and, if parenterally, either systemically or topically. Parenteral routes include subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. One or more such routes may be employed. Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time.

Generally, vaccines are prepared as injectables, in the form of aqueous solutions or suspensions. Vaccines in an oil base are also well known such as for inhaling. Solid forms which are dissolved or suspended prior to use may also be formulated. Pharmaceutical carriers, diluents and excipients are generally added that are compatible with the active ingredients and acceptable for pharmaceutical use.

Examples of such carriers include, but are not limited to, water, saline solutions, dextrose, or glycerol. Combinations of carriers may also be used. These compositions may be sterilized by conventional, well known sterilization techniques including sterile filtration. The resulting solutions may be packaged for use as is, or the aqueous solutions may be lyophilized, the lyophilized preparation being combined with sterile water before administration. Vaccine compositions may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.

The concentration of the CTL stimulatory peptides of the invention in pharmaceutical formulations are subject to wide variation, including anywhere from less than 0.01% by weight to as much as 50% or more. Factors such as volume and viscosity of the resulting composition must also be considered. The solvents, or diluents, used for such compositions include water, possibly PBS (phosphate buffered saline), or saline itself, or other possible carriers or excipients.

The immunogens of the present invention may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the immunogenicity and/or half-life of the peptides or polypeptides in serum. Liposomes include emulsions, foams, micelies, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like. Liposomes for use in the invention are formed from standard vesicle-forming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally determined by considerations such as liposome size and stability in the blood. A variety of methods are available for preparing liposomes as reviewed, for example, by (Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York) and see also U.S. Pat. Nos. 4,235,871, 4,501,728, 4,837,028, and 5,019,369.

Liposomes containing the peptides or polypeptides of the invention can be directed to the site of lymphoid cells where the liposomes then deliver the selected immunogens directly to antigen presenting cells. Targeting can be achieved by incorporating additional molecules such as proteins or polysaccharides into the outer membranes of said structures, thus resulting in the delivery of the structures to particular areas of the body, or to particular cells within a given organ or tissue. Such targeting molecules may a molecule that binds to receptor on antigen presenting cells. For example an antibody that binds to CD80 could be used to direct liposomes to dendritic cells.

The immunogens of the present invention may also be administered as solid compositions. Conventional nontoxic solid carriers including pharmaceutical grades of mannitol, lactose, starch, magnesium, cellulose, glucose, sucrose, sodium saccharin, and the like. Such solid compositions will often be administered orally, whereby a pharmaceutically acceptable nontoxic composition is formed by incorporating the peptides and polypeptides of the invention with any of the carriers listed above. Generally, such compositions will contain 10-95% active ingredient, and more preferably 25-75% active ingredient.

Aerosol administration is also an alternative, requiring only that the immunogens be properly dispersed within the aerosol propellant. Typical percentages of the peptides or polypeptides of the invention are 0.01%-20% by weight, preferably 1%-10%. The use of a surfactant to properly disperse the immunogen may be required. Representative surfactants include the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride. Mixed esters, such as mixed or natural glycerides may be employed. The surfactant may constitute 0.1-20% by weight of the composition, preferably 0.25-5%. Typical propellants for such administration may include esters and similar chemicals but are by no means limited to these. A carrier, such as lecithin for intranasal delivery, may also be included.

The peptides and polypeptides of the invention may also be delivered with an adjuvant. Adjuvants include, but are not limited to complete or incomplete Freund's adjuvant, Montanide ISA-51, Lymphocyte Activation Gene-3 (LAG-)3, aluminum phosphate, aluminum hydroxide, alum, and saponin. Adjuvant effects can also be obtained by injecting a variety of cytokines along with the immunogens of the invention. These cytokines include, but are not limited to IL-1, IL-2, IL-7, IL-12, and GM-CSF.

The peptides and polypeptides of the invention can also be added to professional antigen presenting cells such as dendritic cells that have been prepared ex vivo. For example, the dendritic cells could be prepared from CD34 positive stem cells from the bone marrow, or they could be prepared from CD14 positive monocytes obtained from the peripheral blood. The dendritic cells are generated ex vivo using cytokines such as GM-CSF, IL-3, IL-4, TNF, and SCF. The cultured DC are then pulsed with peptides at various concentrations using standard methods that are well known in the art. The peptide-pulsed dendritic cells can then be administered either intraveneously, subcutaneously, or intradermally, and the immunization may also include cytokines such as IL-2 or IL-12.

The present invention is also directed to a vaccine in which an immunogen of the present invention is delivered or administered in the form of a polynucleotide encoding the a polypeptide or active fragment as disclosed herein, whereby the peptide or polypeptide or active fragment is produced in vivo. The polynucleotide may be included in a suitable expression vector and combined with a pharmaceutically acceptable carrier. For example, the peptides or polypeptides could be expressed in plasmid DNA and nonreplicative viral vectors such as vaccinia, fowlpox, Venezuelan equine encephalitis virus, adenovirus, or other RNA or DNA viruses. These examples are meant to be illustrative only and should not be viewed as self-limiting A wide variety of other vectors are available and are apparent to those skilled in the art from the description given herein. In this approach, a portion of the nucleotide sequence of the viral vector is engineered to express the peptides or polypeptides of the invention. Vaccinia vectors and methods useful in immunization protocols are described in U.S. Pat. No. 4,722,848, the disclosure of which is incorporated herein by reference in its entirety.

Regardless of the nature of the composition given, additional therapeutic agents may also accompany the immunogens of the present invention. Thus, for purposes of treating tumors, compositions containing the immunogens disclosed herein may, in addition, contain other antitumor pharmaceuticals. The use of such compositions with multiple active ingredients is left to the discretion of the clinician.

In addition, the immunogens of the present invention can be used to stimulate the production of antibodies for use in passive immunotherapy, for use as diagnostic reagents, and for use as reagents in other processes such as affinity chromatography.

The present invention also relates to antibodies that react with immunogens, such as a polypeptide comprising one or more of the epitopic peptides of SEQ ID NO: 1-791 and 1514-1533 as disclosed herein. Active fragments of such antibodies are also specifically contemplated. Such antibodies, and active fragments of such antibodies, for example, and Fab structure, may react with, including where it is highly selective or specific for, an immunogenic structure comprising 2, 3, 4 or more of the epitopic peptides of the invention.

With the advent of methods of molecular biology and recombinant technology, it is now possible to produce antibody molecules by recombinant means and thereby generate gene sequences that code for specific amino acid sequences found in the polypeptide structure of the antibodies. Such antibodies can be produced by either cloning the gene sequences encoding the polypeptide chains of said antibodies or by direct synthesis of said polypeptide chains, with in vitro assembly of the synthesized chains to form active tetrameric (H2L2) structures with affinity for specific epitopes and antigenic determinants. This has permitted the ready production of antibodies having sequences characteristic of neutralizing antibodies from different species and sources.

Regardless of the source of the antibodies, or how they are recombinantly constructed, or how they are synthesized, in vitro or in vivo, using transgenic animals, such as cows, goats and sheep, using large cell cultures of laboratory or commercial size, in bioreactors or by direct chemical synthesis employing no living organisms at any stage of the process, all antibodies have a similar overall 3 dimensional structure.

This structure is often given as H2L2 and refers to the fact that antibodies commonly comprise 2 light (L) amino acid chains and 2 heavy (H) amino acid chains. Both chains have regions capable of interacting with a structurally complementary antigenic target. The regions interacting with the target are referred to as “variable” or “V” regions and are characterized by differences in amino acid sequence from antibodies of different antigenic specificity.

The variable regions of either H or L chains contains the amino acid sequences capable of specifically binding to antigenic targets. Within these sequences are smaller sequences dubbed “hypervariable” because of their extreme variability between antibodies of differing specificity. Such hypervariable regions are also referred to as “complementarity determining regions” or “CDR” regions. These CDR regions account for the basic specificity of the antibody for a particular antigenic determinant structure.

The CDRs represent non-contiguous stretches of amino acids within the variable regions but, regardless of species, the positional locations of these critical amino acid sequences within the variable heavy and light chain regions have been found to have similar locations within the amino acid sequences of the variable chains. The variable heavy and light chains of all antibodies each have 3 CDR regions, each non-contiguous with the others (termed L1, L2, L3, H1, H2, H3) for the respective light (L) and heavy (H) chains. The accepted CDR regions have been described in the text and figures of Kabat et al. (J. Biol. Chem. 252:6609-6616 (1977)).

In all mammalian species, antibody polypeptides contain constant (i.e., highly conserved) and variable regions, and, within the latter, there are the CDRs and the so-called “framework regions” made up of amino acid sequences within the variable region of the heavy or light chain but outside the CDRs.

The antibodies disclosed according to the invention may also be wholly synthetic, wherein the polypeptide chains of the antibodies are synthesized and, possibly, optimized for binding to the polypeptides disclosed herein as being receptors. Such antibodies may be chimeric or humanized antibodies and may be fully tetrameric in structure, or may be dimeric and comprise only a single heavy and a single light chain. Such antibodies may also include fragments, such as Fab and F(ab2)′ fragments, capable of reacting with and binding to any of the polypeptides disclosed herein as being receptors.

A further embodiment of the present invention relates to a method for inducing a CTL response in a subject comprising administering to subjects that express HLA-A1 antigens an effective (i.e., CTL-stimulating amount) of an immunogen of the invention that does not comprise the entire protein expressing the epitopic peptides disclosed herein (i.e., one that comprises less than the entire protein where the protein is a naturally occurring polypeptide) in an amount sufficient to induce a CTL response to tumor cells expressing at least HLA-A1 or HLA-A2, as the case may be, thereby eliciting a cellular response against said tumor cells. A still further embodiment of the present invention relates to a method for inducing a CTL response in a subject, wherein the immunogen is in the form of a polynucleotide. In one non-limiting example, the method comprises administering to subjects that express HLA-A1 at least one CTL epitope, wherein said epitope or epitopes are selected from a group comprising the peptides disclosed according to the invention, and are coded within a polynucleotide sequence that does not comprise the entire protein coding region, in an amount sufficient to induce a CTL response to tumor cells expressing HLA-A1 or HLA-A2.

While the below examples are provided to illustrate the invention, it is to be understood that these methods and examples in no way limit the invention to the embodiments described herein and that other embodiments and uses will no doubt suggest themselves to those skilled in the art. All publications, patents, and patent applications cited herein are hereby incorporated by reference, as are the references cited therein. It is also to be understood that throughout this disclosure where the singular is used, the plural may be inferred and vice versa and use of either is not to be considered limiting.

Example 1

Cell Lines

For HLA-A1 and HLA-A11 studies, ARGOV57, a HLA-A1/11 positive ovarian cell line, was established by culturing tumor cells from an ascitic fluid from an ovarian patient.

For HLA-A2 studies, OVCAR3, a HLA-A2 positive ovarian carcinoma cell line, was established by culturing tumor cells from an ascitic fluid from an ovarian patient.

SKOV3-A2, a HLA-A2 stably expressing ovarian carcinoma cell line, was established by culturing tumor cells from an ascitic fluid from an ovarian patient and transduced with HLA-A2 gene.

Example 2

Immunoaffinity Purification

ARGOV57 cells were grown in 10-chamber Nunc cell factories (Fisher, Pittsburgh, Pa.). The cells were harvested by treatment with 0.45% trypsin and 0.32 mM EDTA, washed two times in phosphate-buffered saline solution (pH 7.4), and stored as cell pellets at −80° C. Aliquots of 6-8×1010 cells were solubilized at 5-10×106 cells/ml in 20 mM Tris, pH 8.0, 150 mM NaCl, 1% CHAPS, 18.5 μg/ml iodoacetamide, 5 μg/ml aprotonin, 10 μg/ml leupeptin, 10 μg/ml pepstatin A, 5 mM EDTA, 0.2% sodium azide, and 17.4 μg/ml phenylmethylsulfonyl fluoride for 1 h. This and all subsequent steps were performed with ice-cold solutions and at 4° C. The lysates were then centrifuged at 100,000×g, the pellets discarded, and the supernatants passed through a 0.22 μm filter. The supernatants were then passed over a series of columns with the first containing Sepharose, and the second containing the HLA-A1-specific monoclonal antibody, GAP-A1, bound to a protein A-Sepharose matrix. The second column was then sequentially washed with 20 column volumes of 20 mM Tris, pH 8.0, 150 mM NaCl, 20 column volumes of 20 mM Tris, pH 8.0, 1.0 M NaCl, and 20 column volumes of 20 mM Tris, pH 8.0. The peptides were eluted from the column with 5 column volumes of 10% acetic acid. The isolated HLA-A1 molecules were then boiled for 5 min to further dissociate any bound peptide from the heavy chains. The peptides were then separated from the co-purifying class I heavy chain and β2-microglobulin by centrifugation on a Ultrafree-CL membrane with a nominal molecular weight cut-off of 5,000 Daltons (Millipore, Bedford, Mass.).

For a separate study, OVCAR3 or SKOV3 cells were successfully prepared using the same procedure as just described except that HLA-A2 molecules were prepared using HLA-A2 specific antibodies.

Example 3

Peptide Fractionation

The peptide extracts were fractionated by RP-HPLC (Reversed Phase-High Performance Liquid Chromatography) using an Applied Biosystems (ABI) model 140B system. The extracts were concentrated by vacuum centrifugation from about 20 ml down to 250 μl and injected into either a Brownlee (Norwalk, Conn.) C18 Aquapore column (2.1 mm×3 cm; 300 Å; 7 μm) or a Higgins (Mountain View, Calif.) C18 Haisil column (2.1 mm×4 cm; 300 Å; 5 μm). The peptides were eluted by first using a gradient of acetonitrile/0.085% TFA (trifluoroacetic acid) in 0.1% TFA/water, with the concentration of acetonitrile increasing from 0-9% (0-5 minutes), 9-36% (5-55 minutes), and 36-60% (55-62 minutes). A second dimension fractionation of combined fractions 17 and 18 from the first dimension (TFA) fraction was accomplished using the same gradient but with the substitution of HFBA (heptafluorobutyric acid) for TFA. The flow rate was 200 μl/min, and fractions were collected at 1 min (Brownlee column) or 40 second (Higgins column) intervals. A third dimension of RP-HPLC was achieved using an Eldex (Napa, Calif.) MicroPro Pump, a homemade C18 microcapillary column, and an ABI model 785A UV absorbance detector. The column was prepared by packing a 27 cm bed of 10 μm C18 particles in a section of 285 μm o.d./75 μm i.d. fused silica (Polymicro Technologies, Phoenix, Ariz.). Peptides in combined fractions 26 and 27 of the second dimension fraction were loaded onto this column and eluted with a gradient of acetonitrile/0.67% triethylamine acetate/water in 0.1% triethylamine acetate/water, with the concentration of acetonitrile increasing from 0-60% in 40 minutes. The flow rate was about 300 nl/min, and fractions were collected into 25 μl of water every 30 s. In all RP-HPLC experiments, peptides were detected by monitoring UV absorbance at 214 nm.

Example 4

Mass Spectrometric Analysis

The second dimension HPLC fraction was analyzed using an affluent splitter on the microcapillary HPLC column. In this experiment, the column (360 μm o.d. X 100 μm i.d. with a 25 cm C18 bed) was butt connected with a zero dead volume tee (Valco, Houston, Tex.) to two pieces of fused silica of different lengths (25 μm and 40 μm i.d.). Peptides were eluted with a 34 min gradient of 0-60% acetonitrile. The 25 μm capillary deposited one-fifth of the HPLC effluent into the wells of a microtiter plate for use in CTL epitope reconstitution assays, whereas the remaining four-fifths of the effluent was directed into the mass spectrometer. Ions were formed by electrospray ionization, and mass spectra were recorded by scanning between mass to charge ratios (m/z) 300 and 1400 every 1.5 seconds. Peptide sequences were determined by CAD (collision-activated dissociation) tandem mass spectrometry as described in the literature (Hunt, D. F. et al., Proc. Natl. Acad. Sci. U.S.A, 83:6233-6237, (1986)).

Example 5

Homology Searches of Identified Peptide Sequences

Proteins containing peptides corresponding to the masses identified by MS were analyzed with the search algorithm, SEQUEST. Searches were also carried out on the GenBank non-redundant sequence database (http://ncbi.nlm.nih.-gov/Entrez/) as well as on our own unique database of 2943 specific sequences compiled from GenBank and EST data-base entries. Upon experimental confirmation of the peptide sequence, a tBLASTn search of the GenBank non-redundant database was performed to identify any genes containing the DNA sequence encoding the peptide.

Example 6

Peptide Synthesis

Peptides were synthesized using a Gilson (Madison, Wis.) AMS 422 multiple peptide synthesizer. Quantities of 10 μMol were synthesized using conventional FMOC amino acids, resins, and chemical techniques. Peptides were purified by RP-HPLC using a 4.6 mm×100 mm POROS (Perseptive Biosystems, Cambridge, Mass.) column and a 10 min, 0-60% acetonitrile in 0.1% TFA gradient.

Example 7

Generation of Monocyte-Derived DC and Peptide Loading

PBMC were purified from HLA-A2+ normal donor blood using lymphocyte separation media (Cappel ICN Biomedical, Aurora, Ohio). PBMC (5.3×106) were added to individual wells of a 24-well cluster plate (Costar, Corning, N.Y.) in 1.0 ml of serum-free AIM-V medium (Life Technologies) and allowed to adhere for 60 min at 37° C. Non-adherent cells were removed and saved as a source of effector T cells. Adherent PBMC (−8.3×105/well) were then pulsed with 50 mg/ml synthetic peptides in serum-free AIM-V medium containing 1.5 mg/ml β2-microg lobulin (Calbiochem-Novabiochem, San Diego, Calif.) and incubated for 2 h at 37° C. Unbound peptides were aspirated and the wells washed with media.

Monocyte-derived DC were generated as follows. PBMC (5.3×107) were allowed to adhere in T-75 flasks (Corning) in 10 ml of serum-free AIM-V medium for 60 min at 37° C. Non-adherent cells were collected as a source of effector T cells and pooled with the previous collection above. Adherent monocytes in flasks were then exposed to recombinant human granulocyte macrophage colony stimulating factor (GM-CSF, 25 ng/ml; Peprotech) and recombinant human IL-4 (100 ng/ml; Peprotech) in 10 ml of AIM-V medium containing 10% heat-inactivated FBS. DC obtained by this method [immature DC (iDC)] are characterized by expression of low levels of CD83, CD80, CD86, and HLA class I and class II molecules (data not shown).

Mature DC (mDC) were obtained by exposing day 5 DC cultures to recombinant soluble CD40 ligand (sCD40L; Peprotech) at 1.5 mg/ml for 24 h in the presence of 25 ng/ml GM-CSF and are characterized by expression of high levels of CD80, CD86, and HLA class I and class II molecules. mDC were harvested, washed, pulsed with 5 mg/ml peptide in serum-free AIM-V medium and irradiated (5000 rad) prior to use as stimulators.

Example 8

Generation of Peptide-Specific CTL

The protocol used here is a modification of the method described by Plebanski et al. (Eur. J. Immunol. 25:1783, (1995)). CTL to peptide were generated by 3±4 cycles of stimulation with peptide-loaded APC. For the first round of stimulation (day 0), T cells or non-adherent PBMC from above (2.3×106/ml or 4.3×106 per well) were added in bulk (CD4+, CD8+, NK, etc.) to adherent PBMC-loaded peptides in serum-free medium (50 mg/ml), β2-microglobulin (1.5 mg/ml) (Calbiochem-Novabiochem), recombinant human IL-7 (5 ng/ml) (Peprotech) and keyhole limpet hemocyanin (5 mg/ml) (Sigma, St Louis, Mo.). Cultures were re-stimulated with iDC every 7 days, pulsed with varying amounts of peptide (second round 25 mg/ml, third round 10 mg/ml) and irradiated (5000 rad) on day 8. At each re-stimulation, the T cells were transferred to new plates by first aspirating 70% of spent media in wells and then transferring the pooled contents to a new plate. Fresh IL-7 was added at each re-stimulation. The responder:stimulator (T cell:DC) ratio was set at 20 for each stimulation. Recombinant human IL-2 (10 U/ml) was added on day 5 after each re-stimulation.

Prior to 51Cr-release assay, the T cells were harvested and CD8+T cells were purified by positive selection using CD8+ microbeads immunomagnetic cell separation with MACS kit (Miltenyi Biotec, Auburn, Calif.). If a fourth round of stimulation was necessary following CTL analysis, the CTL were pulsed as before, except with 5±10 mg/ml of peptide.

Example 9

Generation of Allospecific CTL

HLA-A2-allospecific CTL were obtained in a mixed lymphocyte reaction by repeated stimulation of HLA-A3+PBMC (responders) with irradiated HLA-A2+ stimulator PBMC at a ratio of 10:1 in the presence of 10 U/ml IL-2. Stimulation was repeated weekly with PBMC from different HLA-A2+ donors so as to minimize alloresponse to non-HLA-A2 antigens. T cells were assessed for lysis on several HLA-A2+ targets including tumor cells, EBV-B cells and HLA-A3+ targets every week after the third round of stimulation.

Example 10

CTL Expansion

Expansion of large numbers of peptide-specific or HLA-A2-allospecific CTL was achieved by culturing 5.3×104±1.3×105 T cells around day 6 or 7 post peptide- or allostimulation in the presence of 2.5-3.0×107 irradiated (5000 rad) allogeneic normal donor PBMC coated with anti-CD3 antibody at 10 ng/ml (BD PharMingen, San Diego, Calif.) and 25 U/ml of recombinant human IL-2 (Peprotech) in a final volume of 30 ml RPMI medium. Media changes with IL-2 addition (50 U/ml) were effected on days 5 and 8. Cells were harvested for cytotoxicity assays on days 10±12 and re-stimulated or frozen for later use.

Example 11

51Cr-Release Cytotoxicity Assay

The standard 4-h Cr-release assay was performed in 96-well V-bottomed microplates. Target cells in suspension (T2, C1R.A2, B-LCL and K562) were labeled with 100 mCi Na251CrO4 (NEN Life Science, Boston, Mass.) per 1.3×106 cells either overnight (˜6±18 h) in 5 ml RPMI 1640 media containing 2±5% FBS or for 60±90 min at 37° C. directly with the cell pellet in the case of adherent cells (tumor cell lines and control lines). Labeling was terminated by washing the targets with cold media containing 5% FBS for a total of three washes. Target cells were resuspended at a concentration of 2−3×104/ml. About 2−3×103 targets in 100 ml were delivered to each well containing CTL (effectors) seeded at different E:T ratios. Spontaneous release wells contained targets in media alone, while maximal release wells contained targets in 2% NP-40 detergent (Igepal CA-630; Sigma). HLA restriction of CTL-mediated killing was achieved by preincubation of targets with HLA-specific antibodies prior to incubation with CTL.

The plate was gently spun for 1±2 min and incubated at 37° C. for 4 h. For harvesting assay plates, 100 ml of supernatants from the wells was transferred to counting tubes (USA Scientific) and g counts were determined in a g counter (ICN Micromedic Systems, Huntsville, Ala.). Cytolytic activity of T cells was expressed in percent specific lysis as follows: specific lysis={[experimental release (c.p.m.)±spontaneous release (c.p.m.)]/[maximal release (c.p.m.)±spontaneous release (c.p.m.)]}.

Example 12

Competitive Inhibition Assay

Peptide-stimulated CTL were reacted with 51Cr-labeled Ov2 tumor cells (E:T ratio of 40) in the presence of excess of cold targets in a 4-h Cr-release assay. Cold targets were either empty T2 cells, T2 cells pulsed with 1 mg/ml relevant peptide (used to stimulate CTL) or irrelevant (control) peptides (HER-2/neu 369±377 or MART 127±35), or IFN-γ pre-treated tumor cells (SKOV3.A2 and OVCAR 3) with the cold target in 5-fold excess of the hot target. Results indicate that (i) CTL show specific interaction with the peptide to which they are sensitized to, and (ii) CTL compete for similar epitopes presented on Ov2 as were found in SKOV3.A2 and OVCAR3 cell lines by MS.

TABLE 2
Description of Fragments, Parent Sequence Identification and Parent
SwissProt Identification Number for peptides 1-791 and 1514-1533
Parent
SEQSwissProt
IDIdentification
NO:FragmentParent Sequence IdentificationNo.
1AEAEFYRQVBCL-6 corepressor long isoformQ6W2J9
2IYNGDMEKIE1B_19K/Bcl-2-interacting proteinQ12983
Nip3
3KEFDGKSLVSimilar to Heat shock protein HSPP08238
90-beta (HSP 84)(HSP 90)
4HIPAGTLVQVCytochrome P450 11B2,P19099
mitochondrial precursor
5SLAEGLRTV2′-5′oligoadenylate synthetase 3Q2HJ14
6YLGDGPKLV26S protease regulatory subunit 4P62191
(P26s4)
7YLASLIRSV26S proteasome non-ATPaseP51665
regulatory subunit 7
8FVDDYTVRV26S proteasome non-ATPaseO00487
regulatory subunit 14
9KLLEPVLLL40S ribosomal protein S16P62249
10KLIEVDDERKL40S ribosomal protein S6P62753
(Phosphoprotein NP33)
11RLFEGNALL40S ribosomal protein S9P46781
12TLYEAVREV60S ribosomal protein L10a (CSA-P62906
19)
13NMVAKVDEV60S ribosomal protein L10a (CSA-P62906
19)
14SLIKQIPRI60S ribosomal protein L10a (CSAP62906
19)
15FLSEEGGHVAV6-phosphofructo-2-kinase/fructose-Q16877
2,6-biphosphatase 4 (6PF-2-K/Fru-
2,6-P2ASE testis-type isozyme)
16IETINFHEVCleavage and polyadenylationQ9UKF6
specificity factor, 73 kDa subunit
(CPSF 73 kDa subunit)
17YLNDLIHSVA kinase anchor protein 10,O43572
mitochondrial precursor
18RVAPEEHPVLActin, cytoplasmic 1 (Beta-actin)P60709
19DVLKIPVQLVActivated T-cell marker CD109Q6YHK3
20LSDFLKANVActivin receptor type 2A precursorP27037
(EC 2.7.11.30)
21DLCFEKVNVADAM19 proteinQ8TBU7
22KLHDINAQLAP-1 complex subunit beta-1Q10567
(Adapter-related protein complex 1
beta-1 subunit)(Beta-adaptin 1)
23GNGAPDVFQTAdaptor-related protein NF01019537Q9BYI8
24IDAIRIPVLLung alpha/beta hydrolase protein 1Q96SE0
25FIASKGVKLVAlpha-actinin-3Q08043
26HRPDLIDYAlpha-actinin-3Q08043
27SPQGLELALPSAnkyrin-2 (Brain ankyrin)(Ankyrin-Q01484
B)
28KIVKRPSLQFLAnkyrin repeat and SOCS boxQ8WXJ9
protein 17
29TLVTVSAAKTAnti-colorectal carcinoma heavyQ65ZQ1
chain
30KVLDGSPIEVAPOBEC1 complementation factorQ9NQ94
(APOBEC1-stimulating protein)
31FLAEHPNVTLProbable DNA dC->dU-editingQ96AK3
enzyme APOBEC-3D (EC 3.5.4.-)
32NLVQDSLDLApolipoprotein L4 precursorQ9BPW4
(Apolipoprotein L-IV)
33ISENEKLQKApoptosis stimulating of p53 proteinQ96KQ4
1
34VLAARNPAKVNucleoporin 188 kDa (arachin)Q5SRE5
35RYFDGNLEKLProtein ariadne-1 homolog (ARI-1)Q9Y4X5
(Ubiquitin-conjugating enzyme E2-
binding protein 1)
36TLADVLYHVSet1/Ash2 histone methyltransferaseQ9UBL3
complex subunit ASH2 (ASH2-like
protein)
37LPSPKPMKMKNATP synthase F0 subunit 8Q85KZ3
38ISSMLVLFFSplice isoform 2 of Q9H7F0Q9H7F0
ATPase_family_homolog_up-
regulated_in_senescence_cells
39SPDEGALVRAProbable phospholipid-transportingQ9Y2Q0
ATPase IA (EC 3.6.3.1)(Chromaffin
granule ATPase II)
40ILLTTLIPYATP-binding cassette A10Q8WWZ4
41NLEQQETEPATP-binding cassette sub-family AQ9BZC7
member 2 (ATP-binding cassette
transporter 2)(ATP-binding cassette
2)
42RKVLYVMELAutoantigen RCD8Q6P2E9
43EAIPARKLKxonemal dynein heavy chain 8Q96JB1
44SLRLENITVButyrophilin-like protein 8 precursorQ6UX41
45SYVLKKAQVUbiquitin carboxyl-terminalQ9Y2K6
hydrolase 20 (EC 3.1.2.15)
46KLIHPKLEYBardet-Biedl syndrome 7 proteinQ8IWZ6
(BBS2-like protein 1)
47EFDQLDQENLarge proline-rich protein BAT2P48634
(HLA-B-associated transcript 2)
48TVLLRLGDELBcl-2 related ovarian killer
49LFEILIEQILipopolysaccharide-responsive andP50851
beige-like anchor protein (CDC4-like
protein)
50KLELDETGQESplice isoform 3 of P35612P35612-3
51LAIGAFTLLLUDP-GlcNAc: betaGal beta-1,3-N-Q9Y2A9
acetylglucosaminyltransferase 3 (EC
2.4.1.-)
52QILLDETLKCell growth inhibiting protein 39Q2TTR2
53DECITNLLVBH3-interacting domain deathP55957
agonist (BID)
54TVVSGSNVTLNCD48 antigen precursor (B-P09326
lymphocyte activation marker
BLAST-1)
55SLDERPVAVBone morphogenetic protein receptorQ13873
type-2 precursor (EC 2.7.11.30)
56MVDSQQKSPBullous pemphigoid antigen 1,Q8WXK8
isoform 7
57SLLLLPEKNBRCA1 associated RING domain 1Q53F80
variant
58VLCVSDIISLBreast cancer type 2 susceptibilityP51587
protein (Fanconi anemia group D1
protein)
59FLPDPSALQNLProtein BRE (Brain and reproductiveQ9NXR7
organ-expressed protein)
(BRCA1/BRCA2-containing
complex subunit 45)
60MLNEHDFEVBreast cancer 1 early onsetQ3LRJ0
61VNTDFSPYLBreast cancer 1 early onsetQ3LRJ0
62EFMLVYKFARBreast and ovarian cancerQ7KYU6
susceptibility protein
63TLWVDPYEVBTG2 protein (NGF-inducible anti-P78543
proliferative protein PC3)
64FLDHIIASVNuclear protein 5qNCAQ7LBC6
65TLNDREYQLCAD protein [Includes: Glutamine-P27708
dependent carbamoyl-phosphate
synthase (EC 6.3.5.5); Aspartate
carbamoyltransferase (EC 2.1.3.2);
Dihydroorotase (EC 3.5.2.3)]
66VEVMVNDVNCadherin EGF LAG seven-pass G-Q9NYQ7
type receptor 3 precursor (Flamingo
homolog 1)(hFmi1)(Multiple
epidermal growth factor-like domains
2)(Epidermal growth factor-like 1)
67LSIYLSIYLCadherin FIB3Q6UW70
68SLSMVNHRLIntegrin alpha-3 precursorP26006
(Galactoprotein B3)
Calcineurin B homologous protein 2
69RVDFPGFVR(Hepatocellular carcinoma-O43745
associated antigen 520)
70MTDKAPPGVCalcium/calmodulin-dependentQ7Z7J9
protein kinase II inhibitor alpha
(CaMKIINalpha)
71WTNPQFKICalpain-11 (EC 3.4.22.-)Q9UMQ6
72IMAQLPQEQKAAlpha-1 catenin (Cadherin-associatedP35221
protein)(Alpha E-catenin)
73KIDPLEVEENeural cell adhesion molecule variant Q59FY0
74KLPEKWESVRibosomal L1 domain-containingO76021
protein 1 (Cellular senescence-
inhibited gene protein)
75LIEKEKVLNCENP-F kinetochore proteinP49454
(Centromere protein F)(Mitosin)
76FEVKEDQVKCentaurin-delta 1 (Cnt-d1)(Ad-Q8WZ64
GAP, Rho-GAP, ankyrin repeat and
pleckstrin homology domain-
containing protein 2)
77DTEAEKSQVCentrosomal protein 2 (CentrosomalQ9BV73
Nek2-associated protein 1)(C-NAP1)
78FLKEHMDEVPericentriol material 1Q15154
79KLLGELHTLPericentriol material 1Q15154
80TLVEAFPTLCervical cancer suppressor gene 5Q8NFX8
81QSNKGFVVINT-complex protein 1 subunit zeta-2Q92526
82LADGALIYRChemokine-like factor (C32)Q9UBR5
83GLGAEIEIRVacuolar protein sorting 13AQ96RL7
84GKLILLDKLChromodomain-helicase-DNA-O14647
binding protein 2 (EC 3.6.1.-)
85PQTICRKPFERM domain-containing protein 6Q96NE9
86RSYYLNEIPutative protein C21orf56Q9H0A9
87TTITVSPFYAdiponutrin (iPLA2-epsilon)Q9NST1
88RLPDDDPTAVCoatomer subunit gamma-2Q9UBF2
89LVAISTVSFSISodium/potassium/calciumQ9UI40
exchanger 2 precursor
90VLIDYQRNVExportin-1 (Chromosome region014980
maintenance 1 protein homolog)
91SILNEGGIKCUB and sushi domain-containingQ7Z407
protein 3 precursor
92YMADRLLGVCullin-7 (CUL-7)Q14999
93YLKDLIEEVCyclic AMP-dependent transcriptionP18848
factor ATF-4
94YLDIKGLLDS-phase kinase-associated protein 1AP63208
(Cyclin A/CDK2-associated protein
p19)
95PCLSELHKACyclin-A1P78396
96TVLDFGVLASICyclin M3, isoform 1Q8NE01
97MPSETPQAECystathionine beta-synthase humanQ58H57
homolog of Cynomolgus monkey
gene product
98FLLEALRKTCytochrome P450 2E1 (ECP05181
1.14.14.1)
99KMLETKWSLKeratin, type II cytoskeletal 8P05787
100QPLLKQSPWCPEB2 proteinQ3B 8N6
101YLLPAIVHIProbable ATP-dependent RNAP17844
helicase DDX5 (EC 3.6.1.-)
102KLLPGDIHQIDedicator of cytokinesis protein 1Q14185
103SLLKGDLKGVDevelopment and differentiation-O43150
enhancing factor 2
104NAEVLLVSEIProbable ubiquitin carboxyl-terminalO00507
hydrolase FAF-Y (EC 3.1.2.15)
105RLWGEPVNLProbable ubiquitin carboxyl-terminalO00507
hydrolase FAF-Y (EC 3.1.2.15)
106QLIDLSSPLIG2 and S phase expressed protein 1Q9NYZ3
107YIDYTGAAYAHUMAN CDNA FLJ30829 fis, cloneQ96NI3
FEBRA2001790, highly similar to
Xenopus laevis RRM-containing
protein SEB-4 mRNA
108VIENKSDEKVIKIAA1799 proteinQ96B95
109PSPQLWTVPeroxisomal proliferator-activatedQ9BYK8
receptor A-interacting complex 285
kDa protein (EC 3.6.1.-)(ATP-
dependent helicase PRIC285)
110EGRGGLPAGLPVHUMAN KIAA1922Q96PW6
111NMYGKVVTVTranscription elongation factor SPT5O00267
(DLC-1)(deleted in liver cancer-1)
112RLYDGLFKVDNA damage-binding protein 1Q16531
(Damage-specific DNA-binding
protein 1)
113QNFVDSKEVDNA excision repair protein ERCC-6Q03468
114ALIEKLVELDNA polymerase alpha subunit BQ14181
(DNA polymerase alpha 70 kDa
subunit)
115VIEDDVNMAIRDNA replication licensing factorP49736
MCM2 (Minichromosome
maintenance protein 2 homolog)
116SQDEIKQEVDNA2-like homolog (EC 3.6.1.-)P51530
(DNA replication ATP-dependent
helicase-like homolog)
117HLNGSCHLLIEstrogen response element bindingO77798
protein (cotton-top Tarmarin),
118ALIDRMVNLDNA2-like homolog (human)P35638
DNA damage-inducible transcript 3
(DDIT-3)(Growth arrest and DNA-
damage-inducible protein GADD153)
119SQKIQEAVKADNA-directed RNA polymerase IO95602
largest subunit (EC 2.7.7.6)
120LFDLVEEVQDnaJ homolog subfamily C memberQ96KC8
1
121LLAALLLDPSplice isoform 2 of P35462P35462-2
122FLDESRSTQYMRuvB-like 2 (EC 3.6.1.-)(48-kDaQ9Y230
TATA box-binding protein-
interacting protein)
123VLLGKVYVVDRE1_proteinQ9NXT9
124TIDELKEQVDynactin-1 (150 kDa dynein-Q14203
associated polypeptide)
125NLAYENVKEDynein heavy chain, cytosolicQ14204
(DYHC)
126SEVEQYVKYDynein heavy chain, cytosolicQ14204
(DYHC)
127ETQLTYRREchinoderm microtubule associatedQ6UYC9
protein-like 5
128IKDDLEDLIECT2 protein (Epithelial cell-Q9H8V3
transforming sequence 2 oncogene)
129QVLGKIERAEndothelial differentiation-related060869
factor 1 (EDF-1)
130IQINLQRKMDevelopmentally-regulatedO43854
endothelial cell locus 1 protein)
131KLIEKLDIKLElongation factor 2 (EF-2)P13639
132YLNEIKDSVElongation factor 2 (EF-2)P13639
133YLAEKYEWDVElongation factor 2 (EF-2)P13639
134VFEESQVAGTElongation factor 2 (EF-2)P13639
135DAQKEIVRAQKJ domain protein C21orf55Q9NX36
136DLEETVFTASJ domain protein C21orf55Q9NX36
137AMLEGGVDGLLEMILIN-3 precursor (EMILIN-5)Q9NT22
(Elastin microfibril interface-located
protein 5)
138RKADEKRIRSynaptotagmin-like protein 4Q96C24
(Exophilin-2)
139ALQEMVHQVEnhancer of filamentation 1 (HEF1)Q14511
140ILAINKPQNKEnhancer of filamentation 1 (HEF1)Q14511
141SMYGVDLHHABand 4.1-like protein 3 (4.1B)Q9Y2J2
(Differentially expressed in
adenocarcinoma of the lung protein
1)(DAL-1)
142SEDITRYYLBand 4.1-like protein 3 (4.1B)Q9Y2J2
(Differentially expressed in
adenocarcinoma of the lung protein
1)(DAL-1)
143NQQEQEDLEEpidermal growth factor receptorP42566
substrate 15
144SKEEDPFNVEpidermal growth factor receptorP42566
substrate 15
145FLDKQGFYVEpidermal growth factor receptorP42566
substrate 15 (Protein Eps15)(AF-1p
protein)
146TGALIYAIHAEpithelial membrane protein 3 (EMP-P54852
3)(YMP protein)
147AVQVLMVLSLEpithelial membrane protein 3 (EMP-P54852
3)(YMP protein)
148TLKEVEELEQLZyxin (Zyxin-2)Q15942
149VLMTEDIKLEukaryotic translation initiationQ04637
factor 4 gamma 1
150FEKKQKEMDEukaryotic translation initiationQ04637
factor 4 gamma 1
151ELQALYALQALEukaryotic translation initiationQ04637
factor 4 gamma 1
152WSNKYDPPLF-actin capping protein beta subunitP47756
153NLSDLIDLVF-actin capping protein beta subunitP47756
154FLSHKLDIKProtocadherin Fat 2 precursor (hFat2)Q9NYQ8
(Multiple epidermal growth factor-
like domains 1)
155VEPALRKPPProtocadherin Fat 2 precursor (hFat2)Q9NYQ8
(Multiple epidermal growth factor-
like domains 1)
156QVVYSLPDSAProtocadherin Fat 2 precursor (hFat2)Q9NYQ8
(Multiple epidermal growth factor-
like domains 1)
157EKISSYQLKProtocadherin Fat 2 precursor (hFat2)Q9NYQ8
(Multiple epidermal growth factor-
like domains 1)
158FMDPQKMPYLKIAA1752 proteinQ9C0B1
159VTNRARASKDFc alpha/mu receptorQ8WWV6
160SMNLTISAGPFc alpha/mu receptorQ8WWV6
161VTYLQNGKGRLow affinity immunoglobulin gammaP08637
Fc region receptor III-A precursor
(IgG Fc receptor 111-2)
162ELLKTARSSKFYVE, RhoGEF and PH domain-Q7Z6J4
containing protein 2 (Zinc finger
FYVE domain-containing protein 4)
163LKEYIQKLPFYVE, RhoGEF and PH domain-Q7Z6J4
containing protein 2 (Zinc finger
FYVE domain-containing protein 4)
164YLNKLLITRFibroblast growth factor receptor-likeQ8N441
1 precursor (FGF receptor-like
protein 1)
165IARPVGSSVRFibroblast growth factor receptor-likeQ8N441
1 precursor (FGF receptor-like
protein 1)
166QCPVEGDPPPLFibroblast growth factor receptor-likeQ8N441
1 precursor (FGF receptor-like
protein 1)
167TEDNVMKIAFibroblast growth factor receptor 4P22455
precursor (EC 2.7.10.1)
168YLLDVLERSFibroblast growth factor receptor 4P22455
precursor (EC 2.7.10.1)
169TASPDYLEIFibroblast growth factor receptor 2P21802
precursor (EC 2.7.10.1)(FGFR-2)
170TENNVMKIAFibroblast growth factor receptor 2P21802
precursor (EC 2.7.10.1)(FGFR-2)
171ETFKQIDMDNDFK506-binding protein 7 precursorQ9Y680
(EC 5.2.1.8)
172GLLELIEEPGlomulin (FKBP-associated protein)Q92990
(FK506-binding protein-associated
protein)
173FVEEVIDNKGlomulin (FKBP-associated protein)Q92990
(FK506-binding protein-associated
protein)
174LQLYINKLDGlomulin (FKBP-associated protein)Q92990
(FK506-binding protein-associated
protein)
175EQSLETTKVFKSG73Q9BWW1
176VFNDELPASIFlavin containing monooxygenase 3Q53FVV5
isoform 2 variant
177SLFPGKLEVProtein flightless-1 homologQ13045
178QKKLVDTIEGuanylate-binding protein 4Q96PP9
179DVGKDQEFTVFilamin-A (Alpha-filamin)(Filamin-P21333
1)(Endothelial actin-binding protein)
180YLLKDKGEYTLFilamin-A (Alpha-filamin)(Filamin-P21333
1)(Endothelial actin-binding protein)
181KTTDDIVKVFLJ10101 proteinQ8WU94
182IEQERLERCDNA FLJ14503 fis, cloneQ96T17
NT2RM1000252, weakly similar to
H. sapiens E-MAP-115 mRNA
183KINSAPSSPIKE2F8 proteinQ5BKY4
184NNDICLDEVHuman Hypothetical proteinQ2VPJ3
185VFAEVGCSPCHUMAN CDNA FLJ34154 fis, cloneQ8NB70
FCBBF3013058
186NIVETVLDLHypothetical protein FLJ43654Q6ZUJ4
(Hypothetical protein C3orf62)
187IYIDGVQEVFHUMAN CDNA FLJ46180 fis, cloneQ6ZRQ5
TESTI4004031
188KIMTEKELLAVFlotillin-2 (Epidermal surfaceQ14254
antigen)(ESA)
189VEAQEILRFlotillin-2 (Epidermal surfaceQ14254
antigen)(ESA)
190MLLDFIQHISerine/threonine-protein kinase ATRQ13535
(EC 2.7.11.1)(Ataxia telangiectasia
and Rad3-related protein)(FRAP-
related protein 1)
191SLLESVQKLSerine/threonine-protein kinase ATRQ13535
(EC 2.7.11.1)(Ataxia telangiectasia
and Rad3-related protein)(FRAP-
related protein 1)
192YLQPKLLGISerine/threonine-protein kinase ATRQ13535
(EC 2.7.11.1)(Ataxia telangiectasia
and Rad3-related protein)(FRAP-
related protein 1)
193YLLVGTLFLLFrizzled 5 precursor (Frizzled-5)Q13467
194MAAGDYPEAFrizzled 5 precursor (Frizzled-5)Q13467
195LYLLVGTLFLFrizzled 5 precursor (Frizzled-5)Q13467
196ALSDHHVYLFructose-bisphosphate aldolase CP09972
(EC 4.1.2.13)
197YLAPHVRTLG protein pathway suppressor 1Q53HS2
isoform 1 variant
198YLQNWSHVLG protein pathway suppressor 1Q53HS2
isoform 1 variant
199FAALMLLGLVKiSS-1 receptor (KiSS-1R)Q969F8
(Kisspeptins receptor)(Metastin
receptor)(G-protein coupled receptor
54)
200MINLAVFDLProbable G-protein coupled receptorQ9Y2T6
55
201EASALAVAPSAKProbable G-protein5 coupled receptorQ9HC97
35
202TFVLTIILVG-protein coupled receptor family CQ9NQ84
group 5 member C precursor
(Retinoic acid-induced gene 3
protein)
203FLLDFEEDLLeucine-rich repeat-containing G-O75473
protein coupled receptor 5 precursor
(Orphan G-protein coupled receptor
HG38)(G-protein coupled receptor
49)(G-protein coupled receptor 67)
204FAMDSYGTSNProbable G-protein coupled receptorQ6QNK2
133 precursor (G-protein coupled
receptor PGR25)
205MELSEPIVENG1 to S phase transition protein 1P15170
homolog (GTP-binding protein
GST1-HS)
206WLENALGKLGamma-aminobutyric-acid receptorQ16445
alpha-6 subunit precursor (GABA(A)
receptor)
207KILEHDDVSYLGanglioside-induced differentiation-Q96MZ0
associated protein 1-like 1 (GDAP1-
L1)
208SQQNTDNLVGap junction alpha-5 proteinP36382
(Connexin-40)(Cx40)
209SKLCEETPIGEM-interacting protein (GMIP)Q9P107
210QLVVELKDIGolgin subfamily B member 1Q14789
(Giantin)
211VFDIFQFAKUDP-N-acetylhexosamineQ16222
pyrophosphorylase (Antigen X)
212NIANHFFTVUDP-N-acetylhexosamineQ16222
pyrophosphorylase (Antigen X)
213HLIHEVTKVNeutral alpha-glucosidase ABQ14697
precursor (EC 3.2.1.84)
214FLDPNNIPKAProbable dolichyl pyrophosphateQ9BVK2
Glc1Man9G1cNAc2 alpha-1,3-
glucosyltransferase (EC 2.4.1.-)
215KINEAVECLLSLBifunctional aminoacyl-tRNAP07814
synthetase [Includes: Glutamyl-tRNA
synthetase (EC 6.1.1.17)(Glutamate-
-tRNA ligase); Prolyl-tRNA
synthetase (EC 6.1.1.15)(Proline--
tRNA ligase)]
216LLQTPKLLLGlycoprotein nmb-like proteinQ8IXJ5
217VLLYSVVVVProlactin-releasing peptide receptorP49683
(PrRP receptor)(PrRPR)(G-protein
coupled receptor 10)
218KFKQCKLLQG protein-coupled receptor 112Q5EGP2
219DVLSTSSAISLG protein-coupled receptor 112Q5EGP2
220YIDDHSWTLGrowth factor receptor-bound proteinQ14449
14 (GRB14 adapter protein)
221SLYEENNKLGRIP and coiled-coil domain-Q8IWJ2
containing protein 2 (Golgi coiled
coil protein GCC185)(CTCL tumor
antigen se1-1)
222KLLEVQILEGRIP and coiled-coil domain-Q8IWJ2
containing protein 2 (Golgi coiled
coil protein GCC185)(CTCL tumor
antigen se1-1)
223KPLLEQKELGRIP and coiled-coil domain-Q8IWJ2
containing protein 2 (Golgi coiled
coil protein GCC185)(CTCL tumor
antigen se1-1)
224FPWELDPDWSGROS1-L proteinQ9HC86
225YLSAAINPILGrowth hormone secretagogueQ92847
receptor type 1 (GHS-R)
226QLSLADVILLGlutathione S-transferase A4-4 (ECO15217
2.5.1.18)
227QSFLVGNQLGlutathione S-transferase A4-4 (ECO15217
2.5.1.18)
228LKNKTKEAAEGTP-binding protein Rhes (RasQ96D21
homolog enriched in striatum)
(Tumor endothelial marker 2)
229EDFHRKVYNIGTP-binding protein Rhes (RasQ96D21
homolog enriched in striatum)
(Tumor endothelial marker 2)
230YIDDVFHALGTP-binding protein Rit1 (Ras-likeQ92963
protein expressed in many tissues)
231EQLAELRQEFVGFG2573Q6UY45
232GLLERVKELHypothetical protein HDLBPQ53QU2
233DAILRIVGEHypothetical protein HDLBPQ53QU2
234RHKLVSDGQHeat shock protein 75 kDa,Q12931
mitochondrial precursor (HSP 75)
(Tumor necrosis factor type 1
receptor-associated protein)
235IQLVMKVIEHeat shock protein apg-1Q53ZP9
236MTREELVKNTumor rejection antigen (Gp96) 1Q5CAQ5
237ALKDKIEKATumor rejection antigen (Gp96) 1Q5CAQ5
238KIILRHLIEHeat-shock protein beta-3 (HspB3)Q12988
(Heat shock 17 kDa protein)
239TLGKLFWVLow-density lipoprotein receptor-O75197
related protein 5 precursor
240KGQGGAGGQFLRegulator of telomere elongationQ9NZ71
helicase 1 (EC 3.6.1.-)(Helicase-like
protein NHL)
241KEFLVVASVHematopoietic protein 1Q52LW0
242KIAQKALDLHeme oxygenase 1 (EC 1.14.99.3)P09601
(HO-1)
243ITEPLPELQLHeparan sulfate glucosamine 3-O-Q8IZT8
sulfotransferase 5 (EC 2.8.2.23)
244KLRKEKEEFHepatocellular carcinoma-associatedQ9NYH9
antigen 66
245EDVFPNILNMelanoma-associated antigen E2Q8TD90
(MAGE-E2 antigen)(Hepatocellular
carcinoma-associated protein 3)
246IAVMLLEGGAN26S proteasome non-ATPaseO75832
regulatory subunit 10 (26S
proteasome regulatory subunit p28)
247VDLFPGTFEVHepatocellular carcinoma-associatedQ5JUU1
protein p28-II
Hephaestin
248MVCGSPDIPLHECT domain and RCC1-likeO95714
domain-containing protein 2
(HERC2)
249DAPHSEGDMHLLHECT domain and RCC1-likeO95714
domain-containing protein 2
(HERC2)
250DTIEIITDRHeterogeneous nuclearP22626
ribonucleoproteins A2/B1 (hnRNP
A2/hnRNP B1)
251RLFVGSIPKHeterogeneous nuclearO43390
ribonucleoprotein R (hnRNP R)
252FLSEYQHQPHEXIM1 protein (HMBA-inducible)O94992
253LALMISMISADHistatin-1 precursor (Histidine-richHistatin-1
protein 1)precursor
(Histidine-rich
protein 1)
254RMLPHAPGVHistone deacetylase 1 (HD1)Q13547
255THNLLLNYGLHistone deacetylase 1 (HD1)Q13547
256SPNMNAVISLHistone deacetylase 9 (HD9)(HD7B)Q9UKV0
(HD7)
257EFIDLLKKMHomeodomain-interacting proteinQ9H2X6
kinase 2 (EC 2.7.11.1)
258KMINHDSEKEDCullin-2 (CUL-2)Q13617
259AVDEDRKMYLCullin-2 (CUL-2)Q13617
260LFELLEKEISWI/SNF-related matrix-associatedO60264
actin-dependent regulator of
chromatin subfamily A member 5
(EC 3.6.1.-)
261FISEFEHRVHUMAN HSPC027 26S proteasomeQ9Y6E3
non-ATPase regulatory subunit 13
Synonyms 26S proteasome
regulatory subunit S 11
26S proteasome regulatory subunit
p40.5
262AMFDHIPVGVHypothetical protein (Novel proteinQ9Y3I0
HSPC117)(DJ149A16.6 protein)
(Hypothetical protein HSPC117)
263WSFCLACVClaudin domain-containing protein 1Q9NY35
(Membrane protein GENX-3745)
Q9NY35
264NLLFPIIYLLarge neutral amino acids transporterQ9UHI5
small subunit 2 (L-type amino acid
transporter 2)(hLAT2)
265SLLENLEKIHeterogeneous nuclearO60812
ribonucleoprotein C-like 1 (hnRNP
core protein C-like 1)
266ILDQKINEVOrnithine decarboxylase (ECP11926
4.1.1.17)(ODC)
267DQINIETKNRegulator of nonsense transcripts 2Q9HAU5
(Nonsense mRNA reducing factor 2)
(Up-frameshift suppressor 2
homolog)(hUpf2)
268PFQNLLKEYRegulator of nonsense transcripts 2Q9HAU5
(Nonsense mRNA reducing factor 2)
(Up-frameshift suppressor 2
homolog)(hUpf2)
269LELELENLEIRegulator of nonsense transcripts 2Q9HAU5
(Nonsense mRNA reducing factor 2)
(Up-frameshift suppressor 2
homolog)(hUpf2)
270GLADASLLKKVATX10_HUMAN Ataxin-10Q9UBB4
271GQILEAAVSVKIAA1833 proteinQ569G6
272RVVSVSFRVHUMAN UDP-GalNAc: betaGlcNAcQ8NCR0
beta 1,3-galactosaminyltransferase,
polypeptide 2 (Beta 1,3-N-
acetylgalactosaminyltransferase-II)
(MGC39558)
273TQKRLDVYLHypothetical protein KIAA1033Q2M389
274AMLTVLHEIActivating signal cointegrator 1Q8N3C0
complex subunit 3 (EC 3.6.1.-)
275ARLAALVQRDelta-interacting protein A (HepatitisQ15834
delta antigen-interacting protein A)
(Coiled-coil domain-containing
protein 85B)
276FAVHFYRSHypothetical protein FLJ14466Q96BP7
Interferon-inducible double stranded
277FNITYLDIDRNA-dependent protein kinaseO75569
activator A
278GLAKRVWSLHypothetical protein C9orf142Q9BUH6
279HLDATKLLLTetratricopeptide repeat protein 17Q96AE7
280IGSFHGVLSLCDNA FLJ14058 fis, cloneQ9H7Z0
HEMBB1000554
281ILDLIDDAWAnaphase promoting complexQ9BS18
subunit 13
282KLLEMVREDHypothetical protein CCDC60Q8IWA6
283LSYLPATVEPSphingosine kinase 2 (EC 2.7.1.-)Q9NRA0
284QLAQFVHEVProbable ATP-dependent RNAQ96FC9
helicase DDX11 (EC 3.6.1.-)
(DEAD/H box protein 11)(CHL1
homolog)(Keratinocyte growth
factor-regulated gene 2 protein)
(KRG-2)
285SYDESDEEEProtein KIAA0182Q14687
286SYSDEFGPSRas GTPase-activating proteinQ96PV0
SynGAP (Synaptic Ras-GTPase-
activating protein 1)(Synaptic Ras-
GAP 1)(Neuronal RasGAP)
287TVERADSSHLSIFibrinogen C domain containing 1Q8N539
288VTENELAVITMGC39581 proteinQ86XM0
289VTYLEDYSABcl-2-like 13 protein (Mill protein)Q9BXK5
(Bcl-rambo)
290YLLEKTRVAMyosin head domain containing 1Q96H55
291TLKILDLMEWD-repeat protein 51AQ8NBT0
292EDLIKELIKKIF27A (OTTHUMP00000021559)Q86VH2
293LSLENLEKIInositol polyphosphate-5-phosphataseQ2T9J4
F, isoform 1
294FLNKAADFIEMyopalladinQ96KF5
295GLDIDGIYRVRho GTPase activating protein 12Q5T2Y2
296QNNNLQTQIHypothetical proteinQ7Z3C5
DKFZp686D0630
297FLDDVVHSLJumonji domain-containing proteinQ15652
1C (Thyroid receptor-interacting
protein 8)(TRIP-8)
298NMVDLNDYCoatomer subunit beta (Beta-coatP53618
protein)(Beta-COP)
299YLLKEDMAGIFLJ10462 fis, clone NT2RP1001494,Q9NVW8
weakly similar to MALE
STERILITY PROTEIN 2
300KLFEKVKEVFLJ10462 fis, clone NT2RP1001494,Q9NVW8
weakly similar to MALE
STERILITY PROTEIN 2
301TVMDEIHTVCell-cycle and apoptosis regulatoryQ6X935
protein 1
302KLISELQKLTelomere-associated protein RIF1Q5UIP0
(Rap1-interacting factor 1 homolog)
303KVIDEIYRVF-box only protein 28Q9NVF7
304SSLSDGLLLECDNA F1110901 fis, cloneQ9NV65
NT2RP5003524
305EEIVKVTFEAcetoacetyl-CoA synthetase (ECQ86V21
6.2.1.16)
306ELLENIIKNPutative cell cycle control proteinQ9NXZ0
(DEP domain containing 1)
307ELLSLVQNLSynaptopodin 2-likeQ68A20
308PQQERDFYCDNA FLJ36560 fis, cloneQ8N9T8
TRACH2009340
309GRGGKDPPLEPCDNA FLJ13330 fis, cloneQ9H8Q0
OVARC1001802
310LADISLHDPVATP-dependent RNA helicaseQ9H8H2
DDX31 (EC 3.6.1.-)(DEAD box
protein 31)(Helicain)
311PSNMGIAIPLProtein C14orf161Q9H7T0
312FMMPQSLGVCysteine protease ATG4B (ECQ9Y4P1
3.4.22.-)(Autophagy-related protein
4 homolog B)
313IMVATAVVAICDNA FLJ14526 fis, cloneQ96T08
NT2RM1001139
314MTKRYEALEHypothetical protein CCDC77Q9BR77
(CDNA FLJ14732 fis, clone
NT2RP3001969, weakly similar to
TRICHOHYALIN)
315SLDAKEIYLCDNA FLJ14790 fis, cloneQ96K38
NT2RP4000973, weakly similar to
PROBABLE PROTEIN DISULFIDE
ISOMERASE P5 (EC 5.3.4.1)
316QLLDIKTRLKeratin 24Q2M2I5
317FLTDYLNDLBCoR protein (BCL-6 corepressor)Q6W2J9
318ANQGGFENGEHypothetical protein FLJ20582Q6IQ21
319ILGLLLLHLEHypothetical protein FLJ22688Q9BT04
320VYQKEGVLASHypothetical protein FLJ22944Q9H5W3
321YLNDFTHEIZinc finger protein, subfamily 1A, 5-Q8TBE5
322SPPLQGEISLeucine-rich repeats and IQ motifQ8IW35
containing 2
323LFFEPVTTPHypothetical protein FLJ23749Q8TEA0
324WISVPVVTHypothetical protein FLJ25336http://www.
expasy.org/
sprot/userman.
html-AC line
Q96LP1
325NMEIMPEGSLHypothetical protein FLJ25660Q8N7G6
CDNA FLJ30058 fis, clone
326QDQLSALQLADRGL2000074, weakly similar toQ96NU6
RHO-GTPASE-ACTIVATING
PROTEIN 6
327MEADPDLSRCDNA FLJ30106 fis, cloneQ96A82
BNGH41000190, weakly similar to
Rattus norvegicus schlafen-4 (SLFN-
4) mRNA.
328LYLPATTPYWhirlinQ9P202
329SEIEKNKKVCDNA FLJ31846 fis, cloneQ96MV0
NT2RP7000425, weakly similar to
MYOSIN HEAVY CHAIN,
NONMUSCLE TYPE B
330SLVQIVTTLFLJ32833 fis, clone TESTI2003228Q96M43
331KILDIRKNVGuanine nucleotide-binding proteinP38405
G(olf), alpha subunit (Adenylate
cyclase-stimulating G alpha protein,
olfactory type)
332QSLELLLLPVCDNA FLJ33811 fis, cloneQ8N279
CTONG2002095
333ALLNNIIEITransmembrane protein 16CQ9BYT9
334FNQSSSLIIHZinc finger protein 31 (Zinc fingerP17040
protein KOX29)(Zinc finger and
SCAN domain-containing protein 20)
(Zinc finger protein 360)
335LSLSALPVSYTransmembrane 6 superfamilyQ9BZW4
member 2
336YLDLTPNQECDNA FLJ90251 fis, cloneQ8NCH3
NT2RM4000115
337YLFERIKELCDNA FLJ90251 fis, cloneQ8NCH3
NT2RM4000115
338FILDVLLPEACDNA FLJ90760 fis, cloneQ8N2I4
THYRO1000061
339EFIPEFEKTubulin--tyrosine 12 ligase-like proteinQ14166
12
340DVFPATPGSQNKIAA0303 proteinO15021
341FIFDVHVHEVPlexin-B2 precursor (MM1)O15031
342ILEVTNNLEZinc finger and BTB domain-O15062
containing protein 5
343ILSKKDLPLCentrosome-associated protein 350Q8WY20
344HEPPKAVDKpiccolo (Aczonin)Q9Y6V0
345ILDDSHLLVKIAA0560 proteinO60306
346YLDNVVNKQKIAA0676 proteinQ96H49
347KLLPYVGLLQHuman homolog of Mus SLIT andQ810B7
NTRK-like protein 5 precursor
348QLKSLIQIDHuman homolog of Mus SLIT andQ810B7
NTRK-like protein 5 precursor
349SLLNNPLSINischarinQ6PIB4
350SSLSDALVLEFERM domain-containing protein 4AQ9P2Q2
351DELQQLFNLLeucine-rich repeats neuronal proteinQ6UXK5
1 precursor (Neuronal leucine-rich
repeat protein 1)(NLRR-1)
352QILSGRKPELKIAA1512 proteinQ9P216
353KLVEVIEEVKIAA1598 proteinQ9HCH4
354QTLLKNPLYhosphatidylinositol-3 phosphate 3-Q96QU2
phosphatase adaptor subunit
355SLLDDLHSAKIAA1730 proteinQ9C0D3
356HILDSSIYSKIAA1786 proteinQ96JN9
357QSSPPPPPPSHypothetical protein MGC20470Q96EK3
358LMCYAIMVTOACT1 proteinQ86XC2
359FLSEEGGHVAV6-phosphofructo-2-kinase/fructose-Q16877
2,6-biphosphatase 4 (6PF-2-K/Fru-
2,6-P2ASE testis-type isozyme)
360SPDQELVLLIkappaB kinase complex-associatedO95163
protein (IKK complex-associated
protein)(p150)
361FLLVVLLKLImmune receptor expressed onQ7Z7I3
myeloid cells 2
362QIIEANYHSHigh-affinity cAMP-specific andO60658
IBMX-insensitive 3′,5′-cyclic
phosphodiesterase 8A (EC 3.1.4.17)
363ILIDKSGKLELBone specific CMF608Q6WRI0
364TVMDSKIVQVImportin alpha-7 subunitO60684
(Karyopherin alpha-6)
365VMDSKIVQVImportin alpha-7 subunitO60684
(Karyopherin alpha-6)
366YQDPLDPTRSVInaD-like protein (Inadl protein)Q8NI35
(hINADL)(Pals1-associated tight
junction protein)(Protein associated
to tight junctions)
367HEFLTPRLInaD-like protein (Inadl protein)Q8NI35
(hINADL)(Pals1-associated tight
junction protein)(Protein associated
to tight junctions)
368GLFPWTPKLInaD-like protein (Inadl protein)Q8NI35
(hINADL)(Pals1-associated tight
junction protein)(Protein associated
to tight junctions)
369CDVQRYNINitric oxide synthase, inducible (ECP35228
1.14.13.39)
370NMYGKVVTVTranscription elongation factor SPT5O00267
(hSPT5)
371QNVQVNQKVInositol-trisphosphate 3-kinase B (ECP27987
2.7.1.127)(Inositol 1,4,5-
trisphosphate 3-kinase B)
372SLINQMTQVType I inositol-3,4-bisphosphate 4-Q96PE3
phosphatase (EC 3.1.3.66)(Inositol
polyphosphate 4-phosphatase type I)
373NVTVAVPTVInsulin receptor beta subunitQ9UCB7
374LGLENLCHLInsulin-like growth factor bindingQ8TAY0
protein, acid labile subunit
375YYEKLHTYFIntegrin beta-4 precursor (GP150)P16144
(CD104 antigen)
376LLAALLLDPSplice isoform 2 of P35462P35462-2
377RRDFGFPQInterferon alpha 2 proteinQ16055
378SLLGFVYKLInterferon-induced protein withP09914
tetratricopeptide repeats 1 (IFIT-1))
(Interferon-induced 56 kDa protein)
(IFI-56K)
379LDRVFKNYInterleukin-20 precursor (IL-20)Q9NYY1
(Four alpha helix cytokine Zcyto10)
380LMVDHVTEVSteroid receptor RNA activatorQ9HD15
isoform 1
381KMDQQEFSIIntersectin-2 (SH3 domain-Q9NZM3
protein 1B)(SH3P18)
(SH3P18-like WASP-associated
protein)
382SLLLLPEELITI-like protein (Inter-alphaQ6UXX5
(Globulin) inhibitor H5-like)
383SQQNTDNLVGap junction alpha-5 proteinP36382
(Connexin-40)
384WLDETLAQVKelch-like protein 8Q9P2G9
385VNLGGSKSISISKeratin, type II cytoskeletal 1P04264
(Cytokeratin-1)
386ANYLDSMYIADAM 9 precursor (EC 3.4.24.-)(AQ13443
disintegrin and metalloproteinase
domain 9)
(Metalloprotease/disintegrin/cysteine-
rich protein 9)(Myeloma cell
metalloproteinase)
387HLWNSIHGLNext to BRCA1 gene 1 proteinQ14596
(Neighbor of BRCA1 gene 1 protein)
(Membrane component, chromosome
17, surface marker 2)(1A1-3B)
388SLADLMPRVHypothetical proteinQ6MZZ8
DKFZp686K2075
389IDLSASLVLNKIAA0100 proteinQ14667
390HLTYLNVYLPre-mRNA-splicing factor ATP-Q92620
dependent RNA helicase PRP16 (EC
3.6.1.-)(ATP-dependent RNA
helicase DHX38)(DEAH box protein
38)
391QLVACIESKLKIAA0251 proteinQ8TBS5
392EGKLVVQDIEHUMAN KIAA0342 proteinO15050
393QALEAGAVVLIKIAA0357 proteinO15064
394VLSCSQALKIHypothetical protein KIAA0372Q6PGP7
395LSIEGEQELKIAA0377 splice variant 2Q86TE7
396EFQDLNQEVKIAA0386 proteinQ9Y4F9
397RTKLTDIQIHUMAN CTCL tumor antigen HD-Q548S1
CL-04
398RECKYDLPPImportin-13 (Imp13)(Ran-bindingO94829
protein 13)
399QLTKIQTELKIAA0769 proteinO94868
400LVNAAQSVFVHypothetical protein KIAA0863Q6IQ32
401VKAEDKARVZinc finger protein KIAA1196-Q96KM6
402VLHDRIVSVCRSP complex subunit 3 (CofactorQ9ULK4
required for Sp1 transcriptional
activation subunit 3)(Transcriptional
coactivator CRSP130)(Vitamin D3
receptor-interacting protein complex
130 kDa component
403RNSIATLQGGR[Pyruvate dehydrogenaseQ9P2J9
[lipoamide]] phosphatase2,
mitochondrial precursor (EC
3.1.3.43)
404TVNILIVDQNProtocadherin-10 precursorQ9P2E7
405YLFDLPLKVLeucine-rich repeats and calponinQ5VUJ6
homology (CH) domain containing 2
406NLAKDNEVLAnkyrin repeat domain 18BQ5W0G2
407SGDKLKLDQTKin17 protein (HsKin17 protein)O60870
(KIN, antigenic determinant of recA
protein homolog)
408KLTDYQVTLKinesin-like protein KIF13AQ9H1H9
(Kinesin-like protein RBKIN)
409KIQEILTQVPutative RNA binding protein KOCO00425
410YLDEQIKKVHUMAN Kinesin-like proteinQ9H1H9
KIF13A (Kinesin-like protein
RBKIN)
411SSIVVEVDSLHHUMAN Kinesin-like proteinQ9H1H9
KIF13A (Kinesin-like protein
RBKIN)
412RLASYLDRVKeratin, type I cytoskeletal 18P05783
(Cytokeratin-18)
413ALLNIKVKLKeratin, type I cytoskeletal 18P05783
(Cytokeratin-18)
414FNIVKNKTEKv3.2d voltage-gated potassiumQ86W09
channel
415KAITAPVSLLethal(3)malignant brain tumor-likeQ9Y468
protein (L(3)mbt-like)(L(3)mbt
protein homolog)
416HEYLKAFKVLactadherin precursor (Milk fatQ08431
globule-EGF factor 8)(MFG-E8)
(HMFG)(Breast epithelial antigen
BA46)(MFGM)
417LKAFKVAYSLactadherin precursor (Milk fatQ08431
globule-EGF factor 8)(MFG-E8)
(HMFG)(Breast epithelial antigen
BA46)(MFGM)
418RLAVYIDRVLamin-A/C (70 kDa lamin)P02545
419YLLGNSSPRTLamin-A/C (70 kDa lamin)P02545
420EMKVSDLDRLaminin gamma-1 chain precursorP11047
(Laminin B2 chain)
421VRLVDAGGVKLLow-density lipoprotein receptor-O75197
related protein 5 precursor
422KPETFEHLFLeptin receptor precursor (LEP-R)P48357
(OB receptor)
423EITDDGNLKLeptin receptor precursor (LEP-R)P48357
(OB receptor)
424ECHHRYAELLeptin receptor precursor (LEP-R)P48357
(OB receptor)
425PSTCPDGFKIMitogen-activated protein kinaseO43283
kinase kinase 13 (EC 2.7.11.25)
426RKGIIDVNLLeukemia virus receptor 2Q08357
427LIQERDVKKLeukemia-associated protein with aQ8NFU7
CXXC domain
428LTLEQVVAIELeukemia-associated protein with aQ8NFU7
CXXC domain
429RDTPHSDFRGRNA-binding protein 6 (RNA-P78332
binding motif protein 6)(RNA-
binding protein DEF-3)(Lung cancer
antigen NY-LU-12)
430HRVLLHLFLung cancer oncogene 5Q7Z5Q7
431LLFDRPMHVHeterogeneous nuclearP52272
ribonucleoprotein M (hnRNP M)
432FLSELTQQLMacrophage migration inhibitoryP14174
factor (MIF)(Phenylpyruvate
tautomerase)(EC 5.3.2.1)
433SLLSHVEQLMitotic spindle assembly checkpointQ9UI95
protein MAD2B (MAD2-like 2)
(hREV7)
434KLILRLHKLMitogen-activated protein kinaseQ9Y6R4
kinase kinase 4 (EC 2.7.11.25)
(MAPK/ERK kinase kinase 4)
435RLTHHPVYISerine/threonine/tyrosine-interacting-Q9Y6J8
like protein 1 (Dual-specificity
protein phosphatase 24)(Map kinase
phosphatase-like protein MK-STYX)
436QDNLEKLLQMicrotubule-associatedQ6P0Q8
serine/threonine-protein kinase 2 (EC
2.7.11.1)
437MKRLLLLFMatrix metalloprotease MMP-27Q9H306
438DPQDILEVKMCM10 proteinQ7L590
439FLFGEVHKAMCM10 proteinQ7L590
440KVIVLVNKVLLInterferon-induced helicase CQ9BYX4
domain containing protein 1 (EC
3.6.1.-)(Melanoma differentiation-
associated protein 5)
441QILSLEEKIMelanoma ubiquitous mutatedQ2TAK8
protein
442MLKDIIKEYMelanoma antigen family D, 2Q5BJF3
443KTWGQYWQVMelanocyte protein Pmel 17P40967
precursor (Melanocyte lineage-
specific antigen GP100)
444LLDGTATLRLMelanocyte protein Pmel 17P40967
precursor (Melanocyte lineage-
specific antigen GP100)
445VLKEIVERVGPI-anchored protein p137Q14444
(p137GPI)(Membrane component
chromosome 11 surface marker 1)
Cytoplasmic activation/proliferation-
associated protein 1
446SLLDEFYKLGPI-anchored protein p137Q14444
(p137GPI)(Membrane component
chromosome 11 surface marker 1)
Cytoplasmic activation/proliferation-
associated protein 1
447TLNQNGYTLVHepatocyte growth factor receptorP08581
precursor (EC 2.7.10.1)(HGF
receptor)(Scatter factor receptor)(SF
receptor)(HGF/SF receptor)(Met
proto-oncogene tyrosine kinase)
448QMPKMNFANMitogen-activated protein kinase 14Q16539
(EC 2.7.11.24)
449KLADFGVSGEMitogen-activated protein kinaseQ12851
kinase kinase kinase 2 (EC 2.7.11.1)
(MAPK/ERK kinase kinase kinase 2)
450SIKDYEQANMitotic kinesin-related proteinQ96Q89
451EDLMEDEDLMitotic kinesin-related proteinQ96Q89
452VLISKELISLSperm-associated antigen 5 (Astrin)Q96R06
(Mitotic spindle-associated protein
p126)
453LIEKVQEARMyeloid/lymphoid or mixed-lineageQ9UMN6
leukemia protein 4 (Trithorax
homolog 2)
454SRVRMKTPTMyeloid/lymphoid or mixed-lineageQ9UMN6
leukemia protein 4 (Trithorax
homolog 2)
455GLDDIKDLKVPutative helicase MOV-10 (ECQ9HCE1
3.6.1.-)(Moloney leukemia virus 10
protein)
456VLAETLTQVMOZ/CBP proteinQ712H6
457DTNADKQLSCalgranulin B (Migration inhibitoryP06702
factor-related protein 14)(MRP-14)
(P14)
458GRWVCKDLPCPMUC2_HUMAN Mucin-2 precursorQ02817
(Intestinal mucin 2)
459FGNMQKINQMUC2_HUMAN Mucin-2 precursorQ02817
(Intestinal mucin 2)
460FPNWTLAQVMucin-5B precursor (Mucin 5Q9HC84
subtype B, tracheobronchial)
461ATPSSTPETVMucin-5B precursor (Mucin 5Q9HC84
subtype B, tracheobronchial)
462FVNDVNLENMultiple PDZ domain protein (MultiO75970
PDZ domain protein 1)(Multi-PDZ-
domain protein 1)
463SENKLILMKRUFY2 (Run and FYVE domain-Q8IW33
containing protein Rabip4
464TFCVQPGEKVMultidrug resistance associatedQ8NHX7
protein 7
465YLNDGLWHMMultiple copies in a T-cellQ9ULC4
malignancies (Malignant T cell
amplified sequence 1)(MCT1)
466GTTLRNLEIDNA mismatch repair protein Msh3P20585
467SPPTLNGAPSPProtein CBFA2T2 (MTG8-likeO43439
protein)(MTG8-related protein 1)
(Myeloid translocation-related
protein 1)
468NEAAIKNVYLMyomesin-1 (190 kDa titin-P52179
associated protein)(190 kDa
connectin-associated protein
469FIDFGMDLQMyosin heavy chain, cardiac muscleP12883
beta isoform (MyHC-beta)
470LLEAKVKELMyosin-13 (Myosin heavy chain,Q9UKX3
skeletal muscle, extraocular)(MyHC-
eo)
471LLAEKVEQLTumor suppressor candidate 3 (N33Q13454
protein)
472LANARGLGLQNebulin-related anchoring proteinQ8TCH0
473VNRIGQESLENeural cell adhesion molecule 1, 1P13592
474YLEIQGITRNeurotrimin precursorQ9P121
475EALENNKELNineinQ8N4C6
476NSMVVERQQLNineinQ8N4C6
477HLLERVDQVNineinQ8N4C6
478PERTQLLYLNotch homolog 2Q5VTD0
479NGGTCEDGINNeurogenic locus notch homologP46531
protein 1 precursor (Notch 1)(hN1)
(Translocation-associated notch
protein TAN-1)[Contains: Notch 1
extracellular truncation; Notch 1
intracellular domain]
480QSAADYLGALNeurogenic locus notch homologQ9UM47
protein 3 precursor (Notch 3)
[Contains: Notch 3 extracellular
truncation; Notch 3 intracellular
domain]
481ALLVVLSPPALNeurogenic locus notch homologQ99466
protein 4 precursor (Notch 4)
(hNotch4)[Contains: Notch 4
extracellular truncation; Notch 4
intracellular domain]-
482LRLDXLFKLPlexin-A1 precursor (SemaphorinQ9UIW2
receptor NOV)
483WLIEDGKVVHUMAN NPD011Q9H2R7
484SQPQEPENKNuclear autoantigen Sp-100P23497
(Speckled 100 kDa)(Nuclear dot-
associated Sp100 protein)
485LLREKVEFLNuclear factor erythroid 2-relatedQ14494
factor 1 (NF-E2-related factor 1)
(NFE2-related factor 1)(Nuclear
factor, erythroid derived 2, like 1)
(Transcription factor 11)
(Transcription factor HBZ17)
(Transcription factor LCR-F1)
(Locus control region-factor 1)
486YLDDVNEIINuclear factor of activated T-cells,O95644
cytoplasmic 1 (NFAT transcription
complex cytosolic component)(NF-
ATc1)
487ALLDQLYLANuclear receptor coactivator 2Q15596
(NCoA-2)(Transcriptional
intermediary factor 2)
488TLFDYEVRLUbiquitin-like PHD and RING fingerQ96T88
domain-containing protein 1 (EC
6.3.2.-)
489SILKVVINNNucleic acid helicase DDXxQ8IWW2
490LLYGGDLHSANucleic acid helicase DDXxQ8IWW2
491KLAENIDAQLNucleoporin 62 kDa (NUP62 protein)Q6GTM2
492SLLTDEEDVDNuclear pore complex proteinP52948
Nup98-Nup96 precursor [Contains:
Nuclear pore complex protein Nup98
(Nucleoporin Nup98)(98 kDa
nucleoporin);
493VDITQEPVLNuclear pore complex proteinP52948
Nup98-Nup96 precursor [Contains:
Nuclear pore complex protein Nup98
(Nucleoporin Nup98)(98 kDa
nucleoporin);
494QLEKKLMENucleoprotein TPRP12270
495GLDPLGYEIQNuclear pore complex proteinP57740
Nup107
496ALLDRIVSVNuclear pore complex proteinQ92621
Nup205
497KILDLETQLODF2 proteinQ6PJQ8
498VTWLKETEVTrophoblast glycoprotein precursorQ6PJQ8
(5T4 oncofetal trophoblast
glycoprotein)
499VDLPGVINTVDynamin-like 120 kDa protein,O60313
mitochondrial precursor (Optic
atrophy 1 gene protein)
500TITCLPATLVOrexin receptor type 2 (Ox2r)O43614
(Hypocretin receptor type 2)
501LLGPRLVLATransmembrane emp24 domain-P49755
containing protein 10 precursor
(Transmembrane protein Tmp21)
502LTTPDAAGVNQOrphan nuclear receptor TR2P13056
(Testicular receptor 2)
503FLDGHDLQLMKL/myocardin-like protein 1Q969V6
(Myocardia-related transcription
factor A)(MRTF-A)
(Megakaryoblastic leukemia 1
protein)(Megacaryocytic acute
leukemia protein)
504KTTEVLDASAOvarian cancer related tumor markerQ8WXI7
CA125-
505TSPTVPWTTSIFOvarian cancer related tumor markerQ8WXI7
CA125-
506WTITDTTEHOvarian cancer related tumor markerQ8WXI7
CA125-
507TITNLQYGEOvarian cancer related tumor markerQ8WXI7
CA125-
508ARLTFLNRGOxysterol-binding protein-relatedQ9BZF1
protein 8 (OSBP-related protein 8)
509KIDALSSEKLCentrosomal protein of 70 kDaQ8NHQ1
(Cep70 protein)(p10-binding
protein)
510LLAEAVLTYLLeucine carboxyl methyltransferase 2O60294
(EC 2.1.1.-)(p21WAF1/CIP1
promoter-interacting protein)
511SLFEKGLKNVF-box/LRR-repeat protein 5 (F-boxQ9UKA1
and leucine-rich repeat protein 5)(F-
box protein FBL4/FBLS)
512LDTPSQPVNNInhibitor of growth protein 3Q9NXR8
513VLDELKNMKCP53 inducible proteinQ9UN29
514PQDYPDKKSLPDNA polymerase alpha catalyticP09884
subunit (EC 2.7.7.7)
515NLLPKLHIVChloride intracellular channel proteinQ9Y696
4 (Intracellular chloride ion channel
protein p64H1
516LAAAGGPGQGWAPaired mesoderm homeobox proteinQ99453
2B (Paired likehomeobox 2B)
(PHOX2B homeodomain protein)
(Neuroblastoma Phox)
517GTPPPPGKPEPRB3 proteinP81489
518SQGAVGLAGVProtein patched homolog 1 (PTC1)Q13635
(PTC)
519ELKKINYQVProtein patched homolog 1 (PTC1)Q13635
(PTC)
520KLFQDLQDLRap guanine nucleotide exchangeQ9Y4G8
factor 2 (Neural RAP guanine
nucleotide exchange protein)(nRap
GEP)(PDZ domain-containing
guanine nucleotide exchange factor
1)(PDZ-GEF1)
521EAIVSHEKNPecanex-like protein 1 (PecanexQ96RV3
homolog)
522GLLPQVNTFVPecanex like protein 1 (PecanexQ96RV3
homolog)-
523KAYDVERELGC-1-related estrogen receptor alphaQ8TDE4
coactivator short isoform
524DVLESWLDFPHD fingerQ86U89
525TMLVLVIRGHypothetical proteinQ6N038
DKFZp686C07187
526DVAQLQALLQPhosphatidylinosito1-4,5-P42338
bisphosphate 3-kinase catalytic
subunit beta isoform (EC 2.7.1.153)
(PI3-kinase p110 subunit beta)
(PtdIns-3-kinase p110)
527QIIEANYHSPhosphodiesterase 8A, isoform 1Q6P9H3
528YVTDVLYRVSerine/threonine-protein kinaseQ96Q15
SMG1 (EC 2.7.11.1)(SMG-1)
(hSMG-1)(Lambda/iota protein
kinase C-interacting protein)
(Lambda-interacting protein)(
529FLDDEVIELPiggyBac transposable elementQ8N328
derived 3
530VICILPNDDKPIWIL3 proteinQ7Z3Z3
531IQNSQLQLQHomeobox protein PKNOX1P55347
(PBX/knotted homeobox 1)
532FAYLLTYMATransmembrane protein 115 (ProteinQ12893
PL6)
533GLIDSLVHYVPlakophilin-2Q99959
534REDHPARPPlectin 6Q6S380
535FLLDPVKGERLPlectin 1 (PLTN)(PCN)Q15149
(Hemidesmosomal protein 1)(HD1)
536RGQNLDVVQPlexin B1; plexin 5; semaphorinO43157
receptor
537SLTGHISTVPleiotropic regulator 1O43660
538EPLRVPPDLBlood vessel epicardial substanceQ8NE79
(hBVES)(Popeye domain-containing
protein 1)(Popeye protein 1)
539EIPVLNELPVCarboxypeptidase-like protein X2Q8N436
precursor
540LYIPAMAFIYIF1B proteinYIF1B protein
541SLLQHLIGLMelanoma antigen preferentiallyP78395
expressed in tumors (Pr4eferentially
expressed antigen of melanoma)
(OPA-interacting protein 4)
542ISSMLVLFFSplice isoform 2 of Q9H7F0Q9H7F0-2
543ENHSSQTDNIP2Y purinoceptor 13 (P2Y13)(G-Q9BPV8
protein coupled receptor 86)(G-
protein coupled receptor 94)
544ILMGVLKEVPutative pre-mRNA-splicing factorO43143
ATP-dependent RNA helicase
DHX15 (EC 3.6.1.-)(DEAH box
protein 15)(ATP-dependent RNA
helicase #46)
545VLFENTDSVHLHUMAN RNA-binding protein 34P42696
(RNA-binding motif protein 34)
546INMRIQDLProlyl 4-hydroxylase alpha-1 subunitP13674
precursor (EC 1.14.11.2)(4-PH
alpha-1)(Procollagen-proline,2-
oxoglutarate-4-dioxygenase alpha-1
subunit)
547KTDKTLVLLProfilin-1P07737
548GLIEILKKVProgrammed cell death protein 5O14737
(TFAR19 protein)(TF-1 cell
apoptosis-related gene 19 protein)
549NMVDIIHSVPropionyl-CoA carboxylase betaP05166
chain, mitochondrial precursor (EC
6.4.1.3)
550ILDAGGHNVTI26S proteasome non-ATPaseQ99460
regulatory subunit 1 (26S proteasome
regulatory subunit RPN2)(26S
proteasome regulatory subunit S1)
(26S proteasome subunit p112)
551YMNLEKPDFI26S proteasome non-ATPaseQ99460
regulatory subunit 1 (26S proteasome
regulatory subunit RPN2)(26S
proteasome regulatory subunit S1)
(26S proteasome subunit p112)
552SLADIAQKL26S proteasome non-ATPaseO43242
regulatory subunit 3 (26S proteasome
regulatory subunit S3)(Proteasome
subunit p58)
553QLVDIIEKVProteasome activator complexP61289
subunit 3 (Proteasome activator 28-
gamma subunit)(PA28gamma)
(PA28g)(Activator of multicatalytic
protease subunit 3)(11S regulator
complex gamma subunit)(REG-
gamma)(Ki nuclear autoantigen)
554SLLKVDQEVProteasome activator complexP61289
subunit 3 (Proteasome activator 28-
gamma subunit)(PA28gamma)
(PA28g)(Activator of multicatalytic
protease subunit 3)(11S regulator
complex gamma subunit)(REG-
gamma)(Ki nuclear autoantigen)
555QILRLLHIEProtein C14orf166Q9Y224
556EMGGGENNLKProtein KIAA1219Q86X10
557NLAEKLIGVProtein KIAA1219Q86X10
558EKSVSVQTNLProtein KIAA1688Q9C0H5
559GLLDSLTGILNProtein Plunc precursor (Palate lungQ9NP55
and nasal epithelium clone protein)
(Lung-specific protein X)
(Nasopharyngeal carcinoma-related
protein)(Tracheal epithelium-
enriched protein)(Secretory protein
in upper respiratory tracts)
560SLLPPDALVGLProtein transport protein Sec23BQ15437
561LEEKNTLIQELLiprin-alpha-2 (Protein tyrosineO75334
phosphatase receptor type f
polypeptide-interacting protein alpha-
2)(PTPRF-interacting protein alpha-
2)
562LLSESNERLLiprin-alpha-2 (Protein tyrosineO75334
phosphatase receptor type f
polypeptide-interacting protein alpha-
2)(PTPRF-interacting protein alpha-
2)
563LADLGSLESPProtocadherin gamma A12 precursorO60330
(PCDH-gamma-A12)(Cadherin-21)
(Fibroblast cadherin 3)
564QLLKFQLNKProtocadherin gamma A10 precursorQ9Y5H3
(PCDH-gamma-A10)
565LLAEAVLTYLLeucine carboxyl methyltransferase 2O60294
(EC 2.1.1.-)(p21WAF1/CIP1
promoter-interacting protein)
566QLLREPHLQKIAA1636 proteinQ9HCD6
567TIPNLEQIEProbable G-protein coupled receptorQ9UJ42
160
568KLWEAESKLProtein C21orf45Q9NYP9
569IFHLHELPEPeriodic tryptophan protein 2Q15269
homolog
570KLFNDAIRLRab-like protein 2BQ9UNT1
571FENQEVQAICell cycle checkpoint protein RAD17O75943
(hRad17)(RF-C/activator 1
homolog)
572EYVEKFYRIDNA repair protein RAD50 (EC 3.6.-.-)Q92878
(hRAD50)
573QIDEIRDKDNA repair protein RAD50 (EC 3.6.-.-)Q92878
(hRAD50)
574FLHEKLESLRas GTPase-activating protein 1P20936
(GTPase-activating protein)(GAP)
(Ras p21 protein activator)
(p120GAP)(RasGAP)
575FELNNELKMRas guanine nucleotide exchangeQ9UK56
factor 2
576LLSNNNQALRas-GTPase-activating protein-Q13283
binding protein 1 (EC 3.6.1.-)(ATP-
dependent DNA helicase VIII)(GAP
SH3-domain-binding protein 1)
(G3BP-1)(HDH-VIII)
577VLCGNKSDLERas-related protein Rab-27A (Rab-P51159
27)(GTP-binding protein Ram)
578LLMYDIANRas-related protein Rab-3DO95716
579SQVNILSKIVSRNuclear pore complex proteinP57740
Nup107 (Nucleoporin Nup107)(107
kDa nucleoporin)
580VMFNGKVYLReceptor-interacting factor 1Q86XS4
581LEVEVIEARRegulating synaptic membraneQ9UJD0
exocytosis protein 3 (Nim3)(Rab-3
interacting molecule 3)(RIM 3)
(RIMS gamma)
582TLLRGIEWRegulator of G protein signalingQ86UV0
protein (Regulator of G-protein
signalling like 1)
583PDFTELDLQMHC class II regulatory factor RFX1P22670
(RFX)(Enhancer factor C)(EF-C)
584DVLFALFSKLRetinoblastoma-associated proteinP06400
(PP110)(P105-RB)
585RSGERKAVQARoundabout homolog 3 precursorQ96MS0
(Roundabout-like protein 3)
586GLNEEIARVRetinoblastoma-associated proteinO14777
HEC (Kinetochore associated 2)
587FLFQEPRSIRetinoblastoma-associated proteinQ9UK61
RAP140
588FLFQEPRSIVTRetinoblastoma-associated proteinQ9UK61
RAP140
589KEVDILNLPAT-rich interactive domain-P29374
containing protein 4A (ARID
domain-containing protein 4A)
(Retinoblastoma-binding protein 1)
590YKLPMEDLKJumonji/ARID domain-containingP29375
protein 1A (Retinoblastoma-binding
protein 2)(RBBP-2)
591TMVDRIEEVJumonji/ARID domain-containingP29375
protein 1A (Retinoblastoma-binding
protein 2)(RBBP-2)
592VEGLLTLSDFDLRhoGTPase regulating proteinQ6RJU5
variant ARHGAP20-1ad
593WMLDKLTGV40S ribosomal protein S4, Y isoformQ8TD47
2
594LLKHLLLLLRNA binding motifQ13380
595ALLSRLEQIRNA binding protein (Autoantigenic,Q2M365
hnRNP-associated with lethal
yellow), long isoform-
596DVYEDELVPRNA-binding proteinQ8NI52
597VMLGGRNIKVRo ribonucleoprotein-binding proteinQ9UHX1
1 (SIAHBP1 protein)
598RLDELGGVYLHUMAN OTTHUMP00000030902Q5JYR6
599FEDKLIEDLRyanodine receptor 2 (CardiacQ92736
muscle-type ryanodine receptor)
(RyR2)(RYR-2)(Cardiac muscle
ryanodine receptor-calcium release
channel)(hRYR-2)
600QLIDKVWQLSEC14-like protein 1Q92503
601FLLEPQMKVSecreted and transmembrane proteinQ8WVN6
1 precursor (Protein K12)
602ILNEDGSPNLNeudesin precursor (Neuron-derivedQ9UMX5
neurotrophic factor)
603LLAILILALP-selectin glycoprotein ligand 1Q14242
precursor (PSGL-1)(Selectin P
ligand)(CD162 antigen)
604SMNRGGYMPSemaphorin-6D precursorQ8NFY4
605EFIDGSLQMSerine/threonine/tyrosine-interactingQ8WUJ0
protein (Protein tyrosine
phosphatase-like protein)
606ILVVYVIGLOlfactory receptor 8G5 (OlfactoryQ8NG78
receptor OR11-298)
607TLSERLWLGShb-like adapter protein, ShfQ7M4L6
608VLWDRTFSLSignal transducer and activator ofP42224
transcription 1-alpha/beta
(Transcription factor ISGF-3
components p91/p84) STAT1
609NVNFFTKPPSignal transducer and activator ofP40763
transcription 3 (Acute-phase response
factor)
610ETFSGVYKK40S ribosomal protein S7P62081
611QLDDLKVEL60S ribosomal protein L35P42766
612MEDLIHEI60S ribosomal protein L7P18124
613QTDVDNDLVThrombospondin-2 precursorP35442
614LLIDPPRYIC3 and PZP-like alpha-2-Q8IZJ3
macroglobulin domain containing 8
615PSIPTSAQHVC3 and PZP-like alpha-2-Q8IZJ3
macroglobulin domain containing 8
616FLDEPTNHLATP-binding cassette sub-family FQ9UG63
member 2 (Iron-inhibited ABC
transporter 2)
617KMDDPDYWRTVRibosome biogenesis protein BOP1Q14137
(Block of proliferation 1 protein)
618LANVQQVQICDNA FLJ13765 fis, cloneQ9H8C5
PLACE4000128, weakly similar to
Mus musculus putative transcription
factor mRNA
619SLFVVILVTCD200 cell surface glycoproteinQ6Q8B3
receptor isoform 2 variant 2
620ARTIKIRNILRRC58 proteinQ96CX6
621LVLTSGIVFVClaudin-6 (Skullin 2)P56747
622VISFDKLKLT-box transcription factor TBX18 (T-O95935
box protein 18)
623DLMELYKVINTS7 proteinQ8WUH5
624LQRRKPTGAFFRAS1-related extracellular matrixQ5SZK8
protein 2 precursor (ECM3 homolog)
625KVNNEKFRTZinc finger protein 318 (EndocrineQ5VUA4
regulatory protein)
626SLDQPTQTVEukaryotic translation initiationQ99613
factor 3 subunit 8 (eIF3 p110)
(eIF3c)
627SVTSEGIKAVHUMAN LOC196394 proteinQ8IY45
628ISLSEPAKPGHypothetical protein FLJ44216Q8NDZ2
629ILDKKVEKVHeat shock protein HSP 90-betaP08238
(HSP 84)(HSP 90)
630KLSAEVESLKSarcoma antigen NY-SAR-41 (NY-Q5T9S5
SAR-41)
631VTWDAALYIProtein FAM86AQ96G04
632YLLPKDIKLRas-like family 11 member AQ6T310
(OTTHUMP00000018162)
633RLLEDGEDFNLKeratin, type I cytoskeletal 18P05783
(Cytokeratin-18)(CK-18)
634RVLPYPFTHU3 small nucleolar RNA-associatedQ9BVJ6
protein 14 homolog A (Antigen NY-
CO-16)
635QNQERLERHypothetical proteinQ68DM0
DKFZp781D1722
636QDNIKELELChromosome-associated kinesinO95239
KIF4A (Chromokinesin)
637ILKQRDNEIKinesin-like protein KIF6Q6ZMV9
638QNELDNVSTLMyosin-10 (Myosin heavy chain,P35580
nonmuscle IIb)(Nonmuscle myosin
heavy chain IIb)
639NIDLLDDGSNHypothetical protein C17orf57Q8IY85
640VLQSNIQHVSimilar to peptide N-glycanaseQ9BVR8
homolog (S. cerevisiae)
641VFFDIAVDGEPLPeptidyl-prolyl cis-trans isomerase AP62937
(EC 5.2.1.8)
642DFHFPKFSISerpin A13 precursorQ6UXR4
643SYVNLPTIAL40S ribosomal protein SA (p40)P08865
(34/67 kDa laminin receptor)(Colon
carcinoma laminin-binding protein)
(NEM/1CHD4)(Multidrug
resistance-associated protein MGr1-
Ag)
644SNLEHLGHEN-acetylglucosamine-1-Q9UJJ9
phosphotransferase subunit gamma
precursor
645LKLKLTAVEKLiprin-beta-1 (Protein tyrosineQ86W92
phosphatase receptor type f
polypeptide-interacting protein-
binding protein 1)
646GLKGRVFEV40S ribosomal protein S3aP61247
647SLADLQNDEV40S ribosomal protein S3aP61247
648NNLPHLQVVLOC124512 protein (Fragment)Q86XA0
649ISFGGSVQLHypothetical protein MGC26744Q96KX1
650SILDQILQHypothetical protein LOC122258Q96KW9
651TLSDLRVYLSulfiredoxin-1 (EC 1.8.98.2)Q9BYN0
652EAFVNSKNBasalinQ5QJ38
653VTWDAALYLProtein FAM86AQ96G04
654VLDDKLVFVTransmembrane protein 16FQ4KMQ2
655YLLDLHSYLTEB4 proteinO14670
656FLALAVIQLSLC10A5Q5PT55
657TLAEVSTRLSerine/threonine-protein kinaseP57059
658VIEVYQEQISNF1-like kinase 1 (EC 2.7.11.1)Q6P094
LOC391257 protein
659RLWEEAVKAZinc finger protein 161 (PutativeQ14119
transcription factor DB1)
660SLKTLMLRSlit homolog 2 protein precursorO94813
(Slit-2)
661EIKKKFKLFYN-binding protein (FYN-T-O15117
binding protein)
662VHKEMFIMVJumonji/ARID domain-containingP41229
protein 1C (SmcX protein)(Xe169
protein)
663VHKEMFIMVJumonji/ARID domain-containingQ9BY66
protein 1D (SmcY protein)
(Histocompatibility Y antigen)
664LAGSEVALAGVMonocarboxylate transporter 3 (MCTO95907
3)
665IPHDLFTELSolute carrier family 4 sodiumQ6U841
bicarbonate cotransporter-like
member 10-
666FLADPDTVNHLLSorting nexin 14, isoform aQ6NUI7
667RVADRLYGVSorting nexin-4O95219
668HRPDLLDYSpectrin beta chain, brain 4 (Spectrin,Q9NRC6
non-erythroid beta chain 4)
669TLDENHPSISpermatogenesis-associated protein 7Q9P0W8
(Spermatogenesis-associated protein
HSD3)
670TLAEIAKVELNon-POU domain-containingQ15233
octamer-binding protein (NonO)
protein)(54 kDa nuclear RNA-and
DNA-binding protein)(p54(nrb))
(p54nrb)(55 kDa nuclear protein)
671DVAVEAIRLCohesin subunit SA-1 (StromalQ8WVM7
antigen 1)(SCC3 homolog 1)
672LMVDHVTEVSteroid receptor RNA activatorQ9HD15
isoform 1
673SLYEMVSRVStructure-specific recognition proteinQ08945
1 (SSRP1)(Recombination signal
sequence recognition protein)(T160)
(Chromatin-specific transcription
elongation factor 80 kDa subunit)
674SINPKRAKLSuppressor of hairy wing homolog 2Q86YH2
(5′OY11.1)(Zinc finger protein 632)
675NMYGKVVTVTranscription elongation factor SPT5O00267
(hSPT5)(DRB sensitivity-inducing
factor large subunit)(DSIF large
subunit)(DSIF p160)(Tat-
cotransactivator 1 protein)(Tat-CT1
protein)-
676SLFATEQLSynaptogyrin-3O43761
677RLQEGDKILSVSynaptojanin-2-binding proteinP57105
(Mitochondrial outer membrane
protein 25)
678AMFDKKVQLSyneminQ8TE61
679ALNELLQHVTalin-1Q9Y490
680RVVSMAALAMTAR RNA loop binding proteinv
(TAR(HIV)RNA binding protein 1)
681GIIMQIIDVTaste receptor type 2 member 3Q9NYW6
(T2R3)
682IFNAIALFLTaste receptor type 2 member 40P59535
(T2R40)(T2R58)(G-protein coupled
receptor 60)
683LEQGLFSKVOxidoreductase HTATIP2 (ECQ9BUP3
1.1.1.-)(HIV-1 TAT-interactive
protein 2)
684KFMHMGKRQKTranscription initiation factor TFIIDP49848
subunit 6 (Transcription initiation
factor TFIID 70 kDa subunit)
(TAF(II)70)(TAFII-70)(TAFII-80)
(TAFII80)
685SNFGNEKLTRA@ proteinQ6PIP7
686FLLDKKIGVT-complex protein 1 subunit betaP78371
(TCP-1-beta)(CCT-beta)
687RSLAASNPILTelomerase-binding protein EST1AQ86US8
(Ever shorter telomeres 1A)
(Telomerase subunit EST1A)(EST1-
like protein A)(hSmg5/7a)
688EMESLTGHQTumor endothelial marker 6Q96PE0
(Hypothetical protein TEM6)
689LDFQEELEVRas GTPase-activating-like proteinQ13576
IQGAP2
690SPNSEGDAGDLTetratricopeptide repeat protein 15Q8WVT3
(TPR repeat protein 15)
691LVYLNESSVLHMyosin-18A (Myosin XVIIIa)Q92614
(Myosin containing PDZ domain)
(Molecule associated with JAK3 N-
terminus)(MAJN)
692VAGIKVNQVKPolycystic kidney and hepatic diseaseQ8TCZ9
1 precursor (Fibrocystin)
693ILYELQVELTMC4 proteinQ7Z5M3
694EVLDELYRVMDC-3.13 isoform 1 (TNFAIP8Q9UER5
protein)
695TNIEDGVFETToll-like receptor 8 precursorToll-like
receptor 8
precursor
696EIRKNEGQITolloid-like protein 1 precursor (ECO43897
3.4.24.-)
697IAAKILSYNDNA topoisomerase I, mitochondrialQ969P6
precursor (EC 5.99.1.2)(TOP1mt)
698LYGRHFNYLPAP associated domain-containingQ8NDF8
protein 5 (EC 2.7.7.-)
(Topoisomerase-related function
protein 4-2)(TRF4-2)
699NLFNKYPALPlastin-3 (T-plastin)P13797
700YLDEIVKEVTranslocated promoter region (ToQ5SWY0
activated MET oncogene)
701ENHSSQTDNIP2Y purinoceptor 13 (P2Y13)(G-Q9BPV8
protein coupled receptor 86)(G-
protein coupled receptor 94)
702RTHMLSSLTranscript Y 5Q9BXH6
703QATIAPVTVTranscription factor Sp4 (SPR-1)Q02446
704NLFRAPIYLTranscription initiation factor TFIIDP21675
subunit 1 (EC 2.7.11.1)
(Transcription initiation factor TFIID
250 kDa subunit)(TAF(II)250)
(TAFII-250)(TAFII250)(TBP-
associated factor 250 kDa)(p250)
(Cell cycle gene 1 protein)
705KLEEEQEKNQLTranscriptional repressor CTCFLQ8NI51
(CCCTC-binding factor)(Brother of
the regulator of imprinted sites)(Zinc
finger protein CTCF-T)(CTCF
paralog
706LNVDTPFPLTransducer of regulated CREBQ6UUV7
protein 3
707ILYELKVELTransmembrane channel-like proteinQ7Z404
4
708KFMHMGKRQKTranscription initiation factor TFIIDP49848
subunit 6 (Transcription initiation
factor TFIID 70 kDa subunit)
(TAF(II)70)(TAFII-70)(TAFII-80)
(TAFII80)
709HSDEGGVASLTrophinin-associated protein (Tastin)Q12815
(Trophinin-assisting protein)
710AMLTGELKKATryptophanyl-tRNA synthetase (ECP23381
6.1.1.2)(Tryptophan--tRNA ligase)
(TrpRS)(IFP53)(hWRS)
711VFPTHVFPTTubulin, gamma complex associatedQ5T9Y2
protein 3
712KELAELRESTSTumor necrosis factor ligandP48023
superfamily member 6 (Fas antigen
ligand)(Fas ligand)(CD178 antigen)
(CD95L protein)(Apoptosis antigen
ligand)(APTL)[Contains: Tumor
necrosis factor ligand superfamily
member 6, membrane form
713LTDKEGWILTumor necrosis factor, alpha-inducedQ13829
protein 1, endothelial (B12 protein)
714VVTYKNENINetrin receptor DCC precursorP43146
(Tumor suppressor protein DCC)
(Colorectal cancer suppressor)
715TVAEGLIEDAdipocyte-derived leucineQ9NZ08
aminopeptidase precursor (EC
3.4.11.-)(A-LAP)(ARTS-1)
(Aminopeptidase PILS)(Puromycin-
leucyl-specific
aminopeptidase)(PILS-AP)(Type 1
tumor necrosis factor receptor
shedding aminopeptidase
716NEKIKKDELU1 small nuclear ribonucleoprotein AP09012
(U1 snRNP protein A)(U1A protein)
(U1-A
717ILDESHERVU6 snRNA-associated Sm-likeO95777
protein LSm8
718NLYSDYILNUbiquitin-protein ligase E3A (ECQ05086
6.3.2.-)(E6AP ubiquitin-protein
ligase)(Oncogenic protein-associated
protein E6-AP)(Human
papillomavirus E6-associated protein)
719RYVNGHAKUbiquitin carboxyl-terminalQ9Y6I4
hydrolase 3 (EC 3.1.2.15)(Ubiquitin
thioesterase 3)(Ubiquitin-specific-
processing protease 3)
(Deubiquitinating enzyme 3)
720KLLDLELAPSUBX domain-containing protein 2Q92575
721YLYDLNHTLUNC93 homolog B1 (UNC-93BQ9H1C4
protein)(hUNC93B1)
722FFFWLMELSplice isoform 5 of Q9H171Q9H171-5
723ELSSLKETHICDNA FLJ46282 fis, cloneQ6ZRK6
TESTI4031066
724KLGSVPVTVCCDC73 proteinQ6P5Q7
725ALWERIEGVCaspase recruitment domain-Q9BWT7
containing protein 10 (CARD-
containing MAGUK protein 3)
(Carma 3)
726VKAQEILRCaspase recruitment domain-Q9BWT7
protein 10 (CARD-
containing MAGUK protein 3)
(Carma 3)
727ANVDAIVVSVChromatin-specific transcriptionQ9Y5B9
elongation factor FACT 140 kDa
subunit
728CKDGEDSIIRBeta-defensin 120 precursorQ8N689
729DNTKKSDKTAlpha-catulin (Catenin alpha-likeQ9UBT7
protein 1)(Alpha-catenin-related
protein)
730EFLGDSIMQRibonuclease III (EC 3.1.26.3)Q9NRR4
(RNase III)
731EFLQEGLEKSeizure related 6 homologQ53EL9
732FLLKCLEQVGranulocyte colony-stimulatingP09919
factor precursor (G-CSF)
(Pluripoietin)(Filgrastim)
(Lenograstim)
733FLTDSNNIKEVLysyl-tRNA synthetaseQ9HB23
734GGVQELLNQQProtein C6orf130Q9Y530
735GKPRRKSNLMelanophilin (Exophilin-3)Q9BV36
(Synaptotagmin-like protein 2a)(Slp
homolog lacking C2 domains a)
736HIKEELMHGNovel protein (Possible ortholog ofQ5VTR6
mouse phosphoinositide-3-kinase
adaptor protein 1 (Pik3ap1)
737HIPFFLHNAER61 glycosyltransferaseQ6P985
738ILEKKVEKVHeat shock protein HSP 90-alphaP07900
(HSP 86)
739ILMEHIHKL60S ribosomal protein L19P84098
740KASQLGIFISKVPDZ domain-containing protein 11Q5EBL8
741KILEVMHTKDedicator of cytokinesis 11-;Q5JSL3
Cdc42-associated guanine nucleotide
exchange factor ACG/DOCK11
742LAVGTSPVLAHypothetical protein FLJ26930Q6ZNX6
743LLAEEARKLLaminin gamma-1 chain precursorP11047
(Laminin B2 chain)
744LLGICFCIAATP-binding cassette transporter sub-Q96J66
family C member 11 (Multidrug
resistance-associated protein 8)
745LMAEMGVHSVUridine/cytidine kinase-like 1Q9NWZ5
746ISRLENITVButyrophilin-like protein 8 precursorQ6UX41
747MISLPGPLVTNEndothelial cell-selective adhesionQ96AP7
molecule precursor
748MLLDVMHTVPoly(A)-specific ribonuclease PARNO95453
(EC 3.1.13.4)(Polyadenylate-
specific ribonuclease)(Deadenylating
nuclease)(Deadenylation nuclease)
749NVMNLIDFVVoltage-gated potassium channelQ96RP8
KCNA7
750NVTMKDNKIF-box protein 11Q52ZP1
751PRSNIDVNIrythrocyte membrane protein bandQ7Z5S1
4.1 like 5
752PSAQPLLSLCDNA FLJ45015 fis, cloneQ6ZT30
BRAWH3014639
753QLKESKLKIFAM13A1_v2 proteinQ24JP0
754RDAPHLPDGHypothetical protein FLJ26432Q6ZP70
755RLPPEGILHNVVPS13D-1A proteinQ709C5
756SEGAEYDDQTCoagulation factor VIII precursorP00451
(Procoagulant component)
(Antihemophilic factor)(AHF)
757SLFERLVKVNFX1-type zinc finger-containingQ9P2E3
protein 1
758SLLDKIIGAPolymerase I and transcript releaseQ6NZI2
factor (PTRF protein)
759SMMDVDHQIT-complex protein 1 subunit epsilonP48643
(TCP-1-epsilon)(CCT-epsilon)
760TLDEKIEKVProbable ATP-dependent RNAQ96GQ7
helicase DDX27 (EC 3.6.1.-)(DEAD
box protein 27)
761TLLEDGTFKVHSCARGQ9HBL8
762TVLKTKFSSCDNA FLJ43956 fis, cloneQ6ZU72
TESTI4015681
763VIFEDVGRQVLMitochondrial-processing peptidaseQ10713
alpha subunit, mitochondrial
precursor (EC 3.4.24.64)(Alpha-
MPP)
764YILDINPLLCDNA FLJ45287 fis, cloneQ6ZSR0
BRHIP3002124
765YKTFSTSMMLLHypothetical protein C12orf62Q96I36
766RLPPEGILHNVVPS13D-2A proteinQ709C4
767LLGPRVLSPCDNA FLJ32009 fis, cloneQ96DN2
NT2RP7009498, weakly similar to
FIBULIN-1, ISOFORM A
768FIILLVTYITransient receptor potential cationQ9HBA0
channel subfamily V member 4
(TrpV4)(osm-9-like TRP channel 4)
(OTRPC4)(Vanilloid receptor-like
channel 2)(Vanilloid receptor-like
protein 2)(VRL-2)
769FYDIETLKVascular endothelial growth factor DO43915
precursor (VEGF-D)(c-fos-induced
growth factor)(FIGF)
770WMAPESIFDKIVascular endothelial growth factorP17948
receptor 1 precursor (EC 2.7.10.1)
(VEGFR-1)(Vascular permeability
factor receptor)(Tyrosine-protein
kinase receptor FLT)(Flt-1)
(Tyrosine-protein kinase FRT)(Fms-
like tyrosine kinase 1)
771LLDQQNPDEProto-oncogene C-crk (P38)(AdapterP46108
molecule crk)
772VMFKKIKSFEVVDUP1 protein (ThioredoxinQ9H3M7
interacting protein)
773KLLEGEESRISLVimentinP08670
774KLLEGEESRISLHUMAN CTCL tumor antigen HD-Q548L2
CL-06 (Vimentin variant)
775RILGAVAKVVinculin (Metavinculin)P18206
776SLSMVNHRLIntegrin alpha-3 precursorP26006
(Galactoprotein B3)(GAPB3)(VLA-
alpha chain)(FRP-2)(CD49c
antigen)[Contains: Integrin alpha-3
heavy chain; Integrin alpha-3 light
chain]
777VGQADGGLSVLRVoltage-dependent T-type calciumO95180
channel alpha-1H subunit (Voltage-
gated calcium channel alpha subunit
Cav3.2)(Low-voltage-activated
calcium channel alpha1 3.2 subunit)
778DVATILSRRWiskott-Aldrich syndrome proteinQ8IV90
family member 4 (WASP-family
protein member 4)
779PKFEVIEKPQAATP synthase coupling factor 6,P18859
mitochondrial precursor (EC
3.6.3.14)(ATPase subunit F6)
780NCTTIDDSLAIProto-oncogene protein Wnt-3P56703
precursor
781ILPTVILANmyloid beta A4 precursor protein-Q99767
binding family A member 2 (Neuron-
specific X11L protein)(Neuronal
Munc18-1-interacting protein 2)
(Mint-2)(Adapter protein X11beta)
782EFLELSAAQEZinc finger CCHC domain-Q8N8U3
containing protein 5
783SLTDKVQEAMyeloid/lymphoid or mixed-lineageQ59FF2
leukemia (Trithorax homolog,
Drosophila) variant
784SKNSALEYQLZinc finger protein DZIP1 (DAZ-Q86YF9
interacting protein 1/2)
785LQDVEEVEIHypothetical proteinQ69YS5
DKFZp761O1618
786FLDEPTNHLATP-binding cassette sub-family FQ9UG63
member 2 (Iron-inhibited ABC
transporter 2)
787KMDDPDYWRTVRibosome biogenesis protein BOP1Q14137
(Block of proliferation 1 protein)
788LANVQQVQICDNA FLJ13765 fis, cloneQ9H8C5
PLACE4000128
789KLDPTKTTLNDRG1 protein (N-myc downstreamQ92597
regulated gene 1 protein)
790HLTYLNVYLPre-mRNA splicing factor ATP-Q92620
dependent RNA helicase PRP16
791ALWDKLFNLNesprin 2 (Nuclear envelope spectrinQ9NU50
repeat protein 2)
1514KIMDQVQQAAdenomatous polyposis coliP25054
1515RLQEDPPAGVUbiquitin conjugating enzyme E2P49459
1516KLDVGNAEVB cell receptor-associated proteinP5572
BAP31 (CDM protein) 6c6-AG
1517FLYDDNQRVTopoisomerase II-alphaP11388
1518FLYDDNQRVTopoisomerase II betaQ02880
1519ALMEQQHYVIntegrin beta8 subunit precursorP26012
1520YLMDTSGKVReplication Protein AP27694
1521ILDDIGHGVAbl Binding protein 3U31089
1522LLDRFLATVCyclin IQ14094
1523LLIDDKGTIKLCell Division Control Protein 2P06493
(CDC2)
1524RLYPWGVVEVSeptin 2 (NEDD5)Q15019
1525KLQELNYNLSTAT1 alpha/betaP42224
1526ILIEHLYGLLDL Receptor-related protein (LRP) Q07954
1527YLIELIDRVTACE (ADAM17)NP-068604
1528NLMEQPIKVJunction plakoglobin (gammaP14923
catenin)
1529FLAEDALNTVEDDR1Q08345
1530TLLNVIKSVIP3 receptor type IIQ14571
1531MLKDIIKEYMelanoma-associated antigen D2Q9UNF1
(MAGE-D2 antigen)(MAGE-D)
(Breast cancer-associated gene 1
protein)(BCG-1)(11B6)
(Hepatocellular carcinoma-associated
protein JCL-1)
1532TSYVKVLEHMelanoma-associated antigen 4P43358
(MAGE-4 antigen)(MAGE-X2)
(MAGE-41)
1533HEYLKAFKVHUMAN Retinoblastoma-likeQ08999
protein 2 (130 kDa retinoblastoma-
associated protein)(PRB2)(P130)
(RBR-2)

TABLE 3
SEQ ID NO, Parent Protein Identification and SwissProt Identification
Number for full-length sequences 792-1513
Parent
SwissProt
SEQIdentification
ID NO:Parent Sequence IdentificationNo.
792BCL-6 corepressor long isoform_Q6W2J9
793E1B_19K/Bcl-2-interacting protein Nip3Q12983
794Similar to Heat shock protein HSP 90-beta P08238
(HSP 84) (HSP 90)
795Cytochrome P450 11B2, mitochondrial P19099
precursor
7962′-5′oligoadenylate synthetase 3Q2HJ14
79726S protease regulatory subunit 4 (P26s4)P62191
79826S proteasome non-ATPase regulatory P51665
subunit 7
79926S proteasome non-ATPase regulatory O00487
subunit 14
80040S ribosomal protein S16P62249
80140S ribosomal protein S6 P62753
(Phosphoprotein NP33)
80240S ribosomal protein S9P46781
80360S ribosomal protein L10a (CSA-19)P62906
8046-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 4 (6PF-2-K/Fru-2,6-P2ASE Q16877
testis-type isozyme)
805Cleavage and polyadenylation specificity Q9UKF6
factor, 73 kDa subunit (CPSF 73 kDa subunit)
806A kinase anchor protein 10, mitochondrial O43572
precursor
807Actin, cytoplasmic 1 (Beta-actin)P60709
808Activated T-cell marker CD109Q6YHK3
809Activin receptor type 2A precursor P27037
(EC 2.7.11.30)
810ADAM19 proteinQ8TBU7
811AP-1 complex subunit beta-1 Q10567
(Adapter-related protein complex 1
beta-1 subunit) (Beta-adaptin 1)
812Adaptor-related protein NF01019537Q9BYI8
813Lung alpha/beta hydrolase protein 1Q96SE0
814Alpha-actinin-3Q08043
815Ankyrin-2 (Brain ankyrin) (Ankyrin-B)Q01484
816Ankyrin repeat and SOCS box protein 17Q8WXJ9
817Anti-colorectal carcinoma heavy chainQ65ZQ1
818APOBEC1 complementation factor Q9NQ94
(APOBEC1-stimulating protein)
819Probable DNA dC->dU-editing enzyme Q96AK3
APOBEC-3D (EC 3.5.4.—)
820Apolipoprotein-L4 precursor Q9BPW4
(Apolipoprotein L-IV)
821Apoptosis stimulating of p53 protein 1Q96KQ4
822Nucleoporin 188 kDa (arachin)Q5SRE5
823Protein ariadne-1 homolog (ARI-1) Q9Y4X5
(Ubiquitin-conjugating enzyme E2-
binding protein 1)
824Set1/Ash2 histone methyltransferase Q9UBL3
complex subunit ASH2
(ASH2-like protein)
825ATP synthase F0 subunit 8Q85KZ3
826Splice isoform 2 of Q9H7F0 ATPase_Q9H7F0
family_homolog_up-regulated_in_
senescence_cells_
827Probable phospholipid-transporting Q9Y2Q0
ATPase IA (EC 3.6.3.1)
(Chromaffin granule ATPase II)
828ATP-binding cassette A10Q8WWZ4
829ATP-binding cassette sub-family A Q9BZC7
member 2 (ATP-binding cassette
transporter 2) (ATP-binding cassette 2)
830Autoantigen RCD8Q6P2E9
831xonemal dynein heavy chain 8Q96JB1
832Butyrophilin-like protein 8 precursorQ6UX41
833Ubiquitin carboxyl-terminal hydrolase 20 Q9Y2K6
(EC 3.1.2.15)
834Bardet-Biedl syndrome 7 protein Q8IWZ6
(BBS2-like protein 1)
835Large proline-rich protein BAT2 P48634
(HLA-B-associated transcript 2)
836Bcl-2 related ovarian killerQ9UL32
837Lipopolysaccharide-responsive and beige-P50851
like anchor protein (CDC4-like protein)
838Splice isoform 3 of P35612P35612-3
839UDP-GlcNAc:betaGal beta-1,3-N-Q9Y2A9
acetylglucosaminyltransferase 3
(EC 2.4.1.—)
840Cell growth inhibiting protein 39Q2TTR2
841BH3-interacting domain death agonist (BID)P55957
842CD48 antigen precursor (B-lymphocyte P09326
activation marker BLAST-1)
843Bone morphogenetic protein receptor type-2 Q13873
precursor (EC 2.7.11.30)
844Bullous pemphigoid antigen 1, isoform 7Q8WXK8
845BRCA1 associated RING domain 1 variantQ53F80
846Breast cancer type 2 susceptibility protein P51587
(Fanconi anemia group D1 protein)
847Protein BRE (Brain and reproductive Q9NXR7
organ-expressed protein) (BRCA1/
BRCA2-containing complex subunit 45)
848Breast cancer 1 early onsetQ3LRJ0
849Breast and ovarian cancer susceptibility Q7KYU6
protein
850BTG2 protein (NGF-inducible anti-P78543
proliferative protein PC3)
851Nuclear protein 5qNCAQ7LBC6
852CAD protein [Includes: Glutamine-dependent P27708
carbamoyl-phosphate synthase (EC 6.3.5.5);
Aspartate carbamoyltransferase (EC 2.1.3.2);
Dihydroorotase (EC 3.5.2.3)]
853Cadherin EGF LAG seven-pass G-type Q9NYQ7
receptor 3 precursor (Flamingo homolog 1)
(hFmi1) (Multiple epidermal growth factor-
like domains 2) (Epidermal growth
factor-like 1)
854Cadherin FIB3Q6UW70
855Integrin alpha-3 precursor (Galactoprotein B3)P26006
856Calcineurin B homologous protein 2 O43745
(Hepatocellular carcinoma-associated
antigen 520)
857Calcium/calmodulin-dependent protein Q7Z7J9
kinase II inhibitor alpha (CaMKIINalpha)
858Calpain-11 (EC 3.4.22.—)Q9UMQ6
859Alpha-1 catenin (Cadherin-associated protein) P35221
(Alpha E-catenin)
860Neural cell adhesion molecule variantQ59FY0
861Ribosomal L1 domain-containing protein 1 O76021
(Cellular senescence-inhibited gene protein)
862CENP-F kinetochore protein P49454
(Centromere protein F) (Mitosin)
863Centaurin-delta 1 (Cnt-d1) (Arf-GAP, Q8WZ64
Rho-GAP, ankyrin repeat and pleckstrin
homology domain-containing protein 2)
864Centrosomal protein 2 (Centrosomal Nek2-Q9BV73
associated protein 1) (C-NAP1)
865Pericentriol material 1Q15154
866Cervical cancer suppressor gene 5Q8NFX8
867T-complex protein 1 subunit zeta-2Q92526
868Chemokine-like factor (C32)Q9UBR5
869Vacuolar protein sorting 13AQ96RL7
870Chromodomain-helicase-DNA-binding O14647
protein 2 (EC 3.6.1.—)
871FERM domain-containing protein 6Q96NE9
872Putative protein C21orf56Q9H0A9
873Adiponutrin (iPLA2-epsilon)Q9NST1
884Coatomer subunit gamma-2Q9UBF2
875Sodium/potassium/calcium exchanger 2 Q9UI40
precursor
876Exportin-1 (Chromosome region O14980
maintenance 1 protein homolog)
877CUB and sushi domain-containing Q7Z407
protein 3 precursor
878Cullin-7 (CUL-7)Q14999
879Cyclic AMP-dependent transcription P18848
factor ATF-4
880S-phase kinase-associated protein 1A P63208
(Cyclin A/CDK2-associated protein p19)
881Cyclin-A1P78396
882Cyclin M3, isoform 1Q8NE01
883Cystathionine beta-synthase human homolog Q58H57
of Cynomolgus monkey gene product
884Cytochrome P450 2E1 (EC 1.14.14.1)P05181
885Keratin, type II cytoskeletal 8P05787
886CPEB2 proteinQ3B8N6
887Probable ATP-dependent RNA helicase P17844
DDX5 (EC 3.6.1.—)
888Dedicator of cytokinesis protein 1Q14185
889Development and differentiation-O43150
enhancing factor 2
890Probable ubiquitin carboxyl-terminal O00507
hydrolase FAF-Y (EC 3.1.2.15)
891G2 and S phase expressed protein 1Q9NYZ3
892HUMAN CDNA FLJ30829 fis, clone Q96NI3
FEBRA2001790, highly similar to Xenopus
laevis RRM-containing protein SEB-4 mRNAQ96B95
893KIAA1799 protein
894Peroxisomal proliferator-activated receptor Q9BYK8
A-interacting complex 285 kDa protein
(EC 3.6.1.—) (ATP-dependent helicase
PRIC285)
895HUMAN KIAA1922Q96PW6
896Transcription elongation factor SPT5 O00267
(DLC-1) (deleted in liver cancer-1)
897DNA damage-binding protein 1 Q16531
(Damage-specific DNA-binding protein 1)
898DNA excision repair protein ERCC-6Q03468
899DNA polymerase alpha subunit B Q14181
(DNA polymerase alpha 70 kDa subunit)
900DNA replication licensing factor MCM2P49736
(Minichromosome maintenance protein 2
homolog)
901DNA2-like homolog (EC 3.6.1.—) P51530
(DNA replication ATP-dependent
helicase-like homolog)
902Estrogen response element binding protein O77798
(cotton-top Tarmarin), DNA2-like
homolog (human)
903DNA damage-inducible transcript 3 P35638
(DDIT-3) (Growth arrest and DNA-
damage-inducible protein GADD153)
904DNA-directed RNA polymerase I largest 095602
subunit (EC 2.7.7.6)
905DnaJ homolog subfamily C member 1Q96KC8
906Splice isoform 2 of P35462P35462-2
907RuvB-like 2 (EC 3.6.1.—) (48-kDa Q9Y230
TATA box-binding protein-
interacting protein)
908DRE1_proteinQ9NXT9
909Dynactin-1 (150 kDa dynein-associated Q14203
polypeptide)
910Dynein heavy chain, cytosolic (DYHC)Q14204
911Echinoderm microtubule associated Q6UYC9
protein-like 5
912ECT2 protein (Epithelial cell-Q9H8V3
transforming sequence 2 oncogene)
913Endothelial differentiation-related O60869
factor 1 (EDF-1)
914Developmentally-regulated endothelial O43854
cell locus 1 protein)
915Elongation factor 2 (EF-2)P13639
916J domain protein C21orf55Q9NX36
917EMILIN-3 precursor (EMILIN-5) Q9NT22
(Elastin microfibril interface-located
protein 5)
918Synaptotagmin-like protein 4 (Exophilin-2)Q96C24
919Enhancer of filamentation 1 (HEF1)Q14511
920Band 4.1-like protein 3 (4.1B) (Differentially Q9Y2J2
expressed in adenocarcinoma of the lung
protein 1) (DAL-1)
921Epidermal growth factor receptor P42566
substrate 15
922Epithelial membrane protein 3 (EMP-3) P54852
(YMP protein)
923Zyxin (Zyxin-2)Q15942
924Eukaryotic translation initiation factor 4 Q04637
gamma 1
925F-actin capping protein beta subunitP47756
926Protocadherin Fat 2 precursor (hFat2) Q9NYQ8
(Multiple epidermal growth factor-like
domains 1)
927KIAA1752 proteinQ9C0B1
928Fc alpha/mu receptorQ8WWV6
929Low affinity immunoglobulin gamma P08637
Fc region receptor III-A precursor
(IgG Fc receptor III-2)
930FYVE, RhoGEF and PH domain-Q7Z6J4
containing protein 2 (Zinc finger FYVE
domain-containing protein 4)
931Fibroblast growth factor receptor-like 1 Q8N441
precursor (FGF receptor-like protein 1)
932Fibroblast growth factor receptor 4 P22455
precursor (EC 2.7.10.1)
933Fibroblast growth factor receptor 2 P21802
precursor (EC 2.7.10.1) (FGFR-2)
934FK506-binding protein 7 precursor Q9Y680
(EC 5.2.1.8)
935Glomulin (FKBP-associated protein) Q92990
(FK506-binding protein-associated protein)
936FKSG73Q9BWW1
937Flavin containing monooxygenase Q53FW5
3 isoform 2 variant
938Protein flightless-1 homologQ13045
939Guanylate-binding protein 4Q96PP9
940Filamin-A (Alpha-filamin) (Filamin-1)P21333
(Endothelial actin-binding protein)
941FLJ10101 proteinQ8WU94
942CDNA FLJ14503 fis, cloneQ96T17
NT2RM1000252, weakly similar to
H. sapiens E-MAP-115 mRNA
943E2F8 proteinQ5BKY4
944Human Hypothetical proteinQ2VPJ3
945HUMAN CDNA FLJ34154 fis, Q8NB70
clone FCBBF3013058
946Hypothetical protein FLJ43654 Q6ZUJ4
(Hypothetical protein C3orf62)
947HUMAN CDNA FLJ46180 fis, Q6ZRQ5
clone TESTI4004031
948Flotillin-2 (Epidermal surface antigen) Q14254
(ESA)
949Serine/threonine-protein kinase ATR Q13535
(EC 2.7.11.1) (Ataxia telangiectasia and
Rad3-related protein) (FRAP-related protein 1)
950Frizzled 5 precursor (Frizzled-5)Q13467
951Fructose-bisphosphate aldolase C P09972
(EC 4.1.2.13)
952G protein pathway suppressor 1 isoform Q53HS2
1 variant
953KiSS-1 receptor (KiSS-1R) (Kisspeptins Q969F8
receptor) (Metastin receptor) (G-protein
coupled receptor 54)
954Probable G-protein coupled receptor 55Q9Y2T6
955Probable G-protein coupled receptor 35Q9HC97
956G-protein coupled receptor family C Q9NQ84
group 5 member C precursor (Retinoic
acid-induced gene 3 protein)
957Leucine-rich repeat-containing G-protein O75473
coupled receptor 5 precursor (Orphan
G-protein coupled receptor HG38)
(G-protein coupled receptor 49)
(G-protein coupled receptor 67)
958Probable G-protein coupled receptor 133 Q6QNK2
precursor (G-protein coupled receptor PGR25)
959G1 to S phase transition protein 1 homolog P15170
(GTP-binding protein GST1-HS)
960Gamma-aminobutyric-acid receptor alpha-6 Q16445
subunit precursor (GABA(A) receptor)
961Ganglioside-induced differentiation-Q96MZ0
associated protein 1-like 1 (GDAP1-L1)
962Gap junction alpha-5 protein P36382
(Connexin-40) (Cx40)
963GEM-interacting protein (GMIP)Q9P107
964Golgin subfamily B member 1 (Giantin)Q14789
965UDP-N-acetylhexosamine pyrophosphorylase Q16222
(Antigen X)
966Neutral alpha-glucosidase AB precursor Q14697
(EC 3.2.1.84)
967Probable dolichyl pyrophosphate Q9BVK2
Glc1Man9GlcNAc2 alpha-1,3-
glucosyltransferase (EC 2.4.1.—)
968Bifunctional aminoacyl-tRNA synthetase P07814
[Includes: Glutamyl-tRNA synthetase
(EC 6.1.1.17) (Glutamate--tRNA ligase);
Prolyl-tRNA synthetase (EC 6.1.1.15)
(Proline--tRNA ligase)]
969Glycoprotein nmb-like proteinQ8IXJ5
970Prolactin-releasing peptide receptor P49683
(PrRP receptor) (PrRPR) (G-protein
coupled receptor 10)
971G protein-coupled receptor 112Q5EGP2
972Growth factor receptor-bound protein 14 Q14449
(GRB14 adapter protein)
973GRIP and coiled-coil domain-containing Q8IWJ2
protein 2 (Golgi coiled coil protein GCC185)
(CTCL tumor antigen se1-1)
974GROS1-L proteinQ9HC86
975Growth hormone secretagogue receptor type 1 Q92847
(GHS-R)
976Glutathione S-transferase A4-4 (EC 2.5.1.18)O15217
977GTP-binding protein Rhes (Ras homolog Q96D21
enriched in striatum) (Tumor endothelial
marker 2)
978GTP-binding protein Rit1 (Ras-like protein Q92963
expressed in many tissues)
979VGFG2573Q6UY45
980Hypothetical protein HDLBPQ53QU2
981Heat shock protein 75 kDa, mitochondrial
precursor (HSP75) (Tumor necrosis factor Q12931
type 1 receptor-associated protein)
982Heat shock protein apg-1Q53ZP9
983Tumor rejection antigen (Gp96) 1Q5CAQ5
984Heat-shock protein beta-3 (HspB3) Q12988
(Heat shock 17 kDa protein)
985Low-density lipoprotein receptor-related O75197
protein 5 precursor
986Regulator of telomere elongation helicase 1Q9NZ71
(EC 3.6.1.—) (Helicase-like protein NHL)
987Hematopoietic protein 1Q52LW0
988Heme oxygenase 1 (EC 1.14.99.3) (HO-1)P09601
989Heparan sulfate glucosamine 3-O-Q8IZT8
sulotransferase 5 (EC 2.8.2.23)
990Hepatocellular carcinoma-associated antigen 66Q9NYH9
991Melanoma-associated antigen E2 Q8TD90
(MAGE-E2 antigen) (Hepatocellular
carcinoma-associated protein 3)
99226S proteasome non-ATPase regulatory O75832
subunit 10 (26S proteasome regulatory
subunit p28) Hepatocellular carcinoma-
associated protein p28-II
993HephaestinQ5JUU1
994HECT domain and RCC1-like domain-O95714
containing protein 2 (HERC2)
995Heteregeneous nuclear ribonucleoproteins P22626
A2/B1 (hnRNP A2/hnRNP B1)
996Heteregeneous nuclear ribonuleoprotein R O43390
(hnRNP R)
997HEXIM1 protein (HMBA-inducible)O94992
998Histatin-1 precursor (Histidine-rich protein 1)P15515
999Histone deacetylase 1 (HD1)Q13547
1000Histone deacetlase 9 (HD9) (HD7B) (HD7)Q9UKV0
1001Homeodomain-interacting protein kinase 2 Q9H2X6
(EC 2.7.11.1)
1002Cullin-2 (CUL-2)Q13617
1003SWI/SNF-related matrix-associated actin-O60264
dependent regulator of chromatin subfamily A
member 5 (EC 3.6.1.—)
1004HUMAN HPSC027 26S proteasome non-ATPaseQ9Y6E3
regulatory subunit 13 Synonyms 26S proteasome
regulatory subunit S11 26s proteasome regulatory
subunit p40.5
1005Hypothetical protein (Novel protein HSPC117)Q9Y3I0
(DJ149A16.6 protein) (Hypothetical protein
HSPC117)
1006Claudin domain-containing protein 1 Q9NY35
(Membrane protein GENX-3745) Q9NY35
1007Large neutral amino acids transporter small Q9UHI5
subunit 2 (L-type amino acid transporter 2)
(hLAT2)
1008Heterogeneous nuclear ribonucleoprotein C-like 1O60812
(hnRNP core protein C-like 1)
1009Ornithine decarboxylase (EC 4.1.1.17) (ODC)P11926
1010Regulator of nonsense transcripts 2Q9HAU5
(Nonsense mRNA reducing factor 2)
(Up-frameshift suppressor 2 homolog) (hUpf2)
1011ATX10_HUMAN Ataxin-10Q9UBB4
1012KIAA1833 proteinQ569G6
1013HUMAN UDP-GalNAc:betaGlcNAc beta 1,3-Q8NCR0
galactosaminyltransferase, polypeptide 2
(Beta 1,3-N-acetylgalactosaminyltransferase-II)
(MGC39558)
1014Hypothetical protein KIAA1033Q2M389
1015Activating signal cointegrator 1 complexQ8N3C0
subunit 3 (EC 3.6.1.—)
1016Delta-interacting protein A (Hepatitis deltaQ15834
antigen-interacting protein A) Coiled-coil
domain-containing protein 85B)
1017Hypothetical protein HLJ14466Q96BP7
1018Interferon-inducible double stranded RNA-O75569
dependent protein kinase activator A
1019Hypothetical protein C9orf142Q9BUH6
1020Tetratricopeptide repeat protein 17Q96AE7
1021CDNA FLJ14058 fis, clone HEMBB1000554Q9H7Z0
1022Anaphase promoting complex subunit 13Q9BS18
1023Hypothetical protein CCDC60Q8IWA6
1024Sphingosine kinase 2 (EC 2.7.1.—)Q9NRA0
1025Probable ATP-dependent RNA helicase DDX11Q96FC9
(EC 3.6.1.—) (DEAD/H box protein 11) (CHL1
homolog) (Keratinocyte growth factor-regulated
gene 2 protein) (KRG-2)
1026Protein KIAA0182Q14687
1027Ras GTPase-activitating protein SynGAP Q96PV0
(Synaptic Ras-GTPase-activating protein 1)
(Synaptic Ras-GAP 1) (Neuronal RasGAP)
1028Fibrinogen C domain containing 1Q8N539
1029MGC39581 proteinQ86XM0
1030Bcl-2-like 13 protein (Mil1 protein) (Bcl-rambo)Q9BXK5
1031Myosin head domain containing 1Q96H55
1032WD-repeat protein 51AQ8NBT0
1033KIF27A (OTTHUMP00000021559)Q86VH2
1034Inositol polyphosphate-5-phosphatase F,Q2T9J4
isoform 1
1035MyopalladinQ96KF5
1036Rho GTPase activitating protein 12Q5T2Y2
1037Hypothetical protein DKFZp686D0630Q7Z3C5
1038Jumonji domain-containing protein 1CQ15652
(Thyroid receptor-interacting protein 8)
(TRIP-8)
1039Coatomer subunit beta (Beta-coat protein) P53618
(Beta-COP)
1040FLJ10462 fis, clone NT2RP1001494, weaklyQ9NVW8
similar to MALE STERILITY PROTEIN 2
1041Cell-cycle and apoptosis regulatory protein 1Q6X935
1042Telomere-associated protein RIF1 Q5UIP0
(Rap1-interacting factor 1 homolog)
1043F-box only protein 28Q9NVF7
1044CDNA FLJ10901 fis, clone NT2RP5003524Q9NV65
1045Acetoacetyl-CoA synthetase (EC 6.2.1.16)Q86V21
1046Putative cell cycle control proteinQ9NXZ0
(DEP domain containing 1)
1047Synaptopodin 2-likeQ68A20
1048CDNA FLJ36560 fis, clone TRACH2009340Q8N9T8
1049CDNA FLJ13330 fis, clone OVAR1001802Q9H8Q0
1050ATP-dependent RNA helicase DDX31Q9H8H2
(EC 3.6.1.—) DEAD box protein) (Helicain)
1051Protein C14orf161Q9Y4P1
1052Cysteine protease ATG4B (EC 3.4.22.—)
(Autophagy-related protein 4 homolog B)
1053CDNA FLJ14526 fis, clone NT2RM1001139Q96T08
1054Hypothetical protein CCDC77 (CDNAQ9BR77
FLJ14732 fis, clone NT2RP3001969, weakly
similar to TRICHOHYALIN)
1055CDNA FLJ14790 fis, clone NT2RP4000973,Q96K38
weakly similar to PROBABLE PROTEIN
DISULFIDE ISOMERASE P5 (EC 5.3.4.1)
1056Keratin 24Q2M2I5
1057BCor protein (BCL-6 corepressor)Q6W2J9
1058Hypothetical protein FLJ20582Q6IQ21
1059Hypothetical protein FLJ22688Q9BT04
1060Hypothetical protein FLJ22944Q9H5W3
1061Zinc finger protein, subfamily 1A, 5-Q8TBE5
1062Leucine-rich repeats and IQ motif containing 2Q8IW35
1063Hypothetical protein FLJ23749Q8TEA0
1064Hypothetical protein FLJ25336http://www.ex
pasy.org/sprot/
userman.html
-
-
AC_lineQ96L
P1
1065Hypothetical protein FLJ25660Q8N7G6
1066CDNA FLJ30058 fis, clone ADRGL2000074, Q96NU6
weakly to RHO-GTPASE-ACTIVATING
PROTEIN 6
1067CDNA FLJ30106 fis, clone BNGH41000190,Q96A82
weakly similar to Rattus norvegicus schlafen-4
(SLFN-4) mRNA.
1068WhirlinQ9P202
1069CDNA FLJ31846 fis, clone NT2RP7000425,Q96MV0
weakly similar to MYOSIN HEAVY CHAIN,
NONMUSCLE TYPE B
1070FLJ32833 fis, clone TESTI2003228Q96M43
1071Guanine nucleotide-binding protein G(olf),P38405
alpha subunit (Adenylate cyclase-stimulating G
alpha protein, olfactory type)
1072CDNA FLJ33811 fis, clone CTONG2002095Q8N279
1073Transmembrane protein 16CQ9BYT9
1074Zinc finger protein 31 (Zinc finger protein P17040
KOX29) (Zinc finger and SCAN domain-
containing protein 20) (Zinc finger protein 360)
1075Transmembrane 6 superfamily member 2Q9BZW4
1076CDNA FLJ90251 fis, clone NT2RM4000115Q8NCH3
1077CDNA FLJ90760 fis, clone THYRO1000061Q8N2I4
1078Tubulin--tyrosine ligase-like protein 12Q14166
1079KIAA0303 proteinO15021
1080Plexin-B2 precursor (MM1)O15031
1081Zinc finger and BTB domain-containing protein 5O15062
1082Centrosome-associated protein 350Q8WY20
1083piccolo (Aczonin)Q9Y6V0
1084KIAA0560 proteinO60306
1085KIAA0676 proteinQ96H49
1086Human homolog of Mus SLIT and NTRK-like Q810B7
protein 5 precursor
1087NischarinQ6PIB4
1088FERM domain-containing protein 4AQ9P2Q2
1089Leucine-rich repeats neuronal protein 1 Q6UXK5
precursor (Neuronal leucine-rich repeat
protein 1) (NLRR-1)
1090KIAA1512 proteinQ9P216
1091KIAA1598 proteinQ9HCH4
1092Phosphatidylinositol-3 phosphate 3-phosphataseQ96QU2
adaptor subunit
1093KIAA1730 proteinQ9C0D3
1094KIAA1786 proteinQ96JN9
1095Hypothetical protein MGC20470Q96EK3
1096OACT1 proteinQ86XC2
10976-phosphofructo-2-kinase/fructose-2,6-Q16877
biphosphatase 4 (6PF-2-K/Fru-2,6-P2ASE
testis-type isozyme)
1098IkappaB kinase complex-associated proteinO95163
(IKK complex-associated protein) (p150)
1099Immune receptor expressed on myeloidQ7Z7I3
cells 2
1100High-affinity cAMP-specific and IBMX-O60658
insensitive 3′,5′-cyclic phosphodiesterase
8A (EC 3.1.4.17)
1101Bone specific CMF608Q6WRI0
1102Importin alpha-7 subunit (Karyopherin alpha-6)O60684
1103InaD-like protein (Inadl protein) (hINADL)Q8NI35
(Pals1-associated tight junction protein)
(Protein associated to tight junctions)
1104Nitric oxide synthase, inducible (EC 1.14.13.39)P35228
1105Transcription elongation factor SPT5 (hSPT5)O00267
1106Inositol-trisphosphate 3-kinase B (EC 2.7.1.127)P27987
(Inositol 1,4,5-triphosphate 3-kinase B)
1107Type I inositol-3,4-biphosphate 4-phosphataseQ96PE3
(EC 3.1.3.66) (Inositol polyphosphate 4-
phosphatase type I)
1108Insulin receptor beta subunitQ9UCB7
1109Insulin-like growth factor binding protein,Q8TAY0
acid labile subunit
1110Integrin beta-4 precursor (GP150) P16144
(CD104 antigen)
1111Splice isoform 2 of P35462P35462-2
1112Interferon alpha 2 proteinQ16055
1113Interferon-induced protein with tetratricopeptideP09914
repeats 1 (IFIT-1) ) (Interferon-induced
56 kDa protein) (IFI-56K)
1114Interleukin-20 precursor (IL-20) (Four alphaQ9NYY1
helix cytokine Zcyto10)
1115Steroid receptor RNA activator isoform 1Q9HD15
1116Intersectin-2 (SH3 domain-containing protein
1B) (SH3P18) (SH3P18-like WASP-associated Q9NZM3
protein)
11117ITI-like protein (Inter-alpha (Globulin) inhibitor Q6UXX5
H5-like)
1118Gap junction alpha-5 protein (Connexin-40)P36382
1119 Kelch-like prolein 8Q9P2G9
1120 Keratin, type II cytoskeletal 1 (Cylokeralin-1) P04264
1121ADAM 9 precursor (EC 3.4.24.—)Q13443
(A disintegrin and metalloproteinase domain 9)
(Metal loprotcase/disintegrin/cysteine-rich
protein 9) (Myeloma cell metalloproleinase)
1122Next to BRCA1 gene 1 protein (Neighbor of Q14596
BRCA1 gene1 protein) (Membrane component,
chromosome 17, surface marker 2) (1A1-3B)
1123Hypothetical protein DKFZp686K2075Q6MZZ8
1124 KIAA0100 proteinQ14667
1125 Pre-mRNA-splicing factor ATP-dependent RNA Q92620
helicase PRP16 (EC 3.6.1.—) (ATP-dependent
RNA helicase DHX38) (DEAH box prolein 38)
1126KIAA0251 protein Q8TBS5
1127HUMAN KIAA0342 proteinO15050
1128KIAA0357 protein O15064
1129Hypothetical protein KIAA0372Q6PGP7
1130KIAA0377 splice variant 2 Q86TE7
1131 KIAA0386 proteinQ9Y4F9
1132 HUMAN CTCL tumor antigen HD-CL-04Q548S1
1133Importin-13 (Imp13) (Ran-binding protein 13)O94829
1134 KIAA0769 proleinO94868
1135Hypothetical protein KIAA0863Q6IQ32
1136Zinc finger protein KIAA1196-Q96KM6
1137CRSP complex subunit 3 (Cofactor required for Q9ULK4
Sp1 transcriptional activation subunit 3)
(Transcriptional coactivator CRSP130)
(Vitamin D3 receptor-interacting protein
complex 130 kDa component
1138[Pyruvate dehydrogenase [lipoamide]]-Q9P2J9
phosphatase 2, mitochondrial precursor
(EC 3.1.3.43)
1139Protocadherin-10 precursorQ9P2E7
1140 Leucine-rich repeats and calponin homology Q5VUJ6
(CH) domain containing 2
1141 Ankyrin repeat domain 18BQ5W0G2
1142Kin17 protein (HsKin17 protein) (KIN, antigenic O60870
determinant of recA protein homolog)
1143Kinesin-like protein KIF13A Q9H1H9
(Kinesin-like protein RBKIN)
1144 Putative RNA binding protein KOCO00425
1145 Keratin, type I cytoskeletal 18 (Cytokeratin-18) P05783
1146 Kv3.2d voltage-gated potassium channelQ86W09
1147 Lethal(3)malignant brain tumor-like protein Q9Y468
(L(3)mbt-like) (L(3)mbt protein homolog)
1148Lactadherin precursor (Milk fat globule-EGF Q08431
factor 8) (MFG-E8) (HMFG) (Breast
epithelial antigen BA46) (MFGM)
1149Lamin-A/C (70 kDa lamin)P02545
1150 Laminin gamma-1 chain precursor P11047
(Laminin B2 chain)
1151 Low-density lipoprotein receptor-related O75197
protein 5 precursor
1152Leptin receptor precursor (LEP-R) P48357
(OB receptor)
1153 Mitogen-aclivated protein kinase kinase O43283
kinase 13 (EC 2.7.11.25)
1154 Leukemia virus receptor 2Q08357
1155 Leukemia-associated protein with a CXXC Q8NFU7
domain RNA-binding protein 6 (RNA-binding
motif protein 6)
1156 (RNA-binding protein DEF-3) (Lung cancer P78332
antigen NY-LU-12)
1157 Lung cancer oncogene 5Q7Z5Q7
1158 Heterogeneous nuclear ribonuclcoprotein M P52272
(hnRNP M)
1159 Macrophage migration inhibitory factor (MIF) P14174
(Phenylpyruvate lautomerase) (EC 5.3.2.1)
1160 Mitotic spindle assembly checkpoint protein Q9UI95
MAD2B (MAD2-like 2) (hREV7)
1161 Mitogen-activated protein kinase kinase kinase 4 Q9Y6R4
(EC 2.7.11.25) (MAPK/LRK kinase kinase 4)
1162Serine/threonine/tyrosine-interacting-like Q9Y6J8
protein 1 (Dual-specificity protein
phosphatase 24) (Map kinase phosphatase-like
protein MK-STYX)
1163Microtubule-associated serine/threonine-protein Q6P0Q8
kinase 2 (EC 2.7.11.1)
1164Matrix metalloprotease MMP-27Q9H306
1165MCM10 proteinQ7L590
1166 Interferon-induced helicase C domain-containing Q9BYX4
protein 1 (EC 3.6.1.—) (Melanoma
differentiation-associated protein 5)
1167 Melanoma ubiquitous mutated protein Q2TAK8
1168 Melanoma antigen family D, 2 Q5BJF3
1169 Melanocyte protein Pmel 17 precursor P40967
(Melanocyte lineage-specific antigen GP100)
1170GPI-anchored protein p137 (p137GPI) Q14444
(Membrane component chromosome 11
surface marker 1) Cytoplasmic activation/
proliferation-associated protein 1
1171Hepatocyte growth factor receptor P08581
precursor (EC 2.7.10.1) (HGF receptor)
(Scatter factor receptor) (SF receptor)
(HGF/SF receptor) (Met proto-oncogene
tyrosine kinase)
1172Mitogen-activated protein kinase 14 Q16539
(EC 2.7.11.24)
1173Mitogen-activated protein kinase kinase kinase Q12851
kinase 2 (EC 2.7.11.1) (MAPK/ERK kinase
kinase kinase 2)
1174 Mitotic kinesin-relaled protein Q96Q89
1175 Sperm-associated antigen 5 (Astrin) (Mitotic Q96R06
spindle-associated protein p126)
1176 Myeloid/lymphoid or mixed-lineage leukemia Q9UMN6
protein 4 (Trithorax homolog 2)
1177 Putative helicase MOV-10 (EC 3.6.1.—)Q9HCE1
(Moloney leukemia virus 10 protein)
1178 MOZ/CBP protein Q712H6
1179 Calgranulin B (Migration inhibitory factor-P6702
related protein 14) (MRP-14) (P14)
1180 MUC2_HUMAN Mucin-2 precursor Q02817
(Intestinal mucin 2)
1181Mucin-5B precursor (Mucin 5 subtype B,Q9HC84
tracheobronchial)
1182 Multiple PDZ domain protein O75970
(Multi PDZ domain protein 1)
(Multi-PDZ-domain protein 1)
1183 RUFY2 (Run and FYVE domain-containing Q8IW33
protein Rabip4
1184Multidrug resistance-associated protein 7Q8NHX7
1185Multiple copies in a T-cell malignancies Q9ULC4
(Malignant T cell amplified sequence 1)
(MCT1)
1186DNA mismatch repair protein Msh3P20585
1187 Protein CBFA2T2 (MTG8-like protein) O43439
(MTG8-relaled protein 1)
(Myeloid translocation-relaled protein 1)
1188Myomesin-1 (190 kDa titin-associated protein) P52179
(190 kDa) connectin-associated protein
1189 Myosin heavy chain, cardiac muscle beta P12883
isoform (MyHC-beta)
1190 Myosin-13 (Myosin heavy chain, skeletal muscle, Q9UKX3
extraocular) (MyHC-eo)
1191 Tumor suppressor candidate 3 (N33 protein)Q13454
1192 Nebulin-related anchoring proteinQ8TCH0
1193 Neural cell adhesion molecule 1, 1 PI3592
1194Neurotrimin precursor Q9P121
1195 NineinQ8N4C6
1196 Notch homolog 2 Q5VTD0
1197Neurogenic locus notch homolog protein 1 P46531
precursor (Notch 1) (hN1) (Translocation-
associated notch protein TAN-1) [Contains:
Notch 1 extracellular truncation; Notch 1
intracellular domain]
1198Neurogenic locus notch homolog protein 3 Q9UM47
precursor (Notch 3) [Contains: Notch 3
extracellular truncation; Notch 3 intracellular
domain ]
1199 Neurogenic locus notch homolog protein 4 Q99466
precursor (Notch 4) (hNotch4) [Contains:
Notch 4 extracellular truncation; Notch 4
intracellular domain]-
1200Plexin-A1 precursor (Semaphorin receptor NOV)Q9UIW2
1201 HUMAN NPD011 Q9H2R7
1202 Nuclear autoantigen Sp-100 (Speckled 100 kDa) P23497
(Nuclear dot-associated Sp100 protein)
1203Nuclear factor erythroid 2-related factor 1 (NF-Q14494
E2-related factor 1) (NFE-2-related factor 1)
(Nuclear factor, erythroid derived 2, like 1)
(Transcription factor 11) (Transcription factor
HBZ17) (Transcription factor LCR-F1) (Locus
control region-factor 1)
1204 Nuclear factor of activated T-cells, cytoplasmic 1 O95644
(NFAT transcription complex cytosolic
component) (NF-ATc1)
1205 Nuclear receptor coactivator 2 (NCoA-2) Q15596
(Transcriptional intermediary factor 2)
1206 Ubiquitin-like PHD and RING finger domain-Q96T88
containing protein 1 (EC 6.3.2.—)
1207Nucleic acid helicase DDXx Q8IWW2
1208 Nucleoporin 62 kDa (NUP62 protein) Q6GTM2
1209Nuclear pore complex protein Nup98-Nup96 P52948
precursor [Contains: Nuclear pore complex
protein Nup98 (Nucleoporin Nup98)
(98 kDa nucleoporin);
1210Nucleoprotein TPRP12270
1211Nuclear pore complex protein Nup107P57740
1212Nuclear pore complex protein Nup205Q92621
1213ODF2 protein QAPJQ8
1214Trophoblast glycoprotein precursor Q13641
(5T4 oncofetal trophoblast glycoprotein)
1215Dynamin-like 120 kDa protein, mitochondrial O60313
precursor (Optic atrophy 1 gene protein)
1216 Orexin receptor type 2 (Ox2r) (Hypocretin O43614
receptor type 2)
1217 Transmembrane emp24 domain-containing P49755
protein 10 precursor (Transmembrane protein
Tmp21)
1218 Orphan nuclear receptor TR2 (Testicular P13056
receptor 2)
1219MKL/myocardin-like protein 1 (Myocardin-Q969V6
related transcription factor A) (MRTF-A)
(Megakaryoblastic leukemia 1 protein)
(Megacaryocytic acute leukemia protein)
1220Ovarian cancer related tumor marker CA125- Q8WXI7
1221Oxysterol-binding protein-related protein 8 Q9BZF1
(OSBP-related protein 8)
1222Centrosomal protein of 70 kDa (Cep70 protein) Q8NHQ1
(p10-binding protein)
1223Leucine carboxyl methyl transferase 2 O60294
(EC 2.1.1.—) (p21WAF1/CIP1 promoter-
interacting protein)
1224F-box/LRR-repeat protein 5 (F-box and Q9UKAJ
leucine-rich repeat protein 5) (F-box protein
FBL4/FBL5)
1225 Inhibitor of growth protein 3 Q9NXR8
1226P53 inducible protein Q9UN29
1227DNA polymerase alpha catalytic subunit P09884
(EC 2.7.7.7)
1228 Chloride intracellular channel protein 4 Q9Y696
(Intracellular chloride ion channel protein p64H1
1229Paired mesoderm homeobox protein 2B (Paired-Q99453
like homeobox 2B) (PXOX2B homeodomain
protein) (Neuroblastoma Phox)
1230 PRB3 proteinP81489
1231 Protein patched homolog 1 (PTC1) (PTC) Q13635
1232 Rap guanine nucleotide exchange factor 2 Q9Y4G8
(Neural RAP guanine nucleotide exchange
protein) (nRap GEP) (PDZ domain-containing
guanine nucleotide exchange factor 1)
(PDZ-GEF1)
1233 Pecanex-likc protein 1 (Pecanex homolog)-Q96RV3
1234 GC-1-related estrogen receptor alpha coactivator Q8TDK4
short isoform
1235 PHD finger Q86U89
1236 Hypothetical protein DKFZp686C07187Q6N038
1237 Phosphalidylinositol-4,5-bisphosphate 3-kinase P42338
catalytic subunit beta isoform (EC 2.7.1.153)
(PI3-kinase p110 subunit beta) (PtdIns-3-kinase
p110)
1238Phosphodiesterase 8A, isoform 1Q6P9H3
1239 Serine/threonine-protein kinase SMG1 Q96Q15
(EC 2.7.11.1) (SMG-1) (hSMG-1) (Lambda/iota
protein kinase C-interacting protein) (Lambda-
interacting protein) (
1240 PiggyBac transposable element derived 3 Q8N328
1241 PIWIL protein Q7Z3Z3
1242 Homeobox protein PKNOX1 (PBX/knotted P55347
homeobox 1)
1243 Transmembrane protein 115 (Protein PL6) Q12893
1244 Plakophilin-2 Q99959
1245 Plectin 6Q6S380
1246 Plectin 1 (PLTN) (PCN) Q15149
(Hemidesmosomal protein 1) (HD1) O43157
1247Plexin B1; plexin 5; semaphorin receptor
1248 Pleiotropic regulator 1 O43660
1249Blood vessel epicardial substance (hBVES) Q8NE79
(Popeye domain-containing protein 1) (Popeye
protein 1)
1250Carboxypeptidase-like protein X2 precursor Q8N436
1251 YIF1B protein Q5BJH7
1252 Melanoma antigen preferentially expressed in P78395
tumors (Pr4eferentially expressed antigen of
melanoma) (OPA-interacting protein 4)
1253Splice isoform 2 of Q9H7F0 Q9H7F0-2
1254 P2Y purinoceptor 13 (P2Y13) (G-protein coupled Q9BPV8
receptor 86) (G-protein coupled receptor 94)
1255Putative pre-mRNA-splicing factor ATP-O43143
dependent RNA helicase DHX15 (EC 3.6.1.—)
(DEAH box protein 15) (ATP-dependent RNA
helicase #46)
1256 HUMAN RNA-binding protein 34 (RNA-binding P42696
motif protein 34)
1257 Prolyl 4-hydroxylase alpha-1 subunit precursor
(EC 1.14.11.2) (4-PH alpha-1) (Procollagen-P13674
proline,2-oxoglutarate-4-dioxygenase alpha-1
subunit)
1258Profilin-1 P07737
1259Programmed cell death protein 5 (TEAR 19 O14737
protein) (TF-1 cell apoptosis-related gene 19
protein)
1260Propionyl-CoA carboxylase beta chain, P05166
mitochondrial precursor (EC 6.4.1.3)
1261 26S proteasome non-ATPase regulatory Q99460
subunit 1 (26S proteasome regulatory subunit
RPN2) (26S proteasome regulatory subunit S1)
(26S proleasome subunit p112)
126226S proteasome non-ATPase regulatory subunit 3 O43242
(26S proteasome regulatory subunit S3)
(Proteasome subunit p58)
1263Proteasome activator complex subunit 3 P61289
(Proteasome activator 28-gamma subunit)
(PA28gamma) (PA28g) (Activator of
multicatalytic protease subunit 3) (11S regulator
complex gamma subunit) (RFG-gamma) (Ki
nuclear autoantigen)
1264 Protein C14orf166 Q9Y224
1265Protein KIAA1219Q86X10
1266 Protein KIAA1688 Q9C0H5
1267Protein Plunc precursor (Palate lung and nasal Q9NP55
epithelium clone protein) (Lung-specific protein
X) (Nasopharyngeal carcinoma-related protein)
(Tracheal epithelium-enriched protein) (Secretory
protein in upper respiratory tracts)
1268 Protein transport protein Sec23B Q15437
1269 Liprin-alpha-2 (Protein tyrosine phosphatase O75334
receptor type f polypeptide-interacting protein
alpha-2) (PTPRF-interacting protein alpha-2)
1270 Protocadherin gamma A12 precursor (PCDH-O60330
gamma-A12) (Cadherin-21)
(Fibroblast cadherin 3)
1271 Protocadherin gamma A10 precursor (PCDH-Q9Y5H3
gamma-A10)
1272Leucine carboxyl methyltransferase 2 O60294
(EC 2.1.1.—) (p21WAF1/CIP1 promoter-
interacting protein)
1273 KIAA1636 proteinQ9HCD6
1274 Probable G-protein coupled receptor 160Q9UJ42
1275 Protein C21orf45Q9NYP9
1276 Periodic tryptophan protein 2 homologQ15269
1277 Rab-like protein 2BQ9UNT1
1278 Cell cycle checkpoint protein RAD17 (hRad17) O75943
(RF-C/activator 1 homolog)
1279 DNA repair protein RAD50 (EC 3.6.—.—) Q92878
(hRAD50)
1280Ras GTPase-activating protein 1 (GTPase-P20936
activating protein) (GAP) (Ras p21 protein
activator) (p120GAP) (RasGAP)
1281 Ras guanine nucleotide exchange factor 2 Q9UK56
1282 Ras-GTPase-activating protein-binding protein 1 Q13283
(EC 3.6.1.—) (ATP-dependent DNA helicase
VIII) (GAP SH3-domain-binding protein 1)
(G3BP-1) (HDH-VIII)
1283 Ras-related protein Rab-27A (Rab-27) (GTP-P51159
binding protein Ram)
1284 Ras-related protein Rab-3D O95716
1285 Nuclear pore complex protein Nup107 P57740
(Nucleoporin Nup107) (107 kDa nucleoporin)
1286 Receptor-interacting factor 1 Q86XS4
1287 Regulating synaptic membrane exocytosis protein Q9UJD0
3 (Nim3) (Rab-3 interacting molecule 3) (RIM 3)
(RIM3 gamma)
1288 Regulator of G protein signaling protein Q86UV0
(Regulator of G-protein signalling like 1)
1289 MHC class II regulatory factor RFX1 (RFX) P22670
(Enhancer factor C) (EF-C)
1290Retinoblastoma-associated protein (PP110) P06400
(P105-RB)
1291 Roundabout homolog 3 precursor (Roundabout-Q96MS0
like protein 3)
1292 Retinoblastoma-associated protein HEC O14777
(Kinetochore associated 2)
1293Retinoblastoma-associated protein RAP140 Q9UK61
1294 AT-rich interactive domain-containing protein P29374
4A (ARID domain-containing protein 4A)
(Retinoblastoma-binding protein 1)
1295Jumonji/AKID domain-containing protein 1A P29375
(Retinoblastoma-binding protein 2) (RBBP-2)
1296RhoGTPase regulating protein variant Q6RJU5
ARHGAP20-1ad
1297 40S ribosomal protein S4, Y isoform 2Q8TD47
1298RNA binding motif Q13380
1299 RNA binding protein (Autoantigenic, hnRNP- Q2M365
associated with lethal yellow), long isoform -
1300 RNA-binding protein Q8NI52
1301Ro ribonucleoprotein-binding protein 1 Q9UHX1
(SIAHBP1 protein)
1302 HUMAN OTTHUMP00000030902 Q5JYR6
1303 Ryanodine receptor 2 (Cardiac muscle-type Q92736
ryanodine receptor) (RyR2) (RYR-2) (Cardiac
muscle ryanodine receptor-calcium release
channel) (hRYR-2)
1304SEC14-like protein 1 Q92503
1305Secreted and transmembrane protein 1 precursor Q8WVN6
(Protein K12)
1306 Neudesin precursor (Neuron-derived Q9UMX5
neurotrophic factor)
1307 P-selectin glycoprotein ligand 1 precursor Q14242
(PSGL-1) (Selectin P ligand) (CD162 antigen)
1308 Semaphorin-6D precursor Q8NFY4
1309 Serine/threonine/tyrosine-interacting protein Q8WUJ0
(Protein tyrosine phosphatase-like protein)
1310Olfactory receptor 8G5 (Olfactory receptor Q8NG78
OR11-298)
1311 Shb-likc adapter protein, Shf Q7M4L6
1312 Signal transducer and activator of transcription P42224
1-alpha/beta (Transcription factor ISGF-3
components p91/p84) STAT1
1313 Signal transducer and activator of transcription 3 P40763
(Acute-phase response factor)
1314 40S ribosomal protein S7 P62081
1315 60S ribosomal protein L35P42766
1316 60S ribosomal protein L7 P18124
1317 Thrombospondin-2 precursor P35442
1318C3 and PZP-like alpha-2-macroglobulin Q8IZJ3
domain containing 8
1319 ATP-binding cassette sub-family F member 2 Q9UG63
(Iron-inhibited ABC transporter 2)
1320 Ribosome biogenesis protein BOP1 (Block of Q14137
proliferation 1 protein)
1321 CDNA FLJ13765 fis, clone PLACE4000128, Q9H8C5
weakly similar to Mus musculus putative
transcription factor mRNA
1322CD200 cell surface glycoprotein receptor Q6Q8B3
isoform 2 variant 2
1323 LRRC58 protein Q96CX6
1324 Claudin-6 (Skullin 2) P56747
1325 T-box transcription factor TBX18 O95935
(T-box protein 18)
1326 INTS7 protein Q8WUH5
1327FRAS1-related extracellular matrix protein 2 Q5SZK8
precursor (ECM3 homolog)
1328 Zinc finger protein 318 (Endocrine regulatory Q5VUA4
protein)
1329Eukaryotic translation initiation factor 3 subunit Q99613
8 (eIF3 p110) (eIF3c)
1330HUMAN LOC196394 protein Q8IY45
1331Hypothetical protein FLJ44216 Q8NDZ2
1332 Heat shock protein HSP 90-beta (HSP 84) P08238
(HSP 90)
1333 Sarcoma antigen NY-SAR-41 (NY-SAR 41) Q5T9S5
1334 Protein FAM86A Q96G04
1335 Ras-like family 11 member A Q6T310
(OTTHUMP00000018162)
1336Keratin, type I cytoskeletal 18 (Cytokeratin-18) P05783
(CK-18)
1337U3 small nucleolar RNA-associated protein Q9BVJ6
14 homolog A (Antigen NY-CO-16)
1338 Hypothetical protein DKFZp781D1722 Q68DM0
1339 Chromosome-associated kinesin KIF4A O95239
(Chromokinesin)
1340 Kinesin-like protein KIF6Q6ZMV9
1341Myosin-10 (Myosin heavy chain, nonmuscle IIb) P35580
(Nonmuscle myosin heavy chain IIb)
1342 Hypothetical protein C17orf57Q8IY85
1343 Similar to peptide N-glycanase homolog Q9BVR8
(S.cerevisiae)
1344 Peptidyl-prolyl cis-trans isomerase A P62937
(EC 5.2.1.8)
1345Serpin A13 precursor Q6UXR4
134640S ribosomal protein SA (p40) (34/67 kDa P08865
laminin receptor) (Colon carcinoma laminin-
binding protein) (NEM/1CHD4) (Multidrug
resistance-associated protein MGr1-Ag)
1347N-acetylglucosamine-1-phosphotransferase Q9UJJ9
subunit gamma precursor
1348 Liprin-beta-1 (Protein tyrosine phosphatase Q86W92
receptor type f polypeptide-interacting protein-
binding protein 1)
134940S ribosomal protein S3a P61247
135040S ribosomal protein S3aP61247
1351LOC124512 protein (Fragment)Q86XA0
1532Hypothetical protein MGC26744Q96KX1
1535Hypothetical protein LOC122258Q96KW9
1354Sulfiredoxin-1 (EC 1.8.98.2)Q9BYN0
1355BasalinQ5QJ38
1356Protein FAM86AQ96G04
1357Transmembrane protein 16FQ4KMQ2
1358TEB4 proteinO14670
1359SLC10A5Q5PT55
1360Serine/threonine-protein kinase SNF1-like P57059
kinase 1 (EC 2.7.11.1)
1361LOC391257 proteinQ6P094
1362Zinc finger protein 161 (Putative transcription Q14119
factor DB1)
1363Slit homolog 2 protein precursor (Slit-2)O94813
1364FYN-binding protein (FYN-T-binding protein)O15117
1365Jumonji/ARID domain-containing protein 1C P41229
(SmcX protein) (Xe169 protein)
1366Jumonji/ARID domain-containing protein 1DQ9BY66
(SmcY protein) (Histocompatibility Y antigen)
1367Monocarboxylate transporter 3 (MCT 3)O95907
1368Solute carrier family 4 sodium bicarbonate Q6U841
cotransporter-like member 10-
1369Sorting nexin 14, isoform aQ6NUI7
1370Sorting nexin-4O95219
1371Spectrin beta chain, brain 4 Q9NRC6
(Spectrin, non-erythroid beta chain 4)
1372Spermatogenesis-associated protein 7 Q9P0W8
(Spermatogenesis-associated protein HSD3)
1373Non-POU domain-containing octamer-Q15233
binding protein (NonO protein) (54 kDa
nuclear RNA- and DNA-binding
protein) (p54(nrb) (p54nrb) (55 kDa
nuclear protein)
1374Cohesin subunit SA-1 (Stromal antigen 1) Q8WVM7
(SCC3 homolog 1)
1375Steroid receptor RNA activator isoform 1 Q9HD15
1376Structure-specific recognition protein 1 (SSRP1)
(Recombination signal sequence recognition Q08945
protein) (T160) (Chromatin-specific
transcription elongation factor 80 kDa subunit)
1377Suppressor of hairy wing homolog 2 (5′OY11.1) Q86YH2
(Zinc finger protein 632)
1378Transcription elongation factor SPT5 (hSPT5) O00267
(DRB sensitivity-inducing factor large subunit)
(DSIF large subunit) (DSIFp160) (Tat-
cotransactivator 1 protein) (Tat-CT1 protein)-
1379Synaptogyrin-3O43761
1380Synaptojanin-2-binding protein (Mitochondrial P57105
outer membrane protein 25)
1381Synemi Q8TE61
1382Talin-1Q9Y490
1383TAR RNA loop binding protein Q13395
(TAR (HIV) RNA binding protein 1)
1384Taste receptor type 2 member 3 (T2R3)Q9NYW6
1385Taste receptor type 2 member 40 (T2R40) P59535
(T2R58) (G-protein coupled receptor 60)
1386Oxidoreductase HTATIP2 (HC 1.1.1.—) Q9BUP3
(HIV-1 TAT-interactive protein 2)
1387Transcription initiation factor TFIID subunit 6P49848
(Transcription initiation factor TFIID
70 kDa subunit) (TAF(II)70) (TAFII-70)
(TAFII-80) (TAFII80)
1388TRA@ proteinQ6PIP7
1389T-complex protein 1 subunit beta (TCP-1-beta) P78371
(CCT-beta)
1390Telomerase-binding protein EST1A (Ever shorterQ86US8
telomeres 1A) (Telomerase subunit EST1A)
(EST1-like protein A) (hSmg5/7a)
1391Tumor endothelial marker 6 (Hypothetical protein Q96PE0
TEM6)
1392Ras GTPase-activating-like protein IQGAP2Q13576
1393Tetratricopeptide repeal protein 15 Q8WVT3
(TPR repeat protein 15)
1394Myosin-18A (Myosin XVIIIa) (Myosin Q92614
containing PDZ domain) (Molecule associated
with JAK3 N-terminus) (MAJN)
1395Polycystic kidney and hepatic disease 1 Q8TCZ9
precursor (Fibrocyslin)
1396TMC4 proteinQ7Z5M3
1397MDC-3.13 isolorm 1 (TNFAIP8 protein)Q9UER5
1398Toll-like receptor 8 precursorQ9NR97
1399Tolloid-like protein 1 precursor (EC 3.4.24.—)O43897
1400DNA topoisomerase I, mitochondrial precursor Q969P6
(EC 5.99.1.2) (TOP1mt)
1401PAP associated domain-containing protein 5 Q8NDF8
(EC 2.7.7.—) (Topoisomerase-related function
protein 4-2) (TRF4-2)
1402Plastin-3 (T-plastin) P13797
1403Translocated promoter region Q5SWY0
(To activated MET oncogene)
1404P2Y purinoceptor 13 (P2Y13) (G-protein Q9BPV8
coupled receptor 86) (G-protein coupled
receptor 94)
1405Transcript Y 5Q9BXH6
1406Transcription factor Sp4 (SPR-1) Q02446
1407Transcription initiation factor TFIID subunit 1 P21675
(EC 2.7.11.1) (Transcription initiation factor
TFIID 250 kDa subunit) (TAF(II)250)
(TAFII-250) (TAFII250) (TBP-associated factor
250 kDa) (p250) (Cell cycle gene 1 protein)
1408Transcriptional repressor CTCFL (CCCTC-Q8NI51
binding factor) (Brother of the regulator of
imprinted sites) (Zinc finger protein CTCF-T)
(CTCF paralog
1409Transducer of regulated CREB protein 3Q6UUV7
1410Transmembrane channel-like protein 4 Q7Z404
1411Transcription initiation factor TFIID subunit 6P49848
(Transcription initiation factor TFIID 70 kDa
subunit) (TAF(II)70) (TAFII-70) (TAFII-80)
(TAFII80)
1412Trophinin-associated protein (Tastin) Q12815
(Trophinin-assisting protein)
1413Tryptophanyl-tRNA synthetase (EC 6.1.1.2) P23381
(Tryptophan--tRNA ligase) (TrpRS) (IFP53)
(hWRS)
1414Tubulin, gamma complex associated protein 3 Q5T9Y2
1415Tumor necrosis factor ligand superfamily member 6
(Fas antigen ligand) (Fas ligand) (CD178 antigen)P48023
(CD95L protein) (Apoptosis antigen ligand)
(APTL) [Contains: Tumor necrosis factor ligand
superfamily member 6, membrane form
1416 Tumor necrosis factor, alpha-induced protein 1, Q13829
endothelial (B12 protein)
1417 Netrin receptor DCC precursor (Tumor suppressor P43146
protein DCC) (Colorectal cancer suppressor)
1418Adipocyte-derived leucine aminopeptidase Q9NZ08
precursor (EC 3.4.11.—) (A-LAP) (ARTS-1)
(Aminopeptidase PILS) (Puromycin-insensitive
leucyl-specific aminopeptidase) (PILS-AP)
(Type 1 tumor necrosis factor receptor
shedding aminopeptidase
1419 U1 small nuclear ribonucleoprotein AP09012
(U1 snRNP protein A) (U1A protein) (U1-A
1420 U6 snRNA-associatcd Sm-like protein LSm8 O95777
1421 Ubiquitin-protein ligase E3A (KC 6.3.2.—) Q05086
(E6AP ubiquilin-protein ligase)
(Oncogenic protein-associated protein E6-AP)
(Human papillomavirus E6-associated protein)
1422Ubiquitin carboxyl-terminal hydrolase 3 Q9Y6I4
(EC 3.1.2.15) (Ubiquitin thioesterase 3)
(Ubiquitin-specific-processing protease 3)
(Deubiquitinating enzyme 3)
1423UBX domain-containing protein 2Q92575
1424UNC93 homolog B1 (UNC-93B protein) Q9H1C4
(hUNC93B1)
1425Splice isoform 5 of Q9H171Q9H171-5
1426CDNA FLJ46282 fis, clone TESTI4031066Q6ZRK6
1427CCDC73 proteinQ6P5Q7
1428Caspase recruitment domain-containing protein 10 Q9BWT7
(CARD-containing MACUK protein 3) (Carma 3)
1429Chromatin-specific transcription elongation Q9Y5B9
factor FACT 140 kDa subunit
1430Beta-defensin 120 precursorQ8N689
1431Alpha-catulin (Catenin alpha-like protein 1) Q9UBT7
(Alpha-catenin-related protein)
1432Ribonuclease III (EC 3.1.26.3) (RNase III)Q9NRR4
1433Seizure related 6 homologQ53EL9
1434Granulocyte colony-stimulating factor precursor P09919
(G-CSF) (Pluripoietin) (Filgrastim) (Lenograstim)
1435Lysyl-tRNA synthetaseQ9HB23
1436Protein C6orf130Q9Y530
1437Melanophilin (Exophilin-3) (Synaptotagmin-like Q9BV36
protein 2a) (Slp homolog lacking C2 domains a)
1438Novel protein (Possible ortholog of mouseQ5VTR6
phosphoinositide-3-kinase adaptor protein 1
(Pik3ap1)
1439AHR61 glycosyltransferaseQ6P985
1440Heat shock protein HSP 90-alpha (HSP 86)P07900
144160S ribosomal protein L19P84098
1442PDZ domain-containing protein 11 Q5EBL8
1443Dedicator of cytokinesis 11-; Cdc42-
associated guanine nucleotide exchange factor
ACG/DOCK11Q5JSL3
1444Hypothetical protein FLJ26930Q6ZNX6
1445Laminin gamma-1 chain precursorP11047
(Laminin B2 chain)
1446ATP-binding cassette transporter sub-family Q96J66
C member 11 (Multidrug resistance-
associated protein 8)
1447Uridine/cytidine kinase-like 1Q9NWZ5
1448Butyrophilin-like protein 8 precursorQ6UX41
1449Endothelial cell-selective adhesion moleculeQ96AP7
precursor
1450Poly(A)-specific ribonuclease PARN O95453
(EC 3.1.13.4) (Polyadenylale-specific
ribonuclease) (Deadenylating nuclease)
(Deadenylation nuclease)
1451Voltage-gated potassium channel KCNA7Q96RP8
1452F-box protein 11Q52ZP1
1453rythrocyte membrane protein band 4.1 like 5Q7Z5S1
1454CDNA FLJ45015 fis, clone BRAWH3014639Q6ZT30
1455FAM13A1_v2 proteinQ24JP0
1456Hypothetical protein FLJ26432Q6ZP70
1457VPS13D-1A proteinQ709C5
1458Coagulation factor VIII precursor P00451
(Procoagulant component)
(Antihemophilic factor) (AHF)
1459NFX1-type zinc finger-containing protein 1Q9P2E3
1460Polymerase I and transcript release factor Q6NZI2
(PTRF protein)
1461T-complex protein 1 subunit epsilon P48643
(TCP-1-epsilon) (CCT-epsilon)
1462Probable ATP-dependent RNA helicase DDX27 Q96GQ7
(EC 3.6.1.—) (DEAD box protein 27)
1463HSCARGQ9HBL8
1464CDNA FLJ43956 fis. clone TESTI4015681Q6ZU72
1465Mitochondrial-processing peptidase alpha Q10713
subunit, mitochondrial precursor
(EC 3.4.24.64) (Alpha-MPP)
1466CDNA FLJ45287 fis, clone BRHIP3002124Q6ZSK0
1467Hypothetical protein C12orf62Q96I36
1468VPS13D-2A proteinQ709C4
1469CDNA FLJ32009 fis, clone NT2RP7009498,Q96DN2
weakly similar to FIBUUN-1, ISOFORM A
1470Transient receptor potential cation channel Q9HBA0
subfamily V member 4 (TrpV4) (osm-9-like
TRP channel 4) (OTRPC4) (Vanilloid
receptor-like channel 2) (Vanilloid
receptor-like protein 2) (VRL-2)
1471Vascular endothelial growth factor D O43915
precursor (VFGF-D) (c-fos-induced
growth factor) (FIGF)
1472Vascular endothelial growth factor receptor 1 P17948
precursor (EC 2.7.10.1) (VFGFR-1)
(Vascular permeability factor receptor)
(Tyrosine-protein kinase receptor FLT)
(Flt-1) (Tyrosine-protein kinase FRT)
(Fms-like tyrosine kinase 1)
1473Proto-oncogene C-crk (P38) (Adapter molecule crk)P46108
1474VDUP1 protein (Thioredoxin interacting protein)Q9H3M7
1475VimentinP08670
1476HUMAN CTCL tumor antigen HD-CL-06 Q548L2
(Vimentin variant)
1477Vinculin (Metavinculin) P18206
1478Integrin alpha-3 precursor (Galaetoprotein B3) P26006
(GAPB3) (VLA-3 alpha chain) (FRP-2) (CD49c
antigen) [Contains: Integrin alpha-3 heavy chain;
Integrin alpha-3 light chain]
1479Voltage-dependent T-type calcium channel
alpha-1H subunit (Voltage-gated calcium O95180
channel alpha subunit Cav3.2) (Low-voltage-
activated calcium channel alpha1 3.2 subunit)
1480Wiskott-Aldrich syndrome protein family Q8IV90
member 4 (WASP-family protein member 4)
1481ATP synthase coupling factor 6, mitochondrial P18859
precursor (EC 3.6.3.14) (ATPase subunit F6)
1482Proto-oncogene protein Wnt-3 precursor P56703
1483Amyloid beta A4 precursor protein-binding Q99767
family A member 2 (Neuron-specific X11L
protein) (Neuronal Munc18-1-interacting
protein 2) (Mint-2) (Adapter protein X11beta)
1484Zinc finger CCHC domain-containing protein 5Q8N8U3
1485Myeloid/lymphoid or mixed-lineage leukemia Q59FF2
(Trithorax homolog, Drosophila) variant
1486Zinc finger protein DZIP1 Q86YF9
(DAZ-interacting protein 1/2)
1487Hypothetical protein DKFZp761O1618Q69YS5
1488ATP-binding cassette sub-family F member 2 Q9UG63
(Iron-inhibited ABC transporter 2)
1489Ribosome biogenesis protein BOP1Q14137
(Block of proliferation 1 protein)
1490CDNA FLJ13765 fis, clone PLACE4000128Q9H8C5
1491NDRG1 protein (N-myc downstream Q92597
regulated gene 1 protein)
1492Pre-mRNA splicing factor ATP-dependent Q92620
RNA helicase PRP16
1493Nesprin 2 (Nuclear envelope spectrin Q9NU50
repeat protein 2)
1494Adenomatous polyposis coliP25054
1495Ubiquitin conjugating enzyme E2P49459
1496B cell receptor-associated protein BAP31P5572
(CDM protein) 6c6-AG
1497Topoisomerase II-alphaP11388
1498Topoisomerase II betaQ02880
1499Integrin beta8 subunit precursorP26012
1500Replication Protein AP27694
1501Abl Binding protein 3U31089
1502Cyclin IQ14094
1503Cell Division Control Protein 2 (CDC2)P06493
1504Septin 2 (NEDD5)Q15019
1505STAT1 alpha/betaP42224
1506LDL Receptor-related protein (LRP)Q07954
1507TACE (ADAM 17)NP-068604
1508Junction plakoglobin (gamma catenin)P14923
1509EDDR1Q08345
1510IP3 receptor type II Q14571
1511Melanoma-associated antigen D2 (MAGE-D2
antigen) (MAGE-D) (Breast cancer-associated Q9UNF1
gene 1 protein) (BCG-1) (11B6) (Hepatocellular
carcinoma-associated protein JCL-1)
1512Melanoma-associated antigen 4 (MAGE-4 P43358
antigen) (MAGE-X2) (MAGE-41)
1513HUMAN Retinoblastoma-like protein 2 Q08999
(130 kDa retinoblastoma-associated protein)
(PRB2) (P130) (RBR-2)